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INTRODUCTION 
Treatment with oral anticoagulant therapy entails a delicate balance between over-
(risk of bleeding) and under- (risk of thrombemboli) anticoagulation. Therapy is 
therefore monitored to maintain its anticoagulant effect within a narrow range. The 
main aim of this research was to determine the optimal intensity of long-term 
anticoagulant therapy in 3404 post-myocardial infarction patients. 
Chapter 1 gives a review of long-term clinical trials which assessed the mertts 
of anticoagulant therapy in the secondary prevention of morbidity and mortality after 
myocardial infarction. This review includes the results of more than thirty trials 
reported in the literature in the past forty years, however, unpublished data or results 
of small trials, were not considered. Few of these trials were randomized, and the 
level of anticoagulation was properly maintained in only some of these studies. The 
results of most of these trials have failed to convincingly demonstrate the beneficial 
effects of long-term anticoagulant therapy as a secondary preventive measure and 
the use of such therapy has therefore remained controversial. 
Chapters 2 and 3 describe the design and execution of the ASPECT 
(Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis) 
trial. The main results of this trial are submitted in Appendix-A. ASPECT was 
designed to be a randomized, double-blind, placebo controlled, multicentre trial 
which compared standard oral anticoagulant therapy with placebo with regards to 
mortality and cardiovascular events. Chapter 2 describes the design and procedures 
of the ASPECT trial in detail, in particular the methods for double-blind anticoagulant 
titration. Chapter 3 presents an outline of the data processing system as used in 
ASPECT. A standardized procedure which was developed for data handling insured 
a high level of data quality derived from the participating centres. 
Chapters 4, 5 and 6 addresses the effectiveness and safety of oral 
anticoagulant therapy. Chapter 4 reviews various methods, previously described, to 
evaluate therapeutic achievement of anticoagulant therapy in the ASPECT trial. In 
Chapter 5, the optimal achieved intensity of anticoagulant therapy required to 
prevent recurrence of arterial thromboembolic and haemorrhagic complications was 
quantitatively evaluated with regard to the international normalized ratio (INR) 
intensity preceding the event, enabling the calculation of INR-specific incidence 
rates. The INR expresses the level of anticoagulant therapy in an internationally 
agreed term. It is the common term for the prothrombin time as measured in a 
patient on oral anticoagulant therapy. Chapter 6 gives a detailed description of the 
risk of stroke in the ASPECT population. 
Finally, a discussion of the findings is provided in Chapter 7, followed by 
recommendations for further research. 

CHAPTER ONE 
LONG-TERM ORAL ANTICOAGULANT THERAPY AFTER MYOCARDIAL 
INFARCTION 
AJ Azar and JW Deckers 
INTRODUCTION 
Among the multiple therapeutic interventions and publications in the past decades, 
few have given rise to as much controversy as the use of oral anticoagulant therapy 
in the prevention of re-infarction and death in survivors of myocardial infarction [1 ,2]. 
Following the discovery of dicumarol and other anticoagulant congeners, the use of 
these drugs came into clinical use in the late forties, at which time the need for 
randomized controlled clinical trials and blinding principles were not generally 
appreciated. Since then, a multitude of short and long-term clinical trials have been 
performed to evaluate the effectiveness of coumarin treatment for patients who had 
sustained a myocardial infarction [3]. Only few of these trials, however, were 
randomized and properly controlled [4]. The first largest non-randomized short-term 
clinical trial was conducted in 1948 when Wright assessed the benefrts of dicumarol 
in the prevention of myocardial re-infarction [5]. This study, a non-randomized, open, 
short term trial of 6 weeks, inaugurated the anticoagulant era because a positive 
treatment for the reduction of mortality and myocardial infarction associated with 
dicumarol was reported [6]. The results of subsequent studies were also suggestive 
of possible benefits of long-term anticoagulant treatment, albeit against an increased 
risk of bleeding. The most recent Dutch ASPECT trial, the largest randomized, 
double-blind, placebo controlled, multicentre, clinical trial which evaluated the 
effectiveness of anticoagulant therapy in post myocardial infarction patients, was 
conducted to solve the anticoagulant controversy. ASPECT will be extensively 
described in this dissertation. 
In this chapter, the discovery of anticoagulant factors will be described as well 
as their abundant use from the fifties until the early seventies, and a description of the 
major long-term clinical trials that assessed the benefits of anticoagulant therapy in 
the secondary prevention of myocardial infarction and associated morbidity and 
mortality will be presented. 
THE ANTICOAGULANT FACTORS 
Sweet clover disease 
The anticoagulant era began in 1920 when farmers in the Dakota plains and Canada 
complained of the deaths of their cattle due to profused internal bleeding [7]. At that 
time, haemorrhagic disease was labelled in veterinary terms the 'sweet clover 
disease'[7,8]. The cattle consumed stacked sweet clover that flourished on poor soil 
used to substitute for corn. 
In 1933 a Wisconsin farmer drove more than 300 kilometres to Karl Paul Link's 
laboratory: with him he had a can of uncoagulable milk and spoiled clover. Link, who 
once was a farmer himself, proceeded to find the cause of the disease. He wrote 
[7,8]: 
" ... on a Saturday afternoon in February 1933 ... while a blizzard was 
howling and the mercury was hovering near zero, a farmer from ... 
Wisconsin, some 190 miles ... the farmers name was Ed Carlson. The 
haemorrhagia sweet clover disease of cattle was rampant on his farm. 
He had fed sweet clover hay for years previously without encountering 
any difficulties ... Farmer Carlson's multiple evidence was a dead heifer, 
a milk can containing blood completely destitute of clotting capacity, and 
about 100 pounds of spoiled sweet clover- the only hay he had to feed 
the cattle ... He had to stop feeding that hay, and possibly transfuse 
those desperately sick cattle if he wanted to save them ... I can still see 
him take off ... and his bam must have appeared to him like a 
trachureous and somber ocean ... Schoeffel stormed back and forth in 
the laboratory shouting ... "a farmer shtruggles nearly 200 miles in dis 
Sau-Wetter, driven by a shpectre and den has to go home vit promises 
dat might come true in five, ten, fifteen years, maybe never ... Get some 
good hay-transfuse ... how can you do dat ven you haf no money ... Vat 
viii he find when he gets home ? Sicker cows ... vat viii dey haf on 
Monday? MORE DEAD COWS!! He has no udder hay to feed- he can't 
buy any." 
A few years thereafter, Roderick traced the cause of death of the cows by use of the 
Quick 1-stage method developed in 1935 by Armond Quick [8,9]. He found that the 
disease was due to congesting spoiled hay made from sweet clover. The improperly 
cured hay was found to produce a deficiency of a circulating procoagulant factor; 
prothrombin. Prothrombin converts to thrombin, one of the final steps in the 
coagulation pathway. The principal role of thrombin is to convert fibrinogen to fibrin 
which in turn combines to form a network. This network becomes a structured fibrin 
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clot that prevents excessive bleeding. The disease of the cows was reversed by 
stopping the feeding of the spoiled hay and substituting a vitamin K rich plant to their 
diet, such as alfalfa [7]. 
Discovery of Dicumarol 
"Finally in the dimness of dawn on June 28, 1939, after working all 
night, Campbell saw on a microscope slide what turned out to be 
crystalline Dicumarol. Two hours later he had collected about 6.0 mg. 
of it" 
The haemorrhagic agent which gave the sweet smell and bitter taste to the uncured 
hay was identified to be dicumarol by Campbell in Link's laboratory [7, 1 OJ. Coumarin 
upon oxidation and in the presence of formaldehyde converts to dicumarol. It was 
observed that the time between oral administration of dicumarol and its effect in each 
species tested took about one day with a cumulative effect following repeated 
administration with large individual variations. This lead to the conclusion that, to 
achieve optimal therapeutic effect, dosages needed to be individually adjusted [7]. 
Link and co-workers also synthesised other coumarin derivatives, including Warfarin, 
a compound that was subsequently used not only as oral anticoagulant in the battle 
against thrombosis in man but even more widely as a rodenticide. 
The coagulation cascade 
A dynamic equilibrium exists between the coagulation system and the fibrinolytic 
system. These systems are associated with the formation and degradation of fibrin 
within the blood vessels. With the occurrence of for instance a disruption of the 
endothelial layer, the haemostatic system triggers the coagulation cascade in a series 
of reactions to stop the bleeding while, at the same time, the fibrinolytic system is 
activated to prevent excessive coagulation. The various coagulation factors are 
synthesised in the liver and transported to the tissues by the blood. An uncontrolled 
haemostatic response may either lead to excessive bleeding or to fibrin formation at 
non-injured sites, and may thus reduce blood flow to important tissues such as the 
myocardium and the brain [11,12]. 
The intrinsic and the extrinsic pathways are the two major independent 
activation pathways involved in the activation of prothrombin to thrombin (see Figure 
1.1) [13]. Contact activation initiates the intrinsic pathway by activation of factors XII 
(Hageman factor) to Xlla (activated Hageman factor) with the interaction of 
prekallikrein and high-molecular-weight kinogen (HMW Kinogen). Factor Xlla 
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activates factor XI which converts in a cascade the factors IX, VIII, X and V to their 
active forms [11,12]. Tissue activation starts the extrinsic coagulation pathway in a 
similar cascade like fashion, by separately activating factors VII, IX and X. Both 
pathways mediate thrombin formation from prothrombin. The final coagulation step 
is fibrin formation from fibrinogen under the infiuence of thrombin. The large fibrin 
fragments, the fibrin monomers, combine to form a network which in the presence of 
factor XIII (the fibrin stabilizing factor) and calcium becomes a structured fibrin clot. 
The production of the procoagulant factors II, VII, IX, and X, as well as the 
anticoagulant factors protein C and its co-factor protein S, depends on the availability 
of vitamin K, and is thus diminished in the absence of vitamin K [11 ]. Antithrombin Ill 
and proteins C and S are the most important natural coagulation inhibitors and help 
to balance the coagulation cascade [11, 14]. 
Coumarin derivatives diminish the production of the vitamin K dependent 
coagulation factors by preventing their carboxylation as well as of the coagulation 
inhibitor proteins C and S [14-17]. These precursors of coagulation factors (PIVKAs: 
Protein Induced by Vitamin K Absence or Antagonists) circulate in the plasma but lack 
any coagulative properties [14, 15, 18]. Because the coumarin derivatives inhibit the 
synthesis of coagulation factors it takes some time before a new equilibrium at a 
lower coagulation level is reached. 
Figure 1.1 The coagulation cascade. Reproduced from Harrison's principles of 
internal medicine [11 ]. 
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The most widely used test to control oral anticoagulant therapy is the one-stage 
prothrombin time test [14, 16, 19-24]. This test is sensitive to the reduction of three of 
the vitamin K dependent coagulation factors, i.e., factors II, VII and X [16] and 
measures the time needed for a plasma sample to clot when thromboplastin and 
calcium are added. Thromboplastin is a phospholipid-protein extract of tissue which 
contains the tissue factor and the phospholipid necessary to promote the activation 
of factor X by factor VII [16,20]. The prothrombin time is a measure of the extrinsic 
system coagulation activity [11, 14,22]. The activated partial thromboplastin time, on 
the other hand, measures the intrinsic system coagulation activity and is used in 
patients on heparin therapy [11, 14,22,25]. 
REVIEW OF LONG-TERM ANTICOAGULANT TRIALS 
The therapeutic value of coumarin derivatives in the treatment of patients who suffer 
from deep venous thrombosis [1, 15,26-29] and pulmonary embolism [16] is not 
disputed. In addition, prophylactic use of coumarin has been shown to prevent 
recurrent embolism secondary to intracardiac thrombi in patients with atrial fibrillation 
and enlarged left atria [16,30], or in patients with severely diminished left ventricular 
function [28]. Thromboembolic complications after major surgery [30,31] or after 
implantation of endovascular prosthetic materials [15,30,32-34] such as artificial heart 
valves, bifurcation prostheses or intracoronary stents are also prevented by oral 
anticoagulant therapy. However, the application of long-term anticoagulant therapy 
as a secondary preventive measure in patients who have sustained a myocardial 
infarction has remained controversial [20,28,35] although more than thirty 
randomized, non-randomized, blind and open trials have been reported in the 
literature. The results of the large clinical trials which assessed the benefits of long-
term oral anticoagulant therapy after myocardial infarction will be reviewed in the 
following section. 
Early trials (1950 -1970) 
In Norway, long-term anticoagulant therapy after myocardial infarction was introduced 
by Owren who described his initial clinical experience with coumarin in a group of 79 
patients in 1948 [36]. In 1955, he subsequently published the results of active 
anticoagulant therapy with a duration of 1Y, to 6 years in 247 patients. In 1957, 
Bjerkelund reported the effect of long-term dicumarol treatment in patients after 
recovery from acute myocardial infarction [36]. In that study, patients were assigned 
by ward to different treatment groups. Patients admitted to department 'seven' were 
assigned to the control group, patients admitted to department 'eight' were allocated 
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to long-term anticoagulant therapy, and patients admitted to department 'nine' were 
assigned to control or active therapy for alternating periods of approximately 6 
months. On the whole, 118 patients were assigned to control and 119 to active 
therapy with a mean follow-up of 37 months. Mortality in placebo treated patients was 
32.2% compared to 19.3% in the anticoagulated group, and the relative risk (RR) 
associated with anticoagulant therapy was 0.57 with a 95% confidence interval (CI) 
of 0.37 to 0.87. It was concluded that long-term anticoagulant therapy in the form of 
dicumarol reduced mortality. Myocardial infarction rates were also reduced [36] 
(39.8% in placebo and 21.8% after anticoagulant therapy (RR, 0.57; 95% Cl 
0.36,0.91)). These results as well as a summary of the findings of all long-term 
anticoagulant therapy in post myocardial infarction patients are presented in table 1.1. 
Only few of these early trials were double-blind. The trial conducted by 
Borchgrevink in 1960 is a typical example of a randomized, single blind trial. This trial 
aimed to assess the merits of moderate versus intense long-term anticoagulant 
therapy which was measured using the prothrombin- proconvertin (P&P) method of 
Owren and Aas [37]. The patients studied were mainly suffering from angina, 
although a few had previously sustained a myocardial infarction [38]. The results of 
the trial were in favour of more intense anticoagulant therapy. In 1962, Harvald 
randomly allocated 315 post myocardial infarction patients by date of birth to either 
anticoagulant therapy (phenprocoumon or dicoumarol) or placebo [39]. Eighty five 
percent of the treated patients were found to be in the therapeutic range of 1 0%-25% 
on the basis of prothrombin time determinations. A lower death and re-infarction 
rates were detected in the treated group, but only during the first year. In addition, a 
higher risk of haemorrhagic complications was observed. The authors concluded that 
it was not justifiable to advise anticoagulant therapy routinely for long-term use after 
myocardial infarction. 
The results of the first report of the working party to the British Medical 
Research Council (BMRC) in 1959 were in agreement with the positive findings of 
Bjerkelund previously described [38,40]. The drug phenindione was randomly given 
to 195 patients, and doses were adjusted to maintain the prothrombin time using brain 
thromboplastin 2-2.5 times the control values. The control group of 188 patients 
received low dose (1mg) phenindione which was insufficient to affect prothrombin 
time. Prothrombin times were only measured in the high dose group. The authors 
reported a lower death rate and a significant reduction in recurrent myocardial 
infarction during the three years of follow-up, against an increased risk of 
haemorrhagic episodes in the higher dose group. In their Second Report published 
in 1964, the mortality data at the end of 5 years were similar in both treatment groups, 
although the rate of reinfarction was less in the anticoagulant group [38,41 ,42]. One 
criticism of this investigation was that the trial was open and that the physicians, 
involved assessed the EGG's for reinfarction, knew the treatment being received and 
were thus not blinded. 
16 CHAP1ER 1 
In 1964, Aspenstrom allocated 131 patients in a non-randomized single blind study 
to receive either dicoumarol or placebo with a follow-up from 5 to 8 years [43]. The 
results of the study indicated a higher risk of cerebrovascular incidents in the 
anticoagulant group and no difference in mortality in the two groups. 
Given these discrepant findings, long-term anticoagulant therapy in the 
prevention of ischemic heart disease was still controversial in the early sixties 
(Bjerkelund, 1957; Borchgrevink, 1960; Harvald, 1962; British Medical Research 
Council, 1959, 1964; and Aspenstrom, 1964 ). In addition, many physicians found the 
management of the anticoagulant treatment too demanding and therefore were 
abandoning its use [21]. The high frequency of haemorrhagic complications induced 
by anticoagulant therapy increased this controversy [36]. 
For this reason, in an attempt to reassess the values of long-term anticoagulant 
therapy, a second trial was conducted by Loeliger in the Netherlands, in 1967, the 
very first double-blind long-term anticoagulant trial [44]. In this relatively small study, 
250 patients were randomly and in a double-blind manner allocated to receive either 
phenprocoumon or placebo. This trial achieved adequate therapeutic control: 68% of 
the patients had a Thrombotest value lying between 5%-1 0%. The mean daily dose 
of phenprocoumon was 2.8 mg. Death rates were similar in both treatment groups but 
reinfarction occurred more frequently in placebo as compared to the anticoagulated 
group (9.8% vs 1.6%). The authors emphasised that the favourable clinical outcome 
as well as the low rate of bleeding complications were the results of a high but stable 
intensity of hypocoagulability. In that same year, Love! reported the results of a 
randomized trial in which 62 patients were allocated to heparin, 172 patients to 
phenprocoumon in doses aimed at reducing the prothrombin activity to between 15% 
and 30% of nonmal, and 178 patients to un-controlled low dose phenprocoumon. This 
trial demonstrated improved survival for the high dose group, but only over the first 
two years [45]. 
The final report of the Veterans Administration Cooperative Study was 
published in 1969 by Ebert [46]. In this study, patients were randomly allocated to 
receive either dicoumaroVwarfarin or placebo and were followed for at least 2 years. 
The dose of warfarin was adjusted to maintain the one-stage prothrombin time, using 
human brain thromboplastin, between 2 to 2.5 times normal. Anticoagulant therapy 
was found to increase survival rate in the anticoagulated group during the first three 
years after an acute myocardial infarction. However, an increased risk of 
haemorrhagic episodes was observed. 
In the same year, S¢rensen published the results of a non-randomized trial 
with patients allocated to either dicoumarol or placebo depending on the day of 
admission. A 46% reduction in mortality was observed between the two groups in 
favour of anticoagulant therapy. A reduction in recurrent myocardial infarction was 
also reported in patients at least 60 years of age. The risk of haemorrhagic episodes 
was increased for the anticoagulated group. 
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Table 1.1 
Author or 
study name 
(year) 
\Jrightl 
(1948) 
Bjerkelund 
(1957) 
Borgrevink 
(1960) 
Harvald 
(1962) 
Medical 
Research 
Council 
(1959,1964) 
Aspenstrom 
(1964) 
Abbreviations: 
Results of long term anticoagulant therapy in post myocardial infarction patients 
country 
U.S.A. 
Norway 
Norway 
Denmark 
U.K. 
sweden 
design 
non-random! zed 
open 
non· randomized 
open 
randomized 
single blind 
non-randomized 
open 
randomized 
open 
non- random! sed 
singe! blind 
""'" follow-up 
6 weeks 
37 months 
17 months 
31 months 
25 months 
46 months 
AC level 
(%in range) 
30·50 sec 
(link-
Shapi ro) 3 
10%·20% P&P 
(46%) 
treatment 
conventional vs 
dicunarol with or 
with-out heparin 
no control 
dicunarol 
10%-20% P&P moderate vs 
(48%) intense 
10%'-25% P&P 
(85%) 
doubting 1-
stage PT 
(45%) 
10%·25% P&P 
(69% 
P&P<30%) 
anticoagulation 
placebo vs 
phenprocouoon or 
dicounarol 
ineffective vs 
effective dose 
phenindione 
ineffective vs 
effective dose 
dicounarol 
No. 
368 
432 
118 
119 
100 
103 
170 
145 
188 
195 
113 
118 
mortality (%) 
RR (95% C. I.) 
23.9% 
15.0% 0.63 (0.4-0.84) 
32.2% 
19.3% 0.57 (0.37-0.87) 
8.0% 
1.0% 0.12 (0.01-0.95) 
26.5% 
23.4% 0.89 (0.60·1.30) 
21.3% 
14.9% 0.70 (0.45·1.1) 
44.2% 
33.1% 0.75 (0.54-1.0) 
recurrent HI (%) extra- 1 
RR (95%C.L) cranial 
bleeding 
15.5% 22 
4.5% 0.28 (0.17-0.47) 53 
39.8% 8 
21.8% 0.57 (0.36·0.91) 37 
13.0% 1 
1.9% 0.15 (0.035-0.65) 10 
39,4% 11 (38) 
35,9% 0.67 (0.50·0.90) 53 (102) 
43.1% 10 
17.4% 0.41 (0.29·0.57) 80 
45 events4 17 (28) 
20 events4 56 (104) 
AC, anticoagulant; No, number of patients per treatment group; RR, rate ratios; C. I., confidence intervals; HI, myocardial infarction; P&P, prothrombin-proconvertin; INR, 
international normalized ratio; PT, prothroobin time; n, throobotest. 
1Number of patients and number of episodes (in brackets). 
2This short term study has been included since it was the first large trial which assessed the merits of anticoagulant therapy in patients with an acute myocardial infarction. 
'Modification of the Quick one-stage test. 
4Number of patients with events not available. 
Table 1. 1 (contined) Results of Long term anticoagulant therapy in post myocardial infarction patients 
Author or country design mean AC Level treatment No. mortality (%) recurrent MI (%) extra· 1 
study name fol low·up (%in range) RR (95% C. I.) RR (95% C. I.) cranial 
(year) bleeding 
\.lasserman U.S.A randomised <36 10%-30% no anticoagulant 
(1966) open months Quick 1- control vs 70 21.4% 6 
stage warfarin 77 15.6% 0. 73 (0.37-1. 50) 13 
Loel iger Hot Land randomised 6 months 5%·10% TT placebo vs 122 9.0% 9.8% 1 
( 1967) double blind (68,2%) phenprocolEilOn 128 6.3% 0.69 (0.29·1.67) 1.6% 0.16 (0.036·0.70) 17 
Lovell Australia random! zed 18 months 15%-30% ineffect lve vs 178 21.9% 9.6% a 
(1967) open ProthrOIT'bin effective dose 172 19.2% 0.88 (0.58-1.32) 7.0% 0.73 (0.36-1.48) 48 
activity phenprocounon 
(67%) 
u.s. U.S.A randomized 53 months doubting 1- placebo vs 359 31.8% 20.9% (11) 
veterans sinlge blind stage PT dicoU'llarol or 388 30.9% 0.97 (0.79-1.20) 15.6% 0.75 (0.55-1.0) (72) 
(1965, 1969) warfarin 
Sfrensen Oenmark non-randomized 17 months 10%-30% P&P placebo vs 95 20.0% 39.0% 1 
( 1969} open (74%) dlcunarol 139 10.8% 0.54 (0.29·1.00} 5.0% 0. 72 (0.12-0.62) 32 (34) 
Meuwissen Hot Land randomized 20 months 5%-15% TT placebo vs 70 11.4% 10.0% 0 
(1969) double blind (91%) phenprocounon 68 1.5% 0.13 (0.017-1.0) 7.4% 0.74 (0.25·2.20) 7 (8) 
Ritland Norway randomized 12 months 20%-30% P&P phenlndione 3 mo. 106 6.6% 8.5% 
(1969) 
'"'" 
(55%) phenindione 12mo. 102 7,8% 1.17 (0.43-3.10) 4.9% 0.58 (0.20-1.66) 
Seamen U.S.A. randomized 73 months 10%-30% P&P placebo vs 87 35.6% 37.9% 44 (96) 
(1969) double blind (61%) phenindi one 88 40.9% 1.15 (0.79-1.68) 40.0% 1.05 (0.72-1.52) 59 (179) 
Table 1.1 (continued) Results of long term anticoagulant therapy In post myocardial infarction patients 
Author or country design ""'n AC level (% treatment No. mortality (%) recurrent HI (%) extra· 
study name follow·up pt• RR (95% C. I.) RR (95% C. I.) cranial 
(year) in range) bleeding 
Mersk:ey U.S.A. randomized maxi non <10% TT pacebo vs 153 23.5% 
( 1974) open 12 months (58%) anticoagulant 175 16.6% 0.70 (0.45·1.09) 
Breddin German· randomized 24 months 5%·12% TT placebo 309 10.4% 8.1% 0 
(1980} Austrian open (58%) phenprocolll!On 320 12.2% 1.18 (0.76·1.83} 5.0% 0.62 (0.34·1. 13) 12 
Sixty· Plus Hot land randomized 24 months JNR 2.7·4.5 placebo vs 439 15.7% 15.2% (10) 
(1982) double blind (71.6%) acenocoumarin or 439 11.6% 0.74 (0.53·1.04) 6.9% 0.45 (0.30·0.68) (84) 
phenprocolJllOn 
EPSIM group France random! zed 29 months <35% acetyl salycilic 
(1982) open prothrorrhin acid vs 651 11. 1% 4.9% 35 (55) 
time anticoagulant 652 10.3% 0.93 (0.68·1.27) 3.1% 0.62 (0.36·1.08) 104(171) 
(44%) 
WAR IS Nor~ay randomized 37 months 2.8·4.8 INR placebo vs 607 20.3% 20.4% (25) 
(1990) double blind (67%) warfarin 607 15.5% 0.76 (0.60·0.98) 13.5% 0.66 (0.51·0.85) (52) 
ASPECT Holland random! zed 37 months 2.8·4.8 INR placebo vs 1704 11.1% 14.2% 17' 
(1992) double blind (74%) acenocoumarin or 1700 10.0% 0.90 (0.73·1.11) 6.7% 0.47 (0.38·0.59) 56' 
phenprocolll!On 
'Number of patients with major extracranial bleeding. 
Ritland [47] assessed the effect of 3 and 12 months anticoagulant therapy in patients 
who had survived their first myocardial infarction. Mortality and re-infarction rates 
were observed to be similar in both groups. These results may be attributed to the 
moderate anticoagulant intensity achieved. 
The second Dutch trial that assessed long-term anticoagulant therapy after 
myocardial infarction was perfonmed by Meuwissen in 1969 [6]. In a prospective 
double-blind trial, patients were randomly allocated to phenprocoumon or placebo. 
A significant decrease in mortality for the anticoagulated group was noted and only 
minor bleeding complications were observed in the anticoagulated group. The main 
drawback of this trial was the small number of patients. Nevertheless, the authors 
were convinced of the positive outcome and, at the end of the trial, switched all 
placebo patients to phenprocoumon treatment. In that era, the late sixties, long-term 
administration of oral anticoagulant therapy for patients suffering from myocardial 
infarction was increasingly being accepted by the medical community, at least in 
Europe [2,48]. In the United States of America long-term anticoagulant treatment for 
this indication was considered ineffective [50]. 
As an indication of the popularity of anticoagulant treatment in the Netherlands, 
Jordan, in 1949 founded the first anticoagulant control centre, the Thrombosis Centre 
which was build on voluntary basis [49]. Following this model, a nation-wide system 
of regionally centralized Thrombosis Centres for out-patients and home patients was 
subsequently established in the Netherlands [1]. 
Decline of the anticoagulant therapy (1970's) 
Although the late sixties were considered as the anticoagulant era, long-tenm 
anticoagulant therapy was not yet very prominent during that time. Gifford, in 1969, 
was one of the first to comment on the poor methodological design of the early 
studies [51]. The positive findings were criticized because the trials were open, not 
properly randomized, historical controls were used and sample sizes were 
inadequate. On the other hand, the increased recognition of the role of thrombus 
fonmation in the pathogenesis of myocardial infarction was in favour of a more liberal 
use of anticoagulant therapy [41 ,52,59]. In an attempt to re-examine the controversy 
of this therapy, the International Anticoagulant Review Group (IARG), combined 
results of 9 published trials concerned with long-tenm anticoagulant administration in 
patients who had recovered from the acute phase of myocardial infarction in 1970 
[35]. Treatment allocation of five of these trials were at random and the allocation 
method used was considered acceptable by the review group in the other four. In 
these 9 trials, the total number of patients at study amounted to 2487, 1230 in the 
anticoagulated and 1257 in the placebo group. Adequate level of anticoagulation was 
achieved in 50% of the trials only. Total mortality was 28.4% in the treated group and 
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30.5% in placebo. Based on the above, the IARG recommendations did not favour 
long-term anticoagulant therapy. 
Chalmers and co-workers in 1977 also reviewed the evidence from 32 trials for 
short and long-term anticoagulant therapy. A total of 3854 patients were included in 
this analysis with 2106 patients in the anticoagulant group and 1748 placebo patients. 
A 21% mortality reduction was reported, but an increased risk of haemorrhages in the 
anticoagulated group (10.4% in the active treatment and 4.6% in placebo) [3]. The 
authors concluded that 'anticoagulant therapy is beneficial after acute myocardial 
infarction' and that 'further experimental trials would be unethical'. This review also 
reported a 50% reduction in thromboembolic episodes and re-infarctions. Chalmer's 
review and the pooled results of the IARG were criticized because both reports 
pooled trials of dissimilar study designs, protocols and anticoagulant quality [8,53]. 
The results of the same 32 trials were subsequently re-examined by Peto [54] as well 
as by Armitage [55]. Peto demonstrated a 53% (95% Cl, 46% to 60%) mortality 
reduction for the non-randomized trials and a 20% mortality reduction for the 
randomized trials (95% Cl, 5% to 35%). Armitage confirmed Peto's results. 
Meanwhile, Germany, France, and The Netherlands remained unconvinced 
regarding the role of long-term anticoagulant therapy. The three following randomized 
trials were then conducted: (1) the German-Austrian Aspirin Trial in 1980 [56]; (2) the 
EPSIM group trial: Enquete de Prevention Secondaire de l'lnfarctus du Myocarde in 
1982 [57]; and (3) the Sixty Plus Re-infarction Study in 1982 [58,60,61]. 
The German-Austrian Aspirin Trial had one placebo and two active intervention 
groups: acetyl salicylic acid in 317 patients, phenprocoumon in 320 patients and 
placebo in 309 patients [41 ,56]. The trial was double-blind for acetyl salicylic acid and 
placebo and open for phenprocoumon. The dose of phenprocoumon was adjusted to 
maintain thrombotest levels between 5%-12% corresponding to an INR of about 2.5-
5.0. Patients treated with acetyl salicylic acid received 1.5 g daily. No differences in 
mortality or myocardial infarction between the anticoagulant and placebo treatment 
groups was found but a trend in favour of aspirin. Also, a higher risk of haemorrhages 
in the group treated with anticoagulants as compared to placebo was observed. 
However, the results of this trial were disputed because of the definition of the end-
points used, a combination of sudden death and myocardial infarction [4]. 
The EPSIM research group randomized patients admitted to coronary care 
units to anticoagulant therapy or aspirin [57]. A placebo group was not included for 
comparison. No marked differences between the two groups (11.1% mortality in 
aspirin and 10.3% on anticoagulant therapy) were observed. The negative findings 
were attributed to the inadequacy of anticoagulant therapy, since only 44% of the 
patients had a prothrombin time level below 35% prothrombin activity in a six months 
period. 
The first two trials, the German-Austrian and that of the EPSIM research group, 
not only assessed the use of anticoagulant therapy but also of aspirin. There was no 
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substantial mortality reduction in the anticoagulated group as compared to placebo 
or to aspirin, This may have been the result of the inadequate anticoagulant controL 
Again, the long standing and bitter controversy regarding long-tenm anticoagulant 
therapy was not resolved by these trials. 
The 'Sixty-Plus' Re-infarction Study of the Netherlands (1980) 
One of the major criticisms regarding the previous anticoagulant trials in patients with 
a sustained myocardial infarction, repeatedly emphasised by Paller [62] as well as by 
the Dutch haematologist Loeliger [30,63], was that, in order to obtain beneficial effects 
of long-term anticoagulant control, adequately maintained therapeutic quality control 
with experienced dosage regulation should be maintained [63]. In Loeliger's historical 
review on the use of anticoagulant drugs, an INR range of 2.8-4.8 (equivalent to 
prothrombin time levels of 5% - 1 0%) was considered to be the optimum therapeutic 
range. Patients with values below that range are at higher risk for thrombus fonmation 
and, at levels above a ratio of 5.0, at increased risk for occurrence of severe bleeding 
complications [63]. Loeliger stressed the poor methodology in the earlier post 
myocardial infarction trials. In his opinion, the increased risk of haemorrhagic 
complications observed in the previous trials was also associated with the poor quality 
of thromboplastin used to measure the prothrombin time. Moreover, the findings of 
most of the previous trials lacked external validity because of unsolved agreement on 
the intensity of anticoagulant therapy needed to achieve beneficial effects [1,31]. 
In order to circumvene the problem of variability in the sensitivity of 
thromboplastin, an internationally standardized prothrombin time prolongation range 
was introduced [64-66], According to this new standard, thromboplastin needed to be 
calibrated against the primary international reference preparation of thromboplastin 
established by the World Health Organization (WHO) in 1976, By definition, this 
thromboplastin displayed an International Sensitivity Index (lSI) of 1.0 [64,65]. All 
thromboplastin in use had to be calibrated against this reference preparation and be 
assigned an ISL By means of the latter, prothrombin times are translated into times 
or ratios found with the primary international reference preparation [16,65,67]. The 
procedure is relatively simple: the patienfs prothrombin time is divided by the nonmal 
prothrombin time, and the ratio raised to the lSI is the INR (INR = prothrombin 
ratio'81). 
To reappraise the value of oral anticoagulant therapy and with the availability 
of the prothrombin time standardization, the 'Sixty-Plus' Reinfarction Study was 
initiated by the Federation of Dutch Thrombosis Centres in 1976. Six centralized 
Thrombosis Centres agreed to participate in this trial [58]. The Dutch investigation 
included patients who were receiving anticoagulant therapy following a documented 
myocardial infarction that had occurred at least 6 months earlier. Eight hundred and 
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seventy eight patients were randomly allocated in a double-blind manner to continue 
anticoagulant therapy (439 patients) with either phenprocoumon or acenocoumarol 
or to discontinue active treatment (439 patients). The double-blind character of the 
trial was maintained by having both groups continue with the same pattern of visits 
to the Thrombosis Centre for blood tests. Consequently, 'dosage adjustments' were 
consequently also made in the placebo group. Excluded from the trial were patients 
with increased bleeding tendency, thromboembolism, resistant hypertension, atrial 
fibrillation, malignancy, mental illnesses or on a waiting list for cardiac surgery. The 
Thrombotest, a reliable and standardized modification of the prothrombin time test, 
was used to control anticoagulant therapy. This trial indeed achieved adequate 
therapeutic control because 78% of patients on phenprocoumon were found to be 
between the therapeutic range (thrombotest 5%-10%, at that time corresponding to 
an INR range of2.7-4.5 INR), and 63% for acenocoumarin. Data analysis was carried 
on "intention-to-treat" as well as "clinical efficacy". The former takes into account 
relevant events occurring between time of randomization and the end of observation 
period according to original treatment allocation without considering changes in trial 
therapy occurring during the trial process. The "efficacy" analysis only included events 
that occurred within 28 days after discontinuation of trial medication. The mean age 
of patients at study was 62 years. After a mean follow-up of 2 years, a 26% reduction 
in all cause mortality (placebo 15.7% and active therapy 11.6%) was found on 
"intention-to-treat". Reduction in myocardial infarction for active therapy was 54% 
(placebo 15.2% and active therapy 6.9%). Thromboembolic events occurred less 
frequently in the anticoagulated group, but mortality related to thromboembolic events 
was similar in both treatment groups. A thirty seven percent reduction in intracranial 
events (placebo 4.8%, and active therapy 3.0%) was observed. The incidence of 
major and minor bleeding was higher in the anticoagulated group (1 07 vs 35 in 
placebo). Seventy five percent of the bleeding events occurred in patients within 
target therapeutic range. There were no deaths associated with bleeding. It was 
concluded that intensive and stable anticoagulant therapy substantially reduced the 
risk of death, recurrent myocardial infarction and intracranial events in post 
myocardial infarction patients when the anticoagulant level was kept between 2.7-4.5 
INR in the majority of patients [58]. The risk of bleeding associated with well 
controlled anticoagulant level was considered to be acceptable [58]. 
Pooling of trials 
In an other, more recent attempt to debate the value of long-term anticoagulant 
therapy, Leizorovicz and Beissel pooled data from 7 long-term anticoagulant trials 
[68]. The 'Sixty-Plus' Re-infarction Study was not included in this review because this 
trial was not considered to be a study in which anticoagulant therapy had been 
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initiated. In this pooled review, a 21% mortality was reported for the placebo group 
compared to 18% for treated patients. The reinfarction rates were 14% under placebo 
and 1 0% under active treatment. The pooled review of Leizorovicz and Beissel was 
criticized by Loeliger in 1984, since the quality of oral anticoagulant therapy had not 
been considered. Loeliger, by pooling the results from 19 prospective controlled 
clinical trials in post myocardial infarction patients, concluded that the rate of 
myocardial infarction was lowered by two-third and mortality by 40% in those studies 
that were able to adequately maintain therapeutic quality control, i.e. to achieve a 
level of anticoagulant therapy between 2.5 to 5.0 INR. However, Loeliger's 
conclusions were based on "efficacy" basis rather than on "intention-to-treat" 
analysis. If the latter analysis had been performed, a lower beneficial effect of oral 
anticoagulant therapy would have been obtained. Despite these positive effects, long 
term anticoagulant therapy for patients with a sustained myocardial infarction was not 
recommended by many investigators [4,10,41]. 
The problem of long-term oral anticoagulant therapy remained unsolved. In 
European countries, such as the Netherlands, France and some parts of Genmany, 
a substantial number of patients who had a myocardial infarction were still receiving 
long-term oral anticoagulant therapy, whereas such treatment had long been 
abandoned in other countries, including the United States of America [69] and the 
United Kingdom. 
The Norwegian Warfarin Re-infarction (WARIS) study (1990) 
Results of the large Norwegian Warfarin Re-lnfarction Study (WARIS) were recently 
published [70]. The primary aim of the WARIS study was to assess whether long-tenm 
treatment with warfarin would result in a reduction of mortality for patients who had 
recovered from an acute myocardial infarction. WARIS was a prospective, 
randomized, double-blind, late entry study, with stratification of patients according to 
the use of beta-blockers. In order to protect the double-blinding, placebo prothrombin 
times were also monitored. The level of anticoagulation aimed at was 5%-10% 
thrombotest, corresponding to an INR of between 2.8-4.8. The size of the study was 
based on a biennial mortality on placebo of 12.5% and on a 35% reduction in 
mortality by warfarin. In order to achieve 80% power and 5% significance level, a total 
of 1200 patients were needed. The total planned study period was 5 years, and 
included 3 years of enrollment and 2 years of follow-up. Exclusion criteria were age 
over 75 years, use of anticoagulants, malignant disease, life expectancy shorter than 
2 years, high risk of bleeding and residence outside the study area. The first patient 
was accrued in 1983. At the end of the study, 1214 patients had been randomized. 
Six hundred and seven patients were randomly allocated to placebo and 607 to 
Warfarin. Quality control using the cross-sectional approach revealed that two-thirds 
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of the patients were within the pre-set range. After a mean follow-up of 37 months, 
mortality was 123 in placebo-treated and 94 in warfarin-treated patients, a 24% 
mortality reduction in favour of the warfarin treated group on "intention-to-treat". A 
34% reduction in recurrent myocardial infarctions (124 on placebo, 82 on warfarin), 
and 55% reduction in the occurrence of cerebrovascular accidents (44 on placebo 
and 20 on warfarin) was observed on "intention-to-treat". The incidence of major 
extracranial as well as intracranial bleeding was only 0.6% per year. The authors 
concluded that warfarin significantly reduced mortality and recurrent myocardial 
infarction in patients who had sustained an acute myocardial infarction [70]. 
Summary 
In summary, the value of long-term anticoagulant therapy after myocardial infarction 
has been evaluated in a large number of trials. Most of the early studies lacked 
scientific control groups and their randomization techniques employed could be 
criticized. In addition, they faced laboratory control problems in that a number of 
different laboratory tests were used to monttor anticoagulant therapy. The most widely 
used test was the one-stage prothrombin time test, introduced by Quick in 1935. The 
thromboplastin used to measure prothrombin time was prepared by different methods 
and, consequently, their sensitivity to the reduction of vitamin-K dependent clotting 
factors varied significantly. Therefore, the different thromboplastin reagents used 
which resulted in the same prothrombin time often reflected different levels of 
anticoagulant effects [16]. 
In general, the studies reported in the sixties showed a non-significant 
reduction in mortality, but significantly less thrombo-embolism in the anticoagulated 
group. This was offset by a higher risk of haemorrhagic episodes. In the seventies 
debate over the effectiveness of long-term anticoagulant therapy was prominent, but 
only three major studies were performed: Breddin [56], EPSIM [57], The 'Sixty-Plus' 
Re-infarction Study [58]. The German-Austrian trial (Breddin et.al) and the EPSIM 
research group not only assessed the use of anticoagulant therapy but also that of 
aspirin. In both trials, anticoagulant therapy was as effective as aspirin in reducing 
mortality and morbidity for patients who had sustained a myocardial infarction. The 
Dutch 'Sixty-Plus' Re-infarction Study was carefully performed and controlled but, in 
reality, assessed the risk of discontinuation of long-term anticoagulant therapy in 
patients with a previous transmural myocardial infarction. Cessation of long-term 
anticoagulant therapy induces a 'hypercoagulable state' that is associated with 
increased risk for thromboembolic events [58]. Nevertheless, the positive findings of 
the "Sixty-Plus" study reopened the long standing debate of long-term use of oral 
anticoagulant therapy after acute myocardial infarction. The positive results of the 
Norwegian (WARIS) study were subsequently published in the early nineties. The 
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largest randomized, double-blind, placebo controlled, multicentre clinical trial primarily 
assessed the efficacy of long-term anticoagulant therapy in the prevention of mortality 
in patients who had sustained a recent myocardial infarction was initiated in the 
Netherlands. 
Why the Dutch ASPECT trial? 
The present policy of long-term anticoagulant therapy in the Netherlands is based on 
the results of the three Dutch double-blind trials performed in the late sixties and 
seventies (Loeliger, Meuwissen, and the 'Sixty-Plus' Reinfarction Study) [58]. The 
'Sixty-Plus' Re-infarction Study, a well designed and controlled study, reported a 
positive result for long-term anticoagulant therapy in patients who had survived a 
myocardial infarction. These patients were on anticoagulant therapy for a median of 
six years, the time between the infarction and entry into the trial. However, the 'Sixty-
Plus' study did not answer the question whether oral anticoagulant therapy is 
efficacious in patients with a more recent myocardial infarction. Indeed, the authors 
stated that " .. it is not known whether the patients included are a random sample of 
those with a first myocardial infarction or whether in the period between the first 
myocardial infarction and entry into the study (median 6 years) a selective mechanism 
had in effect weeded out all those but those patients for whom anticoagulant therapy 
was beneficial.." [58]. They concluded that patients who are on long-term 
anticoagulant therapy should continue treatment. Also, the study did not address the 
question of efficacy of long-term anticoagulant therapy, and no information was 
available for younger and female subjects since the population was over 60 years of 
age and 85% male. Finally, the trial did not provide information on the duration of oral 
anticoagulant therapy and the risk of bleeding episodes. Thus, the uncertainties 
regarding the value of long-term anticoagulant therapy in patients with a recent 
myocardial infarction continued to exist after forty years of intense debate [71]. 
It seemed appropriate that the original members of the 'Sixty-Plus' Re-
infarction Study group decided to conduct a study in the Netherlands that would re-
examine the efficacy of long-term anticoagulant therapy in the prevention of 
myocardial infarction and death. The first draft of the ASPECT protocol was approved 
in 1981 by the Federation of Dutch Thrombosis Centres and the ASPECT research 
group was founded under its auspices. Funds were limited at that time, but the 
'Praeventiefonds' of the Netherlands agreed to finance the ASPECT trial in 1985. In 
April 1986, the first ASPECT patient was admitted and in December 1992 the last 
patient was enrolled, bringing the total number of randomized patients to 3404. All 
patients were followed until June 1992. The results of ASPECT are presented in 
appendix A of this dissertation. 
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CHAPTER TWO 
METHODS OF DOUBLE-BLIND TITRATION IN 
THE ASPECT TRIAL OF ANTICOAGULANT THERAPY FOR MYOCARDIAL 
INFARCTION PATIENTS 
AJ Azar, JGP Tijssen, JW Deckers and J Lubsen 
THE CLINICAL TRIAL 
In general, efficacy of treatment can only be judged by comparing groups receiving 
different treatments. This protects against Muench's Second Law which stated that: 
" Results can always be improved by omitting controls" [1 ,2]. 
The concept of controlled clinical trials is not a new one. As pointed out by the 
late A. Lilienfeld, the first successfully conducted trial goes back to the Old 
Testament, Daniel verses 12 through 15. The king assigned to one group of children 
the kings meal, meat and wine, and, to a comparable group of children, vegetables 
and water. Both groups were observed for ten days. The health status of the two 
groups was measured by "our countenance be looked upon". It was observed that the 
countenance of the group of children on vegetables and water "appeared fairer and 
fatter in flesh than those on the king's diet" [3,4]. 
To allow inference about efficacy, the groups compared should indeed be 
comparable. This was recognised, for instance, by James lind in 1747, in an 
experiment regarding the etiology and treatment of scurvy in sailors. The study 
consisted of six dietary regimens with two patients per treatment group. He wrote: 
" ... I took twelve patients in the scurvy on board of the Salisbury at sea. Their cases 
were as similar as I could have them. They all in general had putrid gums, the spots 
and lassitude, with weakness of their knees. They Jay together in one place, living in 
a proper apartment for the sick in the fore-hold; and had one diet common to all ... 
Two of these were ordered each a quarter cider a day. Two others took twenty-five 
gutts of elixir vitriol ... Two others took two spoonful of vinegar ... Two of the worst 
... were put under a course of sea water .... Two others had each two oranges and one 
lemon given them every day. .. The two remaining patients took ... garlic, mustard 
seed, rad raphan, balsam of Per, and gw" myrrh ... The consequences was, that the 
most sudden and visible good effects were perceived from the use of oranges and 
lemons; one of those who had taken them being atthe end of six days fit for duty ... " 
Lind inferred that citrus fruit was essential for curing and subsequently preventing 
scurvy on board ship [3,5]. Fifty years later, in 1795, this was recognized by the 
British Navy, which required the inclusion of limes or lime juice in the diet on board 
of ships. In our century, just after World War II in 1948, the first well designed and 
strictly conducted clinical trial with random allocation was that of the British Medical 
Research Council trial on the efficacy of streptomycin in the treatment of pulmonary 
tuberculosis [6-8]. 
The principles of controlled clinical trials were emphasized by Sir Austin 
Breadford Hill in the late fifties [8-13]. He stated that the first step in conducting a 
clinical trial is the random allocation of patients to the study groups [9, 13]. 
Randomization is the key to proper trial design as it ensures comparability of groups 
by distributing low and high risk subjects equally, thus balancing treatment groups. 
This guarantees validity of comparison between treatment groups [1 ,8-1 0, 14-20]. 
In addition to randomization, double-blinding should be implemented to ensure 
that patient and investigator alike assess the outcome for each treatment group in a 
comparable manner [1, 11, 19-21]. Blinding is required when knowledge of actual 
treatment by both patient and physician may affect the way the outcomes under 
study, or possible side effects, are reported [1, 19]. The drug under study is compared 
to a reference treatment, usually to placebo, in order to eliminate (extraneous) 
placebo effect from the comparison [22]. The use of proper randomization techniques, 
blinding and placebo controls should all be part of the protocol, as has been 
repeatedly emphasized by clinicians, epidemiologists as well as statisticians [10,17]. 
In a randomized, double-blind, placebo controlled trial patients who satisfy the 
requirements of the experiment and who gave consent to participate are randomly 
allocated to either the experimental treatment or the reference treatment. In most 
instances, treatment is administered blindly, such that neither the physician, patient, 
or statistician are aware of treatment allocation. Trial treatment duration can vary from 
hours or weeks to years. Patients are recruited during a certain period of time and 
data on their outcome are continuously gathered and checked, usually by a 
coordinating centre. Finally, after the data have been checked and cleaned, a 
statistical analysis is performed and a report generated, in which the trial results are 
presented and disseminated to the medical world. 
The term "clinical trial", or "therapeutic trial" is used interchangeably in the 
literature [23]. The main objective of a clinical trial is to evaluate to what extent a 
specific therapeutic intervention reduces the incidence of the disease under investiga-
tion, or alters the course of the disease in comparison to a reference treatment. The 
clinical trial in itself should be seen as a device that measures a treatment effect: the 
treatment effect is measured by comparing frequencies of disease outcomes [22]. 
Clinical trials, in most instances placebo controlled, form the final phase of drug 
development but are also performed when the drug is already on the market. 
Multicentre clinical trials are large and complex, often involving a number of 
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institutions and investigators. Adherence to a single protocol is of vital importance to 
unify the conduct of a multicentre trial between the various participating clinical 
centres [24,25]. At the same time, a proper organizational structure is necessary to 
oversee the conduct of the trial [26]. Indeed, the concept of a controlled clinical trial 
not only involves a design and analysis procedure, but also constitutes a broad 
management task with proper planning, implementation, development and quality 
control [27,28]. 
A trial is appropriate in situations when clinicians hold different opinions 
regarding efficacy of certain treatment regimens, in particular in the presence of large 
variations in clinical practice. As indicated in chapter I, one such situation is the use 
of long-term treatment of oral anticoagulant therapy after myocardial infarction. Oral 
anticoagulant therapy was introduced in clinical practice in the early fifties. However, 
the early trials on its efficacy were performed with inappropriate methodologies 
according to modern standards. The 'Sixty-Plus' Re-infarction Study [29] also did not 
settle the anticoagulant issue either because of its specific design (see chapter 1). 
Thus, the controversy regarding the institution of long-tenm oral anticoagulant therapy 
in order to reduce morbidity and mortality after myocardial infarction has continued 
and a new long-term clinical trial was called for. The ASPECT (Anticoagulants in the 
Secondary Prevention of Events in Coronary Thrombosis) trial was designed to be 
a randomized, double-blind, placebo controlled, large scale, multicentre trial that 
compared standard oral anticoagulant therapy with placebo. In this chapter, the 
design and procedures of the ASPECT trial and in particular the methods for double-
blind anticoagulant titration are described. 
THE ASPECT TRIAL 
Objectives 
The main objective of the ASPECT trial was to investigate whether long-term 
anticoagulant therapy initiated shortly after hospital discharge would reduce total 
mortality of post myocardial infarction patients. Secondary objectives were to evaluate 
whether long-term anticoagulant therapy would decrease the incidence of recurrent 
myocardial infarction and whether anticoagulant therapy would affect cerebrovascular 
events and the occurrence or the severity of haemorrhagic episodes. 
Outline of trial design 
ASPECT was a randomized, double-blind, placebo controlled, multicentre, clinical trial 
in patients who had been hospitalized for acute myocardial infarction, with two 
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Figure 2.1 Flow chart of the ASPECT trial. 
CCU, coronary care unit; TC, Thrombosis Centre; PT, prothrombin time 
treatment arms: "active" anticoagulant therapy and matching placebo. Patients were 
eligible for entry up to six weeks after discharge from the hospital provided they met 
the selection criteria and had given informed consent. Treatment was initiated within 
four days after randomization and was continued until trial termination. Randomization 
was stratified by Thrombosis Centre according to the anticoagulant congener 
(acenocoumarin in tablets of 1 milligram (mg) or in tablets of 4 mg, or phenprocoumon 
in tablets of 3 mg) preferred or normally used by the referring cardiologist. Intensity 
of oral anticoagulant therapy was adjusted individually, guided by prothrombin time 
measurements. The target intensity was 10%-5% Thrombotest activity, equivalent to 
2.8-4.8 international normalized ratio (INR) [30]. Therapeutic control was achieved by 
regular visits to the Thrombosis Centre for prothrombin time monitoring. Dosages and 
interval between visits for the placebo group were adjusted in such a manner that 
complete blindness of patient as well as treating physician was ensured. 
While on trial medication, patients were not allowed to receive other 
anticoagulant or anti-platelet drugs. Patients in whom open anticoagulant therapy had 
been administered prior to randomization were requested to return this medication to 
their pharmacy. 
Patients were recruited from September 1, 1986 until December 31, 1991. Data 
on mortality, cardiovascular events, cerebrovascular events and bleeding 
complications were gathered until June 30, 1992, for all patients irrespective of 
premature discontinuation of trial medication [Figure 2.1]. 
Patient selection 
Inclusion and exclusion criteria 
Prior to hospital discharge, male or female patients of any age with a transmural or 
non-transmural myocardial infarction were screened by the treating cardiologist for 
inclusion [appendix B. I]. The diagnosis of the qualifying myocardial infarction (or 
"index" infarction) was based on the presence of at least two of the following three 
criteria: (1) persistent chest pain typical for myocardial infarction; (2) at least one of 
the following cardiac enzymes raised to more than twice the upper limit of normal: 
creatine kinase (CK), MB iso-enzyme of creatine kinase (CK-MB), lactate 
dehydrogenase (LDH), alpha-hydroxybutyrate dehydrogenase (HBDH), serum 
glutamate oxalo-acetic transaminase (SGOT), serum glutamate pyruvate 
transaminase (SGPT); and (3) evolving ST-T segment changes on the electrocar-
diogram. 
Excluded were patients predisposed to bleeding or thromboembolism, such as 
those with a history of haemorrhagic diathesis, severe hepatic or renal insufficiency, 
severe hypertension not controlled by treatment, intracranial bleeding, surgery or 
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trauma of the cerebral nervous system within six weeks prior to hospital admission. 
Also excluded were patients with absolute indication for anticoagulant therapy, such 
as chronic or paroxysmal atrial fibrillation, left ventricular aneurysm, left ventricular 
thrombus (if known), rheumatic valve abnormality, venous or arterial 
thromboembolism, cardiomyopathy, or artificial cardiac valves. Patients on the waiting 
list for coronary bypass surgery and patients with known malignant disease, mental 
disorder, pregnancy, residence outside the study area or with other household 
members receiving active anticoagulant therapy were also not eligible. 
Informed consent 
Patients were informed by their referring cardiologist of the background and the 
objectives of the trial. Also, any possible side-effects associated with anticoagulant 
therapy, such as increased risk of bleeding episodes, were explained. Patients were 
also informed that therapy was initiated by random assignment to either placebo or 
verum. Patients were explicitly informed that they could refuse further participation 
and that they would receive normal standard care in that case. 
The informed consent procedures were carried-out in full accordance with the 
principles ofthe "Declaration of Helsinki" [31]. Patients recruited to the trial gave their 
informed consent orally. The procedures were approved by the Ethical Committee of 
the participating hospitals. Informed consent was also extended to include permission 
for the Coordinating Centre to collect individual data on the clinical course. A 
guideline form was developed in which trial procedures were explained to the patient 
[appendix B.ll]. Also provided was a form which described the follow-up schedules 
and the routine testing procedures of the Thrombosis Centres [appendix B.lll]. The 
patient was given a 'patient card' which provided the information that the patient could 
be either on verum or placebo anticoagulant treatment. The patient was also given 
a telephone number to contact the Thrombosis Centre in cases of emergency. 
Randomization and initiation of treatment 
When a patient agreed to participate, the referring cardiologist notified the regional 
Thrombosis Centre and the Coordinating Centre. The referring cardiologist also 
indicated which anticoagulant congener should be given (acenocoumarin in tablets 
of 1 mg or in tablets of 4 mg, or phenprocoumon in tablets of 3 mg), if the patient were 
to be randomized to verum medication. Within four days up to a maximum of six 
weeks after notification by the cardiologist, the patient visited the Thrombosis Centre. 
Immobilized patients were visited at their home by a nurse. At this first visit, the 
patient was asked to confirm his previously given informed consent. If informed 
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consent was indeed confirmed, the next available randomization number was 
assigned to the patient. 
The anticoagulant drugs and their matching placebo's were indistinguishable 
in appearance. Acenocoumarol was supplied by Ciba Geigy and phenprocoumon by 
Hoffmann-LaRoche. For each anticoagulant congener, bottles containing either verum 
or placebo were delivered to a local pharmacy in the cities where the Thrombosis 
Centres were located. The bottles contained a fixed number of tablets 
(acenocoumarin 1 mg: 400 tablets, 4 mg: 100 tablets, and phenprocoumon 3 mg: 100 
tablets or matching placebo). The pharmacists were also provided with lists of 
treatment codes for each randomization number. For each randomization number, the 
pharmacist prepared a trial medication set of three bottles which contained, 
depending on treatment code, either verum or placebo. Upon the preparation of each 
set, the original label on each bottle was replaced by a new label which indicated the 
ASPECT randomization number (e.g. AMA0001), the anticoagulant congener 'MA' for 
Marcou mar® (phenprocoumon 3 mg) or placebo, or ASI0001, 'SI' for Sintrom® 
(acenocoumarin 4 mg) or placebo, or ASM0001, 'SM' for Sintrom mitis® 
(acenocoumarin 1 mg) or placebo), the number of tablets, and was marked "ASPECT 
medication trial". The pharmacists supplied the Thrombosis Centres with trial 
medication sets for each randomization number and provided additional sets if 
necessary. 
After assignment of the randomization number, patient identifying information 
and the randomization number were entered into the Thrombosis Centre computer 
system. This moment was considered the time of initiation of trial medication and 
therefore the start of follow-up. The patient was seen at the Thrombosis Centre at the 
initial (i.e. randomization) visit (visit 1 ), after 4 to 7 days (visit 2), and subsequently on 
average once a week during the first month and once every 5 weeks thereafter. The 
patient was seen more frequently rr complications occurred. Frequency and character 
of the visits were comparable to those of routine visits to the Thrombosis Centre. At 
each visit, the patient's history was taken, a blood sample was drawn and the 
dosages of the trial medication were adjusted. Dosage adjustment depended on the 
results of the prothrombin times which needed to be maintained between the 
normalized 105 and 180 seconds range corresponding to 10% and 5% or INR range 
of 2.8 and 4.8. The INR expresses the level of anticoagulation in an internationally 
agreed term. It is the common term for the prothrombin time as measured in a patient 
on oral anticoagulant therapy and normalized according to thromboplastin calibration 
standards [32]. The above range has been recommended as the target range for the 
prevention of arterial thrombosis by the Federation of Dutch Thrombosis Centres from 
the early 1970's onwards. 
The Thrombotest reagent was used to determine the prothrombin time [33]. 
When a patient's plasma sample is added to the Thrombotest reagent, the clotting 
time only depends on the activity offactors II (prothrombin), VII (proconvertin) and X 
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(Stuart-Prower factor) [34,35]. In this chapter, as well as in all subsequent chapters, 
the clotting times obtained with Thrombotest are referred to as prothrombin times 
(PT). Based on the prothrombin time results, the dosages were calculated by the 
computer system and checked by the Thrombosis Centre physician in such a manner 
that an optimal therapeutic level was achieved: prothrombin times between the 
normalized 105-180 sec range. 
The laboratory entered the prothrombin times into the Thrombosis Centre 
computer system. Under verum treatment prothrombin times ranged between 105 
and 180 sec and under placebo medication the prothrombin time value was around 
40 sec. For patients on verum the true prothrombin times at all vistts were revealed 
to the Thrombosis Centre physician. In order not to break the double-blinding and in 
an attempt to obtain prothrombin times similar to verum, titration of placebo treated 
patients was simulated. The simulation program was developed by TRODIS and 
TDAS, two institutions responsible for installing and maintaining the anticoagulant 
dosage program at the participating Thrombosis Centres that employed their systems. 
The simulation program was automatically initiated at each visit. The range of the fake 
prothrombin times values was between 80 sec and 210 sees. 
The algorithm was as follows: at the first visit of the ASPECT patient at the 
Thrombosis Centre, the factual prothrombin time were displayed unchanged both for 
patients assigned to verum and to placebo. At visit 2, a multiplication factor of 2 was 
given for patients on placebo matching phenprocoumon for those who used the 
TRODIS system. This was done since phenprocoumon takes a longer time than 
acenocoumarol to exert an effect. For placebo matching acenocoumarol, the 
simulation program was initiated at the second visit for TDAS users only. At all 
subsequent visits, both simulation programs were initiated for all anticoagulant 
congeners in placebo patients. The prothrombin times were displayed as follows: 
values below 45 sec were automatically multiplied by a multiplication factor related 
to the day of visit to the Thrombosis Centre, such that the range of those calculated 
values was between 80 sec and 210 sec. Beginning on January 1, the multiplication 
factor started at a value of 2.3 and increased daily with an increment of 0.1 until the 
maximum value of 4.7 was reached. The multiplication factor then decreased daily 
by 0.1 until the value of 2.3 was reached. This procedure was repeated until the end 
of the year. The transformed (fake) prothrombin times were stored, displayed and 
printed on all computer print-outs in which patients were identified as participants in 
ASPECT. However, the original prothrombin times could not be retrieved by either 
clinical Thrombosis Centre personnel or by computer professionals since they were 
overwritten by fake values. An example is illustrated here. 
On January 8 a true prothrombin time value of 40 seconds was measured on 
the patient on his frflh visit to the Thrombosis Centre. This prothrombin time value was 
entered into the computer system and automatically transformed into a fake 
prothrombin time value of 120 seconds since a multiplication factor of 3.0 was applied 
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at that day. The 120 sec was consequently printed on all patient forms and the 40 sec 
was removed from the computer system. In order to avoid fake prothrombin times 
above the value of 210 sec, the simulation program for TRODIS users replaced 
values exceeding 55 sec with the value of 45 sec. Subsequently, the multiplication 
factor program was initiated. However, for TDAS users, the true prothrombin time was 
stored and displayed to the Thrombosis Centre's physician. A warning signal was 
displayed for placebo prothrombin times exceeding 55 sec for both TROD IS and 
TDAS systems and the patient was identified as a problem case. This procedure was 
developed in order to detect placebo patients inadvertently using verum. The 
multiplication factor program was also suppressed if vitamin K was administered for 
instance preceding a tooth extraction. Based on the prothrombin times (factual or 
fake), the computer system recommended a dose until the next visit, and, in case of 
a high prothrombin time value, recommended the case to be reviewed by the 
Thrombosis Centre physician who manually checked the prothrombin times and made 
a final decision on the dosage of trial medication until the next visit. In the whole 
process it was impossible for the patient, laboratory personnel, Coordinating Centre, 
and Data and Statistics Centre to be aware of treatment allocation. 
The day following every subsequent visit, the patient was informed of the new 
anticoagulant dosage prescription and schedule until the next visit by mail. This 
information was given to the patient by telephone after the first visit. Visits were 
scheduled according to the normal routine procedures of the Thrombosis Centre. The 
computer system scheduled these visits, kept track of the amount of trial medication 
available to the patient and indicated when medication had to be issued and new 
supplies were needed. 
Patients were encouraged to continue trial treatment until June 30, 1992. It was 
the right of the patient, the referring cardiologist or any other physician to discontinue 
trial medication for any reason at any moment. In case of an emergency, the 
cardiologist or any other physician could break the code by determining the 
prothrombin time value in his own laboratory. In the event of conditions in which trial 
medication had temporarily been discontinued, trial medication was resumed when 
possible. Patients who discontinued trial medication prematurely and were not placed 
on open anticoagulant therapy discontinued their regular visits to the Thrombosis 
Centre. 
Data collection and follow-up 
Entry of new patients was reported to the Coordinating Centre on a daily basis by the 
Thrombosis Centre [appendix B.IV). The patient's general practitioner and the 
referring cardiologist were also informed of the patients participation [appendix B.V]. 
Baseline information was gathered from the hospital records. Information on clinical 
CHAPTER 2 39 
events was obtained either at the visits to the Thrombosis Centre or, in case patients 
had discontinued visiting the Thrombosis Centre, from the general practitioner. 
Additional information was gathered from the hospital records, if necessary. 
Baseline information consisted of: age, sex, date of admission and discharge; 
data on previous medical history (angina pectoris, myocardial infarction, 
catheterisation, coronary bypass operation and percutaneous transluminal coronary 
angioplasty and cardiovascular risk factors: hypertension, presence of diabetes 
mellitus, family history and smoking habits); blood pressure and heart rate at 
admission and at discharge; peak blood haematology and bio-chemistry values during 
hospital stay (haemoglobin, haematocrit, thrombocyte count, enzyme values and 
chOlesterol levels); Q-waves at discharge; ventricular tachycardia and fibrillation 
during the first 48 hours; heart failure graded according to the Killip classification 
(worst haemodynamic state during hospital stay); post infarction angina; second and 
third degree AV-block; extension of myocardial infarction; results from investigations 
during hospital stay (echocardiogram, radionuclide scan, ventriculography, coronary 
angiography, thallium perfusion scan and exercise test); interventions performed 
during hospital stay (percutaneous transluminal coronary angioplasty, coronary artery 
bypass grafting, other cardiac or non-cardiac surgery, pacemaker implantation and 
cardioversion or defibrillation); cardiac thoracic ratio at discharge; and medications 
used during hospital stay and at discharge [appendix B.VI]. The last 
electrocardiogram (ECG) prior to hospital discharge was scored according to the 
Minnesota guidelines [36] and the Cardiac Infarction Injury Score [37] was obtained 
[appendix B.VII]. This reading of ECGs was performed by SEAL ('Stichting EGG-
Analyse Leiden') in Leiden. 
Follow-up data included detailed information on the following clinical events: 
death, hospital admissions, bleeding complications and discontinuation of trial 
medication. If a patient had died, information on time, cause and circumstances 
leading to death was collected. If a recurrent myocardial infarction was suspected, 
ECGs, data on occurrence of chest pain and cardiac enzyme values were obtained. 
If a cerebrovascular accident had occurred, relevant information on history and 
clinical course was obtained and a description of the CT-scan result by the 
neurologist or the radiologist was collected. If trial medication was prematurely 
discontinued, the date and reasons were recorded, as was subsequent antithrombotic 
treatment. 
For patients under control of the Thrombosis Centre, all prothrombin times 
values were gathered, irrespective of discontinuation of trial medication. Patients were 
instructed to report any bleeding and were also specifically questioned about bleeding 
at each routine follow-up visit. 
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Outcome events 
Definition of clinical events 
Six major clinical events were considered: (1) death from any cause; (2) vascular 
event; (3) vascular death; (4) recurrent myocardial infarction (fatal or non-fatal); (5) 
cerebrovascular event; and (6) major bleeding. Vascular event was defined as 
vascular death or non-fatal myocardial infarction or non-fatal cerebrovascular event, 
whichever occurred first. 
Vascular death included the following: 1) instantaneous or sudden death (all 
deaths occurring within 1 hour after onset of symptoms); 2) unobserved and 
unexpected death; 3) fatal recurrent myocardial infarction (death within 28 days after 
recurrent myocardial infarction, or the onset of symptoms of acute myocardial 
infarction with subsequent death); 4) death due to congestive heart failure (without 
a recent myocardial infarction within 28 days); 5) fatal cerebrovascular event; and 6) 
death due to extracranial bleeding. All other deaths were considered non-vascular. 
Recurrent myocardial infarction was diagnosed when at least two of the 
following were present [38,39]: (1) a history of chest discomfort of at least 30 minutes 
duration; (2) serial enzyme pattern typical for myocardial infarction with at least one 
cardiac enzyme twice the upper limit of normal; or (3) the development of new Q-
waves (lasting >0.03 seconds (sec) or of a Q-wave equivalent (R >0.03 sec in V1 and 
RIS >1 in V2)) on the standard 12-lead electrocardiogram (ECG). The location of the 
recurrent myocardial infarction was determined from the ECG. Localisations were 
defined as follows: (1) anterior (septal) (leads V1, V2, V3, V4); (2) anterolateral (leads 
I, aVL, V5, V6); (3) inferior (leads II, Ill, aVF); and (4) undetermined. Patients with 
symptoms of acute myocardial infarction who subsequently died were categorised as 
fatal myocardial infarction. 
Cerebrovascular events were diagnosed according to internationally accepted 
criteria for the assessment of cerebrovascular disease [40]. Brief attacks lasting less 
than 24 hours and leaving no residual symptoms were classified as TIA [40]. If death 
occurred within 24 hours, the case was classified as intracranial bleeding unless the 
findings on computed tomography (CT)-scanning indicated otherwise. Events lasting 
beyond 24 hours were specified as cerebral infarction or intracranial bleeding on the 
basis of CT-scanning, if available. If a CT-scan was not available the event was 
classified as unspecified. Of all cerebrovascular events the functional outcome was 
classified as death w~hin 24 hour, death beyond 24 hours, survival wtth no disabiley, 
survival with mild disability (residual symptoms, but no impact on daily activities), 
survival with moderate disabiley (symptoms which significantly interfered w~h normal 
daily activities, with the patient being unable to live independently) or survival w~h 
severe disability (patient completely dependent in all activities of daily living). 
A bleeding was considered major if it lead to death, was clinically suspected 
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or proven intracranial, or in cases of hospital admission for treatment of bleeding. All 
other bleeds including hospital admissions for diagnostic purposes were considered 
minor. 
Classification of clinical events 
The Mortality and Morbidity Classification Committee (MMCC) independently 
reviewed the clinical course of each of the above cases on the basis of a 
standardized patient report prepared by the trial coordinator. A narrative section 
describing the clinical course of the patient was complemented by a summary of all 
pertinent data (ECGs, enzyme values, description of the CT-scans, etc). Potential 
outcome events were reviewed irrespective of discontinuation of trial medication. The 
committee members were blinded to the patient's treatment allocation and were not 
informed of available prothrombin time measurements. The review was first carried 
out in writing [appendix B.VIII]. Cases which evoked differences of opinions were 
reviewed in plenary meetings. In the event of a cardiac complication the case was 
reviewed by the cardiology subcommittee and classified as acute myocardial 
infarction (see above definition), unstable angina pectoris, stable angina pectoris, 
rhythm disturbance, congestive heart failure, dissecting aneurysm, pericarditis, 
endocarditis, elective diagnostic procedures, non-cardiac chest pain, and aspecific 
chest pain. In the event of a neurological complication the case was reviewed by the 
neurology subcommittee. Diagnosis of intracranial haemorrhages were based on the 
findings on CT-scan or autopsy. In all other instances, the case was reviewed by the 
internal medicine subcommittee. 
Definition of outcome events for trial medication effect assessment 
The primary outcome event was death from all causes. Secondary outcome events 
were: (1) vascular event; and (2) vascular death; (3) recurrent myocardial inferction 
(fatal or non-fetal); (4) cerebrovascular event; and (5) major bleeding. 
The main analysis consisted of a comparison of the incidence of the primary 
end-points in the trial medication groups. In this analysis, all randomized patients 
were included irrespective of previous discontinuation of trial medication ("intention-
to-treat" analysis). Analysis involving secondary end-points were carried out as a 
supportive analysis. The occurrence of end-points was compared in terms of the 
hazard ratio; i.e, the risk of the outcome event per unit of time for patients assigned 
to anticoagulant treatment divided by the risk for those assigned to placebo. This 
analysis was based on a comparison of the time to first event or event free survival. 
Hazard ratios were obtained with the use of the Cox proportional-hazards model [41]. 
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The precision of the hazard-ratio estimates were described by 95 percent confidence 
intervals obtained from the Cox model. For "intention-to-treat" analysis censoring was 
applied when the patient died or at the end of follow-up, on June 30, 1992. In a 
subsidiary analysis only those end-points that occurred while the patient was on trial 
treatment (or within 28 days after its cessation) were taken into account ("per-
protocol" analysis). 
Extracranial haemorrhages were reported by number of episodes. Episodes 
that led to hospital admission were separately indicated. 
Intensity of treatment 
Therapeutic anticoagulant quality control achieved by the various participating 
Thrombosis Centres was assessed by calculating the proportion of time spent by the 
patient within the prothrombin time target range of 105 sec- 180 sec corresponding 
to an INR range of 2.8-4.8. To this end, two methods were employed: (1) the 'cross-
section-of-the-files' approach [34,35]; and (2) the cumulative methods [42]. The first 
method is based on a cross section through the total population and considered the 
last prothrombin time 6 months after the date of randomization. The second method 
considered all prothrombin times at 6 months from randomization until the end of trial 
or until the last visit to the Thrombosis Centre. Prothrombin times at 6 months were 
chosen since patients would have reached a stable condition at that time [34]. For 
both methods, all patients under control of the Thrombosis Centre, irrespective of 
discontinuation of trial medication, were included. 
Trial size and interim analysis 
Two types of errors had to be guarded against type I (a) and type II (B) errors. A type 
I error occurs when the trial is declared posttive when in fact the biological difference 
between the anticoagulated and the control group is null. In ASPECT, a 5% 
significance level was set to guard against this type of error. The second type of error, 
type II, fails to declare a difference between the anticoagulated and control group 
when in fact they are different. The investigator must specify a priori the minimal 
relevant clinical difference to be detected with the desired probability (1 - B) of 
reaching that difference. The probabiltty (1 - B) is referred to as the power of the test. 
Sample size calculations were based on cumulative mortality. The estimated 
number of deaths needed and the estimated risk reduction in the control group were 
used to calculate the number of patients required. For a two-sided test with 5% 
significance level, power of 85%, and a 25% reduction in mortality by anticoagulant 
therapy, a total of 350 deaths were required. Under the assumption of a 10% biennial 
total mortality in the control group during an accrual period of 2 years and one year 
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Table 2.1 Cut off points for the one-sided p-value. The trial will be terminated at 
the respective interim evaluations if the one-sided p-value, calculated from the 
available data, is not between the corresponding limits. 
Interim evaluation 
interim 1 
interim 2 
interim 3 
interim 4 
interim 5 
final analysis 
lower boundary 
0.005 
0.005 
0.005 
0.014 
0.023 
0.032' 
upper boundary 
0.95 
0.88 
0.81 
0.74 
0.67 
'This is not a formal boundary but the nominal level that makes the final results 
statistically significant at the 5% level. 
Table 2.2 An example of results that precipitate early termination of ASPECT. It 
was assumed that mortality under placebo is as expected (column 3). Columns 4 and 
5 give the number of deaths in the treated group which cause the p-value to be out 
of its boundaries. 
Interim no. patients no. deaths no. deaths no. deaths 
accrued placebo active active 
(expected) (required) (required) 
interim 1 1000 15 3 26 
interim 2 2000 40 20 51 
interim 3 3000 80 51 92 
interim 4 4000 120 89 130 
interim 5 4000 165 131 173 
final analysis 4000 200 166 
follow-up for all patients after the last patient had been enrolled, a total of 2000 
patients per treatment group was estimated in the original design. 
Since ASPECT was a long-term trial where patient entry and follow-up 
continued over a long period of time, there was an ethical obligation for the Data and 
Monitoring Committee (DMC) to monitor the unblinded data for evidence of adverse 
or beneficial trial medication effect every six months. A specific statistical stopping 
rule was designed before the trial was started [43]. The stopping rule is an aid in the 
decision making process and the DMC was entrtled to deviate from the pre-specified 
stopping rule since secondary end-points and other relevant issues could influence 
the decision to terminate the trial. 
The stopping rule of ASPECT stipulated early termination of the trial at the 
respective interim evaluations ifthe one-sided p-value, calculated from the available 
data was not within the limits given in Table 2.1. This would imply that at the third 
interim analysis the trial would be terminated and positive treatment effect reached 
when p<0.005; the trial would also be terminated but no treatment effect 
demonstrated in case of p>0.81. Table 2.2 shows the number of deaths in the 
anticoagulated group which would cause the p-value to be out of its boundaries based 
on the assumption that mortality in placebo is as expected. Thus, at the third interim 
analysis, with 3000 accrued patients and 80 deaths in placebo, the trial would be 
terminated and positive treatment effect reached in case of a maximum number of 
deaths of 51 in the anticoagulated group: the trial would also be terminated in case 
of 92 deaths in the anticoagulated group but treatment effect would not be reached. 
A statistical stopping rule stipulates under which circumstances the trial will be 
prematurely terminated as in the case of a strong association between use of oral 
anticoagulant therapy and risk of dying. The stopping boundaries employed for the 
group sequential test were based on the one-sided p-value (log rank test) because 
a difference between placebo and anticoagulant therapy was not symmetrical. The 
selected procedure at a 5% significance level guaranteed a power of 84%, compared 
to the original value of 85% if no stopping rule had been employed [43]. As accrual 
was lower than anticipated, six interim analysis were performed on a yearly basis. By 
transforming the stopping rule to an 'a-spending scale' these transformations 
preserved the type I error rate of 5%. These modifications marginally affected the 
power [43]. The yearly interim reports were prepared by the data manager. The 
blinded data were handed over to the secretary of the DMC who had access to the 
patient allocation codes. In such a way the DMC was able to perform an independent 
statistical analysis on an annual basis. 
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Figure 2.2 Participating Thrombosis Centres. 
--
1. Amsterdam 11. Zeeland 
2. The Hague 12. Ttlburg 
3. Groningen 13. Den Bosch 
4. Leiden 14. Hilversum 
5. Rotterdam 15. Eindhoven 
6. Utrecht 16. Am hem 
7. Lichtenvoorde 17. Almelo 
8. Enschede 18. Deventer 
9. Haarlem 19. Hengelo 
10. Breda 
Organization 
Background and history 
The idea for ASPECT was developed by investigators previously associated with the 
'Sixty-Plus' Re-infarction Study. A provisional protocol was approved in 1981 by the 
Federation of Dutch Thrombosis Centres and the ASPECT research group was 
founded under its auspices. Initially this group consisted of the Policy Board and the 
Steering Committee. The first Policy Board meeting was held in 1982. A grant given 
by the Netherlands Thrombosis Foundation in 1984 enabled the development and 
finalization of the study protocol. Additional funds were made available by the 
'Praeventiefonds' of the Netherlands by the end of 1985. In 1986, the Coordinating 
Centre was set up at the Rotterdam Thrombosis Centre and a Data and Statistics 
Centre was set-up at the Thoraxcentre, Rotterdam. Initially, six Thrombosis Centres 
including Amsterdam, Groningen, The Hague, Leiden, Rotterdam, and Utrecht agreed 
to participate. In the course of the trial, the number of participating Thrombosis 
Centres was ex1ended to 19 [Figure 2.2]. These Thrombosis Centres, included 
Almelo, Arnhem, Breda, Den Bosch, Deventer, Eindhoven, Enschede, Haarlem, 
Hengelo, Hilversum, Lichtenvoorde, Middelburg, and Tilburg. 
Research Group 
The ASPECT Research Group consisted of the following unrts [Figure 2.3]: the Policy 
Board (which included the Data Monitoring Committee as a sub-committee), the 
Steering Committee, the Mortality and Morbidity Classification Committee, the 
Coordinating Centre, the Data and Statistics Centre, 62 participating Cardiology 
Departments and 19 participating Thrombosis Centres [appendix B.X]. The 
Cardiology Departments referred the eligible patients to the Thrombosis Centres who 
were responsible for providing the specified anticoagulant treatment to the patient. 
The Coordinating Centre together with the Data and Statistics Centre were 
responsible for proper data collection. The other Committees were established to 
guarantee proper conduct of the trial and quality of operations. 
The Policy Board was composed of senior scientists in the fields of cardiology, 
internal medicine, pharmacology, thrombosis and haemostasis research, biostatistics, 
epidemiology and ethics. They were all appointed by the Federation of Dutch 
Thrombosis Centres. A representative from the 'Sick Funds', a representative from 
the National Institute for Public Health and those appointed by the pharmaceutical 
companies were non-voting members. The Policy Board was responsible for the 
scientific conduct of the trial. Its responsibilities included: (1) approval of the final 
version of the protocol; (2) approval of amendments; (3) monitoring the progress of 
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Policy Board and 
Data Monitoring Committee 
Funding Steering 
Agencies Committee 
Pharmaceutical Coordinating Data and Statistics 
Companies Center Center 
I I 
Monality and 
Morbidity ECGcoding Thrombosis Hospitals 
Oassification Center Services 
Committee 
Fig. 2.3 ASPECT organisation chart 
the trial; (4) advising in issues concerning study decisions and key issues regarding 
data analysis and publication procedures; and (5) to act upon recommendations of 
the Data Monitoring Committee with regards to early termination of the trial. The 
Board met annually from 1987 onwards. The last Policy Board meeting was held at 
the end of 1992 when the primary trial results were disseminated by the data-
manager. 
The Data Monitoring Committee (DMC) was a sub-committee of the Policy 
Board. It consisted of four representatives of the following disciplines: pharmacology, 
biostatistics, epidemiology and internal medicine. The primary responsibilities of the 
Data Monitoring Committee included monitoring the accumulating data for early 
evidence oftreatment effects between placebo and anticoagulant group. In addition, 
the DMC reviewed the quality of operations at the Coordinating Centre, the Data and 
Statistics Centre and the participating Cardiology Departments and Thrombosis 
Centres. The committee met once every year, prior to the Policy Board meeting. The 
DMC was entitled to recommend early termination of the trial to the Policy Board. A 
DMC reporter with access to all patient codes but not involved in the actual execution 
of the trial was responsible for the preparation of the unblinded interim reports. The 
Steering Committee included representatives from each Thrombosis Centre, 
cardiologists, an epidemiologist and statistician. The Steering Committee was 
responsible for the execution of the trial at the operational level. Its responsibilities 
included: (1) selecting Thrombosis Centres and hospitals; (2) providing leadership to 
the Coordinating Centre and to the Data and Statistics Centre; (3) drafting, updating 
and maintaining the trial protocol; (4) reviewing the performances of the centres; (5) 
implementing modifications to the study design established by the policy Board; (6) 
resolving operational problems; and (7) preparing publications and final report 
submission. The Steering Committee met on a monthly basis during the first three 
years (1986 to 1989) and thereafter once every trimester. 
The Mortality and Morbidity Classification Committee consisted of cardiologists, 
internists, pathologists and neurologists. Its members classified death reports, non-
fatal cardiovascular episodes, cerebral vascular events and extracranial 
haemorrhagic bleeding. They were blinded to treatment assignment. The trial 
coordinator acted as secretary to the committee. 
The Coordinating Centre was first located at the Rotterdam Thrombosis Centre 
(1986 through 1990) and thereafter at the Rotterdam Medical Research Group 
(Romeres). The Coordinating Centre staff consisted of a trial coordinator, a data 
manager and administrative staff for data collection and secretarial tasks. The centre 
was primarily responsible for: (1) maintaining communications among the participants 
and proper adherence to the study protocol; (2) distributing trial medications ; (3) data 
collection and quality control; (4) resolving day to day problems; and (5) providing 
patient reports to the Mortality and Morbidity Classification Committee. 
The Data and Statistics Centre was located at the Clinical Epidemiology Unit 
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of the Thoraxcentre, University Hospital Dijkzigt, Rotterdam. The staff consisted of a 
data manager and a scientific computer programmer. The Data and Statistics 
Centre's main functions included: (1) reviewing the data forms; (2) informing the 
Coordinating Centre of outstanding data forms or incomplete and inconsistent data; 
(3) preparing, updating and maintaining the ASPECT computer database; (4) 
preparing the monthly reports submitted to the Steering Committee; and (5) preparing 
the interim reports and the final trial report submitted to the Policy Board Committee. 
All committees, excluding the Data Monitoring Committee (DMC) and the DMC 
reporter were blinded to trial treatment and were not informed of the DMC interim 
results unless the trial was prematurely terminated. 
Quality control 
Treatment compliance and tablets control of randomized patients was accomplished 
by examining the value of the generated prothrombin times. Placebo patients who 
were accidentally administered verum tablets were detected by the Thrombosis 
Centre physician since prothrombin times exceeded 55 sec on these instances. The 
computer was programmed to automatically generate a warning signal for such 
cases. However, placebo patients who missed taking their tablets could not be 
identified. Verum patients who either were administered placebo tablets by accident 
or who missed taking their tablets were identified by the Thrombosis Centre physician 
since the generated prothrombin times were too low. 
Funding agencies 
ASPECT was conducted under the auspices of the Federation of Dutch Thrombosis 
Centres. It was funded by the 'Praeventiefonds' and the 'TromboseStichting' of the 
Netherlands. The anticoagulant drugs and their matched placebo tablets were 
supplied by Hoffmann-LaRoche, and Ciba Geigy, both from Baste, Switzerland. The 
funding agencies had staff representatives in the protocol committee. 
DISCUSSION 
Patient enrollment 
" The common thread that runs through the recruitment experience is the first and 
foremost truth of Muench's Third Law, namely that the number of patients promised 
for a clinical trial must be divided by a factor of at least 10". 
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Muench's Third Law [17,44] was applicable for ASPECT. The patient intake was 
slower than anticipated. Initial recruitment was set originally from September 1, 1986 
until September 1, 1988 with one year follow-up with a total of 4000 enrolled patients. 
However, due to lower than anticipated accrual rate, patient entry was extended until 
December 31, 1991 with six months follow-up for the last recruited patient. A total 
number of 3404 patients were then randomized. Low patient intake was attributed to 
new developments with respect to the institution of thrombolytic therapy and 
increased frequency of angioplasty in patients with an acute myocardial infarction. 
The following measures were taken to increase patient intake: (1) close monitoring 
of all participating centres; (2) presentations at medical meetings to acquaint the 
referral physicians with the trial design, purpose, and type of patients required; (3) 
news- letters to all Dutch cardiologists, with details on the trial progress and the 
number of patients admitted; (4) news articles in the medical and lay press to 
increase motivation and consequently patient accrual; (5) increasing the number of 
participating Thrombosis Centres and hospitals, for the former from six at the start of 
the trial to nineteen and for the latter from eighteen to sixty-two at the termination 
date; finally (6) small compensations were granted to all specialists for each 
randomized patient. 
How was ASPECT blinded? 
In order to insure the double blinding of ASPECT the following criteria were set forth 
by the Steering Committee: (1) patient, attending nurse, treating cardiologist, all 
committees excluding the Data Monitoring Committee (DMC) and the DMC reporter 
were not knowledgeable of treatment allocation; (2) a multiplication factor program 
was employed so that placebo prothrombin times were made similar to verum. For 
this reason, only Thrombosis Centres that provided computerized anticoagulant 
dosage prescriptions were eligible to participate in ASPECT. 
However, one should not underestimate the difficulty of blinding a trial that 
involved dose titration with different anticoagulant congeners. The following problems 
can be visualized. For example, the prothrombin time could have been determined 
by any physician and knowledge of this value would have enabled the identification 
of treatment allocation. For this reason, the patient was requested to reveal to each 
attending physician the patient card that specified his or her enrolment in ASPECT 
as well as the importance of blinding. Dosage adjustment was performed by the 
Thrombosis Centre computer system by checking the factual prothrombin times with 
the given therapy (verum or placebo). If placebo factual prothrombin time values were 
greater than 55 sec then the multiplication factor program was not initiated but a 
warning signal was generated and consequently disclosure of trial medication. This 
safety measure was employed since prothrombin times exceeding 210 sec were an 
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indication for administration of vitamin K. The frequency of disclosure of treatment is 
not known since the factual prothrombin times were overwritten by fake values. The 
Thrombosis Centre personnel speculated that these cases did not exceed 1 %. Finally 
and theoretically, a patient who pricked himself on successive days would be able to 
detect the given therapy. However, members of the Steering Committee speculated 
that such cases would be infrequent. 
Justification for double-blind procedure 
The first largest randomized clinical trial which assessed the benefrts of Dicumarol in 
the prevention of myocardial infarction employed the alternate case method for 
patient recruitment [17,45]. Patients admitted on odd days of the month were 
allocated to anticoagulant therapy, and to placebo on even days. At the end of the 
trial it was noted that patients randomized to anticoagulant therapy out-numbered 
placebo, and the randomization scheme was therefore questioned. At that period of 
time, most physicians favoured anticoagulant therapy over placebo. Apparently, the 
physician rather than chance influenced treatment assignment; consequently, the 
comparability of the two groups and the validity of the results were questionable. 
The nature of ASPECT required the evaluation of clinical observations made 
on individual patients with regard to the effect of oral anticoagulant therapy. These 
evaluations could be assessed either in an open or in a blind design. In an open 
design, the health effects or 'events' are assessed by a physician, aware of the 
treatment group the patient was randomized to. In such a trial, observation of a hard 
endpoint, such as total mortality, would not influence the outcome provided that 
randomization was properly accomplished and not influenced by decisions on 
treatment allocation, methods of data collection and bias in treatment compliance. 
However, evaluations of end-points relating to specific causes of death and definitions 
of myocardial infarction and cerebrovascular events could lead to investigation bias, 
since these are relatively subjecti·Je or 'soft' end-points. The knowledge of the 
physician to treatment assignment may in~uence the occurrence of the 'event' or the 
number of patients discontinuing trial medication. This might have been exerted in a 
conscious or subconscious manner. 
The objective of a clinical trial is to collect data free from treatment related bias 
and treatment related side effects. Therefore, double-blinding was implemented in 
ASPECT with the use of a placebo in view of: (1) the subjectivity involved in defining 
the secondary outcomes; (2) to avoid bias during patient recruitment, data collection, 
data assessment; (3) to eliminate factors unintentionally associated with treatment; 
(4) to preserve the integrity of randomization; and (5) in view ofthe bias which could 
result from selected use of for instance beta blocking agents which have been shown 
to influence prognosis and decrease mortality in patients with myocardial infarction 
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[46,47]. 
Furthermore, to ensure maximum comparability between the treatment groups, 
double-blinding was also implemented with respect to the anticoagulant effect 
induced by the drugs compared, since anticoagulant therapy is not a fixed dose 
therapy. Therefore, dosages, frequency and time between visits for placebo were 
similar to those of patients in the anticoagulated group. 
In summary, trial treatment was given in a double-blind manner, and neither 
the patient nor the treating physician were aware of the treatment the patient 
received. With regard to the physician, this method protected against favouring one 
therapy over the other and against distorting the trial by, for instance, by discontinuing 
study medication to some patients rather than others. The latter would have 
endangered the 'intention to treat' principle which took into account all events 
attributed to the treatment the patient was randomized to, irrespective of 
discontinuation of trial medication. Finally, both physician and patient would be 
unaware of the benefits or side-effects of therapy. In the context of ASPECT, the 
blinded Mortality and Morbidity Classification Committee assessed the health effects 
observed in the patients. Moreover, all committees and the Coordinating Centre, 
excluding the Data Monitoring Committee, remained blinded to treatment allocation 
to avoid bias in interpreting the interim and final results. 
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CHAPTER THREE 
THE ASPECT TRIAL- DATA PROCESSING 
AJ Azar, GA van Es, R van Domburg and JW Deckers 
INTRODUCTION 
" One must go seek more facts, paying less attention to technics of 
handling the data and far more to the development and perfection of 
obtaining them". 
Bradford Hill, 1951 
The success of a clinical trial is dependent on its design, the ability of the physicians, 
the laboratory personnel and others involved to adhere to the predefined study 
protocol and the statistical techniques used for analyzing the collected data [1-4]. In 
addition, its success depends on the quality of the collected data. Collection of data 
should follow standardized methods [5] so as to avoid systematic errors and to 
mm1m1ze random errors. Therefore, the proper planning, development, 
implementation, and quality control are pre-requisites for its successful conduct [6,7]. 
A clinical trial does not only involve a design and analysis procedure but also 
constitutes a broad management task [6], including the development of the study 
protocol, patient recruitment, treatment, data collection, database management, 
follow-up, data analysis and submission of the f!nal report [8,9]. Once the protocol is 
finalized and accepted by the various committees, the procedures therein described 
are used as the manual for actions, operations and definitions by the participating 
centre or, in studies in which no single centre can furnish the required number of a 
selected population, the various collaborating centres [3, 10, 11]. 
In ASPECT, computer systems were employed to assist in data processing 
[2, 12, 13]. Data processing was defined as: 1) data collection; 2) data management; 
and 3) data analysis. Observations and measurements made on individual patients 
were recorded on data forms [14]. These forms were designed such that recording 
information was facilitated and data to be collected was accurate, standardized and 
processible. Information gathered was subsequently entered, stored and ultimately 
validated in the ASPECT database [15, 16]. Data management included the definition 
of the database structure, data entry, editing, monitoring, storage and retrieval 
(queering and report writing) [17, 18]. In order to maximize the quality of the collected 
baseline and 
ECG data 
1 
adminance 
and 1 ASPECT 1 follow-up 
randomisation 
forms 
database data 
1 
prothrombin 
time data 
"cleaned" 
3 interim ASPECT repons 
data. 
t 
final 
repon 
Figure 3.1 Flow ot data in ASPECT. The data entry fields (1), quality control checks 
(2) and data analysis (3) are indicated. 
information, data that was missing, incomplete or outside predefined boundaries was 
managed already at the collection phase [13, 19,20]. Concurrent data collection was 
therefore employed. It is the method in which data collection, entry, storage, checks, 
and analysis are processed simultaneously. Concurrent data collection is essential 
for the optimization of data quality, since it allows for the early detection and correc-
tion of incomplete and out-of range data and facilitates the generation of periodic 
interim reports [1 0, 15]. Such reports assisted the trial committees, in particular the 
Data and Monitoring Committee, in performing its task. Concurrent data collection 
therefore, assured accurate data by assisting in data collection, entry, monitoring, 
storage and retrieval [13, 18]. Errors could occur either during the data-entry phase 
or could result from inconsistencies in the data. During data-entry, on-line interactive 
range and validity checks, such as in range dates, numbers and skipping of not 
applicable parameters were performed. Patient reports were generated after each 
data-entry session and were checked against the values on the medical records for 
keying or transcription errors. Edit queries were run in order to retrieve variables 
which showed inconsiste·ncies during data entry. Data analysis, which involves the 
extraction of information from the data, was considered as a technique to verify the 
collected data [18] and ensured that errors made during the collection phase were 
early detected by adoption of this process. 
In this chapter we will present an outline of the data processing system as 
employed in ASPECT. The system enabled us to achieve high level data quality 
derived from the various collaborating centres while maintaining proper blinding of 
trial treatment groups. 
DATA PROCESSING 
The most important role of the Data and Statistics Centre together with the 
Coordinating Centre, previously described in Chapter 2, was to process the trial data. 
To aid in data collection a variety offorms were designed by the Steering Committee: 
1) Admittance and Randomization Forms; 2) Baseline and Electrocardiogram (ECG) 
Forms and (3) Follow-up Forms. In addition, prothrombin time data, submitted on 
diskettes, were collected as well. In the next section, a description of the processing 
of each of the above items is given. In Figure 3.1 the flow of data, quality control and 
data analysis for each of the above forms is described. 
Admittance and Randomization data 
Two different forms were designed for patient enrollment: Admittance and 
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CC, Coordinating Centre; TC, Thrombosis Centre. 
Randomization Forms. The flow for patient entry into ASPECT is described in Figure 
3.2. 
The Admittance Form was filled-out by the treating cardiologist prior to hospital 
discharge and prior to randomization, for patients who were eligible and had given 
oral informed consent for participation in ASPECT. This form contained information 
on the criteria for eligibility, the patient's sex, date of birth, anticoagulant congener to 
be used, the specialist's name, hospital and general practitioner's names and 
addresses, and name and address of the regional Thrombosis Centre [appendix B.l]. 
This form was sent to the Coordinating Centre. 
The randomization form filled-out at the initial visit at the Thrombosis Centre 
was also sent to the Coordinating Centre. It included information on the Thrombosis 
Centre patient identification number, randomization number and date of 
randomization [appendix B.IV]. The patient's randomization number and date of 
randomization were subsequently entered into the Thrombosis Centre computer 
system. These patients, identified by the randomization number and the treatment 
code (verum or placebo), were tagged. As a matter of course, the randomization 
codes were not assessable to system users. The randomization number was 
subsequently printed on all computer generated patient forms. 
Randomization numbers consisted of a seven digit sequence number, e.g., 
ASI0001. The first letter indicated the Thrombosis Centre name, e.g. 'A' indicated 
Amsterdam. The next two letters represented the registered trade name for the 
anticoagulant congener specified by the referring cardiologist: 'MA' for Marcoumar® 
(phenprocoumon 3 mg), 'SI' for Sintrom® (acenocoumarin 4 mg), and 'SM' for Sintrom 
mitis® (acenocoumarin 1 mg). The four digits represented the patient's sequence 
number. In the example above, ASI0001 was given to the first patient from 
Amsterdam who was assigned to Sintrom® or its placebo. A treatment allocation code 
(verum or placebo) was assigned to each randomization number according to a 
randomization list. Randomization lists, blocked in units of 1 0, were separately 
prepared for each Thrombosis Centre and for each anticoagulant congener. 
Therefore, with 19 Thrombosis Centres and 3 anticoagulant congeners, a total of 57 
strata were formed. Table 3.1 shows the randomization numbers given to the 
ASPECT population. 
For each randomized patient, the Admittance and the Randomization Forms 
were entered into the ASPECT database by the Coordinating Centre personnel. The 
Admittance Form was filed at the Coordinating Centre but not entered into the 
ASPECT database for those patients who withdrew their initially given consent during 
their first visit to the Thrombosis Centre. The Coordinating Centre identified patients 
by their randomization number and date of birth. 
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Table 3.1 Randomization numbers for the ASPECT population 
Thrombosis Marcoumar Sintrom Sintrom mitis 
Centres 
Almelo OMA 0001- 1000 OSI 0001- 0500 OSM 0001 - 1000 
Amsterdam AMA 0001- 1000 ASI 0001- 0500 ASM 0001 - 1000 
Arnhem FMA 0001- 1000 FSI 0001- 0500 FSM 0001 - 1000 
Den Bosch NMA 0001- 1000 NSI 0001- 0500 NSM 0001 - 1000 
Deventer KMA 0001- 1000 KSI 0001- 0500 KSM 0001 - 1000 
TDAS Eindhoven CMA 0001- 1000 CSI 0001- 0500 CSM 0001 • 1000 
Groningen GMA 0001- 1000 GSI 0001- 0500 GSM 0001 - 1000 
Haarlem HMA 0001- 1000 HSI 0001· 0500 HSM 0001 • 1000 
Hengelo IMA 0001- 1000 lSI 0001- 0500 ISM 0001 • 1000 
Hilversum SMA 0001- 1000 SSI 0001· 0500 SSM 0001 - 1000 
Middelburg MMA 0001- 1000 MSI 0001· 0500 MSM 0001 - 1000 
Rotterdam RMA 0001- 1000 RSI 0001· 0500 RSM 0001 - 1000 
Breda SMA 0001- 1000 BSI 0001- 0500 SSM 0001 - 1000 
Den Haag DMA 0001- 1000 DSI 0001- 0500 DSM 0001 - 1000 
TROD IS Enschede EMA 0001- 1000 ESI 0001· 0500 ESM 0001 - 1000 
Leiden LMA 0001· 1000 LSI 0001- 0500 LSM 0001 • 1000 
Lichtenvoorde VMA 0001-1000 VSI 0001· 0500 VSM 0001 • 1000 
Til burg TMA 0001- 1000 TSI 0001· 0500 TSM 0001 - 1000 
Utrecht UMA 0001- 1000 USI 0001- 0500 USM 0001 - 1000 
Prothrombin time data 
After assignment of the randomization number, the following procedures were 
routinely performed by the Thrombosis Centre. At regular intervals, the patient's blood 
sample was drawn to determine the prothrombin time. This is the time needed for a 
blood sample to clot when thromboplastin reagent is added [21]. The obtained 
prothrombin time was either entered automatically from the laboratory computer 
system or manually entered into the Thrombosis Centre computer system. In both 
cases, the laboratory personnel was unaware of the patient's participation in ASPECT 
since only the patient's name and Thrombosis Centre patient identification number 
were indicated on all blood samples. 
Two treatment regimens were employed: "active" anticoagulant therapy 
(verum) or placebo. Under verum treatment prothrombin times are prolonged and 
should range from 105 seconds (sec) to 180 sec. Under placebo medication, 
however, the prothrombin time will not be influenced and will not lie in the magnitude 
of 40 sec. In order to insure the double blinding, described in Chapter 2, a procedure 
was developed which adjusted the prothrombin time values for placebo patients such 
that placebo fake prothrombin times were in the same range as those obtained in 
patients on active anticoagulant therapy. A special computer algorithm was developed 
for this purpose. For each ASPECT patient, this algorithm checked the randomization 
number with the medication code (verum or placebo). For verum patients, the factual 
prothrombin times were entered and stored in the computer system and displayed to 
the Thrombosis Centre physician. For placebo patients the true prothrombin times 
were simulated into fake values by a multiplication factor program (a more detailed 
description of the simulation program was given in Chapter 2). 
The multiplication factor program was developed by two independent 
institutions, TRODIS and TDAS, responsible for installing and maintaining the 
simulation program at the respective Thrombosis Centres that employed their 
systems. The TRODIS system includes a central computer system linked to all its 
users and is primarily based on the pharmaco-kinetics of the coumarin used. TROD IS 
was adopted by 7 of the participating Thrombosis Centres. The TDAS system is a 
personal computer oriented system, and is developed on empirical grounds and trend 
analysis. TDAS was used by 12 of the participating Thrombosis Centres (fable 3.1). 
Because of the different dosage algorithms used in both systems, the multiplication 
factor program was implemented differently for each system. 
For all randomized patients, irrespective whether trial medication was 
discontinued (as long as the patient visited the Thrombosis Centre), information on 
the prothrombin time values with the corresponding date was submitted biannually 
on diskettes to the Data and Statistics Centre. At the Data and Statistics Centre, the 
data were batch entered into an intermediary file. Screening queries were generated 
by the computer programmer who checked for data completeness and validity. 
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Figure 3.3 Flow chart for obtaining the prothrombin time measurements from the 
various participating Thrombosis Centres. Quality control checks are also 
represented. PT, prothrombin time; TC, Thrombosis Centre. 
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Questionable data files were returned to the respective Thrombosis Centres for 
further scrutiny. The files were re-checked and merged into the ASPECT database 
in the absence of ambiguities. Data were not only checked for completeness but also 
for plausibility. This was achieved by performing a statistical analysis on the data. The 
percent of time the patient's prothrombin time within the target range (2.8-4.8 INR) 
[21] was compared to therapeutic achievement usually attained in anticoagulated 
patients treated in that Thrombosis Centre. Discrepant results were discussed in a 
plenary meeting with the data manager and with the Thrombosis Centre. A new file 
was subsequently generated, recontrolled and eventually batch entered into the 
ASPECT database (Figure 3.3). The whole process made it impossible for the patient, 
laboratory personnel, Coordinating Centre and the Data and Statistics Centre to be 
aware of treatment allocation. 
Baseline and ECG data 
All baseline obseNations and 12-lead electrocardiogram (ECG) measurements made 
on individual patients were recorded on Baseline and ECG Forms. The collected data, 
specified in Chapter 2, were abstracted from the medical records of the participating 
hospitals. Relevant clinical information such as the last ECG were photocopied and 
stored at the Coordinating Centre. Nominal and ordinal measurements were coded 
on a Mark Sense Card. Other baseline information of the randomized patients were 
recorded on the Baseline Form. A total of 170 different variables at baseline was 
defined. The ECG Form was scored by SEAL ('Stichting EGG-Analyse Leiden') 
Department in Leiden. A total of 49 variables per ECG were inspected. A random 
sample of 39 EGG's were repeat coded by SEAL: the error rate of 3.2% which was 
found in this analysis was considered acceptable. Discrepant codings were primarily 
reviewed by the trial coordinator and when necessary discussed with SEAL. The final 
ECG was entered into the ASPECT database by the data manager. The data flow 
and quality control steps are represented in Figure 3.4. 
Each Baseline Form was reviewed by the trial coordinator for correctness and 
completeness prior to entry into the ASPECT database. This was performed in order 
to reduce the volume of computer generated error messages. The Baseline Form was 
considered completed when all information was recorded. Data not available were 
coded as missing. The lag time between data acquisition and entry amounted on 
average to two months, with a range of 1 day to 11 months. 
When the form was completed, the patient's seven digit randomization number 
was entered into the ASPECT database. The Coordinating Centre personnel entered 
both the Baseline and the ECG Forms. During data entry, computer edit checks 
defined by the database manager were performed that included: (1) on-line interactive 
range and validity checks, such as in range dates and numbers; (2) out of field data 
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checks, such as gender coded as 3 when only choices 1 or 2 were possible; (3) 
skipping of not-applicable questions, such as skipping exercise test data when no test 
was performed; and (4) syntax checks to differentiate between numeric and 
alphabetic characters, for instance typing a free text in place of a date. For on-line 
checks, the system alerted the user by an audible "beep" sound in case of out of 
range or inconsistent values. Values outside the pre-specified range were only 
entered after additional review. After each data entry session, patient reports were 
generated by the data manager. These were evaluated for completeness and 
consistency and further checked for keying or transcription errors against the values 
on the medical records by the Coordinating Centre personnel. 
Screening queries retrieved variables which showed discrepancies during data 
entry. These included plausibility checks and inventory checks against prior data 
values. Internal protocol violation checks were also implemented. These were 
operations which triggered double defined variables and checked the values of 
variables derived from existing ones; as an example, the age of a subject was 
computed by subtracting date of randomization from date of birth. On various 
occasions, query generated programs were initiated to validate the entered items. 
Also, batch processing at the Data and Statistics Centre was performed to retrieve 
all missing and inconsistent data values. The resulting edit queries were sent to the 
Coordinating Centre for review. A hard copy was documented for data errors detected 
by manual or computer processing. 
Massive updating of selected data items was occasionally performed. A 
retrospective revision of all patient files was performed in such cases. As an example, 
use of acetyl salicylic acid during index admission or at discharge was recorded as 
"use of aspirin: yes/no". At the end of the trial this was redefined into "use of aspirin 
during hospital stay: yes/no" or" use of aspirin at discharge: yes/no". 
During the whole process of data entry, quality control and analysis, the 
Coordinating Centre personnel and the trial coordinator were only permitted to enter 
the raw data and extract data from the database. The data manager only had 
authority to alter data already entered. 
Follow-up data 
The Thrombosis Centres routinely keeps track of all complications occurring in 
patients under oral anticoagulant therapy. This procedure was also adopted for 
patients in the ASPECT trial. All complications referred to as 'events' were centrally 
collected at the Coordinating Centre from the monthly overviews supplied by the 
participating Thrombosis Centres on the 'Clinical Event Form'. A special form was 
designed to acquire information on patients who were no longer followed by the 
Thrombosis Centre [appendix B. IX]. A standardized yearly follow-up letter that 
CHAPTER 3 67 
I Y" follow-up via GP 
I repon re'i~~ed by ~~~>~oordinator 
and b data mana cr 
"' questionable data 
Figure 3.5 Flow chart of handling of events 
during follow-up. Quality control checks are 
also represented. TC, Thrombosis Centre; 
GP, general practitioner; disc. discontinued; 
CC, coordinating centre; MMCC, Mortality and 
Morbidity Classification Committee. 
L"' 
M 
I TC sent monthly overviews to CC l 
=r 
Patient disc. ~its to TC ~ 
l" = 
I follow-up via monthly overviews l 
""T 
relevant events = clinical Event Form 1 
not filled 
1 yes 
I CC contacted hospitals. if ncccs...<::ny I 
I 
r trial coordinat~!repared narrative descri tion l 
I 
MMCC classified outcome event.~ l 
I Clincal Event Form reviewed by trial 
coordinator and entered into database 
J 
r 
rcpon generutcd and reviewed with l Clinical Event Form by data manager (visual checks) 
-.~,.2~, ~ 
l= 
Clinical Event Form completed I 
J. 
r quality control checks 1 (query checks) 
l 
- questionable data "' 
l"= 
r interface to BMDP (ASPECT BMDP-filc) I 
I quality control checks I (data analysis checks) 
1 
- questionable data "" 
T= 
I 'cleaned' ASPECT data I 
inquired on hospitalizations and complications was generated for this purpose by the 
data manager and sent to the general practitioners of these patients. Copies of 
relevant clinical information such as electrocardiograms and enzyme values 
determined during hospital stay were requested. Such ECG's were also scored by 
SEAL, Leiden, and entered into the ASPECT database. All events were classified and 
coded by the Mortality and Morbidity Classification Committee (MMCC). When 
consensus on the diagnosis was reached the Follow-up Form was entered into the 
ASPECT database by the trial coordinator. A patient report was then generated which 
was verified by the data manager for completeness and validity. Questionable data 
were reviewed in plenary meetings by the trial coordinator and the data manager and 
when necessarily returned to the MMCC for a final consensus. Also, query generated 
checks were performed by the data manager. These screening queries retrieved 
inconsistent data which were sent to the Coordinating Centre for inspection. The data 
were subsequently checked and edited in the ASPECT database. A BMDP-file was 
subsequently generated which was ready for analysis. Figure 3.5 shows the flow of 
handling of clinical events during follow-up. During the follow-up period which started 
on April 1986 for the first randomized patient and that ended six years later, any 
deficiencies in baseline collection were corrected prior to trial termination. 
DATABASE MANAGEMENT SYSTEM 
CLINT 
The CLINT clinical trial management system was used for ASPECT [22]. The CLINT 
package was chosen because of the availability of the package at the Data and 
Statistics Centre and of the variety of functions provided by the package. It is 
specifically designed for clinical trials conducted at the Thoraxcentre, University 
Hospital, Dijkzigt, Rotterdam. The package is written in MUMPS (DSM Dec standard 
Mumps, MSM Micromumps and Data Tree) and is available in the Thoraxcentrum 
Utility System (TUS) mainframe computer where the ASPECT database was located. 
The database management system makes use of a hierarchial data structure with a 
varying number of records per patient. 
The CLINT package allows for data acquisition, data processing, consistency 
and range checks. The system verifies data input by internally computerized checks 
which result in an accurate and complete database. Erroneous and missing data are 
therefore spotted early in the trial process. 
The CLINT data dictionary, the heart of the system, contains infonmation on the 
database structure and defines the fonms, data files and follow-up records. Each field 
is specified by type, length, optimal value indicator, valid ranges, default values, 
definition of numeric, text or time variant data and skipping options [23,24]. The 
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system therefore describes and locates each data element in the system. CLINT can 
read, store and retrieve numeric, codes (such as gender with males coded as 1 and 
female as 2), character, text, dates and default data types. The data manager was 
responsible for organizing, defining and maintaining the data dictionary. 
In long term clinical trials, variables are often inserted, modified or deleted. 
Changes in the variable names, their length, type and specification are also common. 
Additionally, new codes for a specific variable are inserted during the process of the 
trial. In ASPECT, the data dictionary was continuously updated. CLINT allowed for 
such modifications without massive restructuring of the database model. 
The system could accept any number of input screens of varying lay-outs. 
Also, adding modules or variables to the data dictionary was possible. The system 
was able to design new screens from existing ones. This was functional considering 
the amount of comparable information gathered, as, for instance, follow-up data 
gathered at various time intervals. At the end of the study, some patients had data 
recorded on as many as 3000 to 4000 variables. 
A special query language was used for report generation and simple data 
analysis. Direct interface to the BMDP statistical packages [25] was essential to 
generate the interim and final report [23]. Variables for each analysis were identified 
by the data manager and transfarred for analysis. The definition of the data file, down 
loading of the desired variables from the database with an automatic format 
generation, group codes, and missing value definitions were processed interactively 
with variable down loading. Data management and data analysis on different 
computer systems led sometimes to inconveniences, but these were more than offset 
by the conveniences of interactive data entry and data management. Interim reports 
were prepared by the data manager on predefined dates. The reports included data 
summaries and exploratory analysis. These were submitted to the DMC reporter who 
was unblinded to the data and was not involved in the operations of the trial. The 
DMC together with the DMC reporter reviewed the unblinded data. Although the 
preparation of the interim reports at reguiar intervals was time consuming and 
tedious, it was essential to monitor for evidence of adverse or beneficial treatment 
effects during the course of the trial. The beneficial byproduct of these interim reports 
was an up-to date database in which extra quality control checks were performed by 
the Data and Statistics Centre on data level and independently by the DMC on 
medical plausibility [appendix A]. 
On the whole, CLINT is a database management system which was relatively 
easy to maintain and conveniently structured for ease of data retrieval and data 
management. 
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Database protection and security 
The continuous fiow of patient data, checks and edits hindered the ability to 
reproduce the database at any specific time. In order to reproduce the interim results, 
the ASPECT database was 'frozen', i.e. saved on tape by the data manager after 
each analysis. 
The ASPECT database was protected against unauthorized users. In order to 
execute any function, the user had to have authorization before entry which included: 
the study name, password and function [24]. At the Data and Statistics Centre, 
Rotterdam, back-up copies of the database were made on a daily, weekly, monthly, 
and yearly basis. The daily, weekly, and monthly copies were saved on tape and 
stored in a safe at the Thoraxcentre; the yearly copy was stored at the Coordinating 
Centre. 
DISCUSSION 
The proper development, implementation, and maintenance of the large and complex 
ASPECT database required a major effort which depended on proper management 
once the protocol was finalized. The primary objective and function ofthe Data and 
Statistics Centre and the Coordinating Centre was to achieve data of high quality. 
Surprising as it may seem now, at that time, however, little information was available 
in the literature regarding standards for data quality control. There was a general 
agreement that quality control is important to assure accurate data, but no systematic, 
clear description on the issue was available [26]. 
We defined data processing objectives as one which insured high quality 
research data. The quality of data from the multicentre ASPECT trial was dependent 
on: (1) the quality of data submitted on each form; (2) the data entry procedures 
including record completeness, interactive system checks [11], consistency, 
plausibility and validity checks; [15,26-29]; (3) concurrent data processing, i.e. 
continuous and simultaneous revision of the data entered, altered, inserted or 
deleted; (4) the techniques used for data processing; and finally, (5) preparation of 
the interim and final reports. 
1. The data forms were individually checked for completeness and consistency 
by the trial coordinator, prior to entry into the ASPECT database. The purpose was 
to detect transcription errors in order to reduce the volume of computer generated 
checks. 
2. Single data entry error rates have been reported by other investigators to be 
exceptionally high [30]. For this reascn, double data entry has been considered 
mandatory when a large number of data-entry people are involved [30]. Double-data 
entry could not be performed in ASPECT because of lack of budget. However, a 
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patient report was generated after each data-entry session. Data audit was therefore 
performed, involving an item-by item comparison of information recorded on the forms 
to that contained in the computer file of that form [31]. This was done by the 
Coordinating Centre staff. In that way, transcription errors and incompleteness in the 
computer files, if present, were detected early in the entry process. Therefore, we 
believe that double data-entry would not have decreased the error rate in a 
substantial or significant way. 
3. The data-manager ran edit queries on the data in order to retrieve 
inconsistencies. Questionable data were returned to the Coordinating Centre for 
further scrutiny. We therefore used the technique of concurrent data processing [15] 
to facilitate the detection and correction of inconsistencies during the collection phase 
ofthe trial. 
Data submitted directly on diskettes, the prothrombin time data, were batch 
entered into an intermediary file. These data were considered to be of high quality 
because of the million of patient years of experience of the Thrombosis Centres with 
this method. To validate the quality of the data batch entered, we analyzed each 
Thrombosis Centre separately and compared these results to those presented by the 
individual centres. The data were only merged into the ASPECT database when this 
process was satisfactory. In this manner, the technique of data-analysis was used to 
verify the data. 
4. Use of a computer data management system can assist in data processing. 
However, data management problems tended to increase as the size and the duration 
of the trial became large. Automated computer assisted editing during data entry was 
effective in minimising errors. However, CLINT had no facility options to check 
whether previously entered data had been modified at a later stage. Therefore, 
ASPECT did not possess a system which contained options of tagging altered 
information and indicating the date, time, user's name as well as reason for editing. 
Such facility could have guarded the system against accidental modifications and 
damages. In some clinical trials, modified data are located in files different from the 
original data file, also called the 'master file' [32]. The use of such an organised 
description of past modifications to the study data, entitled an 'audit trial' of course to 
the retrieval of changes performed on the data [33]. In the case of ASPECT, all 
modifications could only be stored on hard copies and this procedure only increased 
the administrative task. 
Also, the data management system should be controlled prior to operation. 
During its conception, CLINT, the database system used in the ASPECT trial, was a 
young package which substantially changed during the course of the trial. Although 
programming errors during the early phases of the trial occurred more frequently than 
during its later stages, the CLINT computer programmer was at our disposal and 
could assist in changes whenever necessary. 
5. Finally, after data have been checked and cleaned, a statistical analysis is 
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performed and a report is generated [31]. This analysis is done in order to assess the 
comparison of the treatment groups for differences in outcome. In the ASPECT trial, 
data analysis and management were performed on different machines. CLINT was 
used for data-entry and management, and the BMDP statistical package was 
employed for data analysis. A direct interface to BMDP was available. Performing 
data management and data analysis on different machines was inconvenient and 
required continuous support by the CLINT computer programmer. 
In short, the quality of findings is not only the function of the type of data 
generated at the centres, but also related to the manner in which these data were 
processed and analyzed [34,35]. The ASPECT data-base could be considered of high 
quality data because of the technique used in thieving out errors from the system. 
Concurrent data processing was applied in this process. Data collection, entry, 
monitoring, storage, retrieval and analysis were in this case processed 
simultaneously. Transcription errors were immediately detected by item-to-item 
comparison of information recorded on the forms to that contained in the computer 
file of that form. Screening were run to retrieve variables which showed 
inconsistencies during data entry. Finally, data-analysis was performed and a report 
generated in which the trial results were presented and checked independently by the 
Data Monitoring Committee for medical plausibility and completeness. This was 
performed on a yearly basis. 
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CHAPTER FOUR 
ASSESSMENT OF THERAPEUTIC ACHIEVEMENT IN A LONG-TERM 
ANTICOAGULANT TRIAL IN POST-MYOCARDIAL INFARCTION PATIENTSM 
AJ Azar, JW Deckers, FR Rosendaal, 
PFMM van Bergen, FJM van der Meer, JJC Jonker, E Briet 
SUMMARY 
To obtain beneficial effects of long-term anticoagulant treatment and to reduce side 
effects associated with therapy, anticoagulant treatment should be maintained within 
a narrow defined therapeutic range. A number of approaches have been proposed 
to assess therapeutic quality control using the international normalized ratio (INR): 
(1) the 'cumulative-INRs' considered the number of INR values and the 'cross-
section-of-the-files' considered the most recent INR obtained in each patient. The 
results expressed as a percentage of all INR values within therapeutic range; (2) an 
estimate of the percent oftime each patient was within the therapeutic range, where 
the INR change occurred either directly after the first or half-way between visits; 
and (3) total volume of observation time of all patients categorised into classes of 
INR values assuming that INR values changed linearly between visits. These 
approaches were evaluated in 1700 post-myocardial infarction patients on active 
anticoagulant (acenocoumarol or phenprocoumon) therapy. Total treatment period 
comprised 3725 patient-years and 61,471 INR measurements. Target anticoagulant 
level was 2.8-4.8 INR. The data revealed that irrespective of the approach used, 
therapeutic achievement stabilized after 6 months of treatment. Under-
anticoagulation decreased between the first and third month and was again lower 
after six months of treatment. Over-anticoagulation (INR>4.8) occurred between 8% 
to 1 0% at any time interval using approaches 1 and 2, and around 5% of the time 
using approach 3. Acenocoumarol was two and a half times more often outside the 
therapeutic range than phenprocoumon. TDAS® and TRODIS dosage systems 
provided similar levels of effectiveness. 
It is concluded that, therapeutic achievement is recommended to be evaluated 
using the third approach, since it incorporates time and has the most realistic 
assumptions. This approach is also most suitable for assessing anticoagulant 
control, since calculation of incidence rates of events at different intensities can be 
made. Finally, the present data call for an improvement by the standard of control 
for patients during the first 3 months of anticoagulant treatment. 
INTRODUCTION 
The therapeutic effects of anticoagulants in the treatment of patients with deep 
venous thrombosis, pulmonary embolism, prosthetic heart valves, atrial fibrillation 
and heart failure are well established [1 ,2]. However, long-term anticoagulant 
therapy for secondary prevention in post-myocardial infarction patients remains 
controversial [1]. Anticoagulant therapy carries potential bleeding risks and therefore 
requires regular supervision by the clinician and demands patient compliance [3]. 
Prothrombin times have been used for many years to monitor therapy with 
orally administered coumarin derivatives. However, the thromboplastins used to 
measure prothrombin time was prepared by different methods and consequently 
their sensitivity to the reduction of the vitamin K dependent clotting factors varied 
significantly [1]. Therefore, similar prothrombin times often reflected in fact different 
levels of anticoagulant effects. At present, any prothrombin time established with any 
thromboplastin reagent can be translated in an internationally agreed norm: the 
international normalized ratio (INR) [4-8]. With this standardized INR, the intensity 
of anticoagulation can be compared not only between different anticoagulant clinics 
but also between studies on the therapeutic efficacy of anticoagulant therapy. 
A number of methods have been described to evaluate efficacy of 
anticoagulant therapy. The purpose of the present analysis was to compare the 
merits of previously proposed methods, including those considering INR 
measurements only [9-19] methods expressing the time each patient's INR was 
within the therapeutic range expressed as a percentage of the total treatment time 
[20-23] as well as a recently suggested patient-time method [3,24,25]. The study 
population comprised 1700 participants in a secondary prevention trial of post-
myocardial infarction patients with anticoagulant therapy. Since different 
anticoagulant congeners were employed in this trial, we were also able to compare 
therapeutic achievement with the anticoagulant congeners acenocoumarol to 
phenprocoumon. In addition, the therapeutic merits of two different dosage systems 
were evaluated. 
METHODS 
Study patients 
The patients who took part in the ASPECT (Anticoagulants in the Secondary 
Prevention of Events in Coronary Thrombosis) trial comprised the study group. This 
trial has been described in detail elsewhere [see Chapter 2]. In short, ASPECT was 
a randomized, double-blind, placebo controlled, multicentre, clinical trial which 
compared anticoagulant therapy with matching placebo on mortality and 
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cardiovascular events in post-myocardial infarction patients. 
Hospital survivors of acute myocardial infarction were screened for eligibility 
just prior to hospital discharge. Informed consent was obtained in all subjects. 
Patients were randomly assigned to treatment with oral anticoagulant therapy or to 
matching placebo. From September 1, 1986 until December 31, 1991, a total of 
3404 patients entered the trial. Follow-up ended on June 30, 1992. The mean age 
of the patients was 61 years and 80% of the study population was male. 
Oral anticoagulation and dose adjustment 
The target anticoagulant range was 2.8 -4.8 INR [26]. Individual dose adjustments 
were guided by the prothrombin time measurements obtained at regular intervals at 
one of the nineteen participating anticoagulant clinics, the Thrombosis Centres. 
Anticoagulant treatment consisted of phenprocoumon given in tablets of 3 milligram 
(mg), acenocoumarol in tablets of 1 mg or acenocoumarol in tablets of 4 mg. 
At each follow-up visit at the Thrombosis Centre, the patient's history was 
taken and a blood sample was drawn to determine the prothrombin time. The 
prothrombin time is the time needed for a blood sample to clot when a small quantity 
of thromboplastin reagent is added [27]. The obtained prothrombin time was either 
entered automatically from the laboratory computer system or manually into the 
Thrombosis Centre computer system. Based on the results of the test, a proposal 
for a new dosage was calculated by the computer system which was subsequently 
checked by the Thrombosis Centre physician. 
Calculation of the dosage adjustment at the Thrombosis Centres was 
performed by two independent systems: TRODIS and TDAS®. The dosage algorithm 
for TRODIS is primarily based on the pharmaco-kinetics of the coumarin used and 
was employed by 7 of the participating Thrombosis Centres [28]. TDAS® is primarily 
based on empirical grounds and trend analysis and was used by 12 of the 
participating Thrombosis Centres. More information of these dosage systems is 
submitted in the appendix. 
Patients were seen at the inttial (i.e. randomization) visit and on a weekly 
basis thereafter until the prothrombin time measurements were within the specified 
target range. The interval between visits was subsequently prolonged until a 
maximum period of eight weeks. Patients requiring frequent dosage adjustments 
were seen more regularly. While on trial medication, patients were advised not to 
take other anticoagulant or anti-thrombotic medication. At the end of trial on June 
1992, trial medication was discontinued in all patients. 
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Assessment of therapeutic anticoagulant control 
Therapeutic anticoagulant control was assessed using three different approaches. 
In the first approach, which is 'INR-oriented', therapeutic achievement was 
assessed using two techniques: (1a) the 'cumulative INRs' [9-16] which considers 
the number of INR measurements within the target range expressed as a 
percentage of the total number of values obtained; (1b) the 'cross-section-of-the-
files' technique [17-19], that only considered the most recent (within 56 days) INR 
obtained in each patient at pre-defined time intervals. The results of both techniques 
are expressed as a percentage of all INR values within the therapeutic range. 
The second approach considered the number of weeks each patient's INR 
was under- (INR<2.8), within- (INR 2.8-4.8) or above- (INR>4.8) target therapeutic 
range. This approach produced an estimate of the percent of time each patient was 
within the defined ranges [20-23]. In order to allocate the exact time between INR 
measurements, it has been proposed to count the weeks preceding a visit as 
belonging to the INR of that visit [22], or to divide these weeks between the previous 
and subsequent visit [21]. Thus, in each of these two techniques, an abrupt change 
in INR, either at the time of the visit (technique 2a, 'initial-interval step'), or half-way 
between visits (technique 2b, 'mid-interval step') is assumed. 
The third approach, which is 'patient-time' oriented, is a recently proposed 
modification of approach 2 [3,24,25]. In this approach, the total volume of 
observation time of all patients is categorized in classes of INR-values. In this 
approach a more realistic linear change of the INR between successive visits is 
assumed, and small increments in time {days) and in INR (0.1 INR) are used to 
allocate time between two INR determinations. Once the number of days is allocated 
to all these small INR classes, they can be grouped in larger categories or be 
divided in person-time within, above or under the therapeutic zone. Since the unit 
of measurement is patient-time, this approach is suitable for assessment of 
anticoagulant control, but also for the calculation of the incidence of events at 
different INR intensities, since the incidence rate is expressed as the number of 
events over the number of patient-years. 
Data analysis 
For obvious reasons, patients in the trial treated with placebo were not included in 
this analysis: their INR values were not based on actual measurements but were 
generated by a computer to simulate the real anticoagulation procedure. 
Measurements obtained after discontinuation of trial medication were excluded, i.e, 
patients who received open label anticoagulant therapy following trial medication 
discontinuation were not considered irrespective of the reason for cessation of trial 
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medication. In addition, in case the interval between two consecutive INR 
measurements exceeded 56 days, this time period was not included in the present 
analyses, since a linear change over this long period becomes unrealistic. 
Calculation of therapeutic anticoagulant control was performed according to 
the descriptions above. As an example, therapeutic achievement was calculated 
using the three different approaches in a hypothetical patient with live INR 
determinations. The patient had an INR measurement of 2 on May 2, an INR value 
of 4 on May 8, an INR measurement of 3 on May 12, an INR of 5 on May 20, and 
an INR of 3 on May 22. Using technique 1a, the 'cumulative INRs', which considered 
INR determinations only, the patient was under-anticoagulated (INR <2.8) for 20% 
of the INR measurements, while he was within therapeutic range (2.8-4.8 INR) for 
60% and over anticoagulated (INR>4.8) for 20% of the measurements. However, 
using the 'cross-section-of-the-files' technique 1 band considering the last INR value 
only, the patient in this case is considered to be within the therapeutic range for 
100% of the measurements. 
Approach 2 considered the percent of time the patient was within the 
therapeutic range and assumed that the change between two consecutive INR 
measurements occurred either immediately after the first (technique 2a) or half-way 
the interval (technique 2b). Using technique 2a, the patient in question had an INR 
value of 2 for 0 days, a value of 4 for 6 days, an INR value of 3 for 6 days, and of 
5 for 8 days. The patient in question will be under anticoagulated for 0% of the time, 
within the therapeutic range for 60% of the time and over-anticoagulated for 40% of 
the time. Using the 'mid-interval step' technique 2b, the results would be: INR <2.8 
for 15% of the time, INR 2.8-4.8 for 60% of the time and INR >4.8 for 25% of the 
time. 
Approach 3 considered the number of patient-days within specific INR ranges 
and calculates the slope of the line between two consecutive INR measurements. 
These slopes are +0.33 for the first 6 days, -0.25 the next 4 days, +0.25 for the next 
8 days, and -1.0 for the last two days. The INR measurements of the patient will 
thus increase daily with an increment of 0.33 from May 2 to May 8, then decreases 
with 0.25 until reaching the value of 3.0 on May 12, increases thereafter daily with 
0.25 until May 20 and finally would decrease with an increment of 1.0, thus 
producing the different anticoagulation levels: INR <2.8 for 12% of the patient-time, 
INR 2.8-4.8 for 83% of the patient-time and INR >4.8 for 5% of the patient-time. 
In order to investigate which variables independently predicted stability of 
anticoagulant therapy, multivariate modelling with logistic regression analysis was 
performed [29]. The following variables were entered in the model: anticoagulant 
congener (acenocoumarol vs phenprocoumon), dosage system (TDAS® vs 
TRODIS), age (categorised on the basis of the median value) and gender. The 
logistic model yields the odds ratio for each variable, adjusted for the other variables 
in the model. This odds ratio may be interpreted as the relative risk, i.e., the risk of 
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unstable anticoagulant therapy in the presence of the particular variable, relative to 
the risk in the absence of that variable. Confidence intervals were derived from the 
likelihood function. 
RESULTS 
A total of 61,471 INR measurements were performed during 3725 patient years of 
follow-up with a median of 30 determinations per patient (range from 1 to 140). In 
the first month following recruitment, the patients visited the Thrombosis Centre for 
a mean of 4.3 visits, while, on average, 2.2 visits per patient were made in the first 
to second month. After the third month INR detenminations were made once in every 
month on average. 
The number of patients alive and on trial medication during the course of the 
trial is presented in Figure 1. The duration of treatment ranged from 1 day to six 
years. The number of patients on trial medication gradually decreased with time. 
After one month following randomization, 94% of the patients were still receiving 
active anticoagulant therapy compared to 82% at 6 months and 64% at 2 years. 
100% 
80% 
~ 60% 
:;; 
• ~
0 
a. 40% 
20% 
Figure 1: Time of discontinuation of trial medication 
no. patients: 
1186 804 529 271 117 
o%L---------r---------r---------r---------r-------~ 
0 2 3 4 5 
time {years) 
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Intensity of anticoagulation was assessed using the three approaches following 
initiation of treatment (Table 4.1). The data revealed that, irrespective of the 
approach and technique used, therapeutic achievement stabilized after 6 months of 
treatment. The lowest percentage of INR measurements within target range (63%) 
were obtained with the INR-oriented 'cumulative' technique 1a, while the highest 
number (80%) was obtained with the INR-oriented 'cross-section-of-the-files' 
technique 1 b. Approaches 2 and 3 yielded intermediate values. In the first month of 
treatment, a large number of INR measurements were below INR<2.8. This number 
was highest for the 'cumulative' technique 1 a (51%) and lowest using the 'cross-
section-of-the-files' technique 1 b (29%). Using any approach and technique, under-
anticoagulation decreased between the first and third month and was again lower 
after 6 months of treatment. Over-anticoagulation (INR>4.8) occurred between 8% 
to 1 0% at any time interval using approaches 1 and 2, and around 5% of the time 
using approach 3. Although there is no formal way to decide on the superiority of 
any of these approaches we have a preference for approach 3 on theoretical 
grounds. Therefore, all further analyses have been carried-out using this approach. 
Table 4.1 Therapeutic achievement (2.8-4.8 INR) at different time intervals after initiation of 
anticoagulant therapy using the described methods 
Approaches Time (months) Time (years) Total 
0-1 1-3 3-6 6-12 1-2 2-3 
1a 'cumulative INRs' 41% 56% 64% 66% 67% 66% 63% 
1 b 'cs-of-the-files' 61% 76% 80% 81% 81% 80% 80% 
2a 'initial-interval step' 45% 61% 67% 70% 71% 70% 70% 
2b 'mid-interval step' 45% 63% 71% 74% 74% 74% 72% 
3 'linear' change 47% 66% 76% 79% 80% 80% 77% 
cs, cross-section. 
Thirty eight percent of the patients were treated with acenocoumarol given in 
tablets of 1 mg, 7% to acenocoumarol in tablets of 4 mg and 55% to 
phenprocoumon in tablets of 3 mg (Table 4.2). Therapeutic achievement per 
anticoagulant congener is presented in Table 4.3. For both congeners, under-
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Table 4.2 Distribution of patients per coumarin congener and dosage system 
TDAS (n=892) 
TRODlS (n=808) 
Total 
Acenocoumarol 
492 (55%) 
278 (35%) 
770 (45%) 
Phenprocoumon 
400 (45%) 
530 (65%) 
930 (55%) 
Table 4.3 Therapeutic achievement per coumarin congener and dosage system 
TDAS TRODlS Total 
lNR A c. Ph. A c. Ph. A c. Ph. 
< 2.8 23% 17% 30% 17% 25% 17% 
2.8-4.8 72% 80% 66% 79% 70% 80% 
>4.8 5% 3% 4% 4% 5% 3% 
Ac., acenocoumarol; Ph., phenprocoumon. 
The observation time for all patients, broken down by dosage system, is given as 
a percentage of the total observation time for each coumarin congener. 
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anticoagulation was observed to occur more frequently than over-anticoagulation 
irrespective of the dosage system used. Patients treated with acenocoumarol were 
within the therapeutic range 70% of the time compared to 80% for phenprocoumon. 
The therapeutic achievement for both congeners is graphically presented in Figure 
4.2. The data illustrate that 60% of the patients treated with acenocoumarol were for 
at least 70% of the time within the target range, compared to 80% for those treated 
with phenprocoumon. In order to assess the independent contribution of the 
anticoagulant congeners to therapeutic achievement, patients were defined as stable 
when 70% of observation time was spent within therapeutic range, calculated using 
approach 3. The relative risk (RR) of unstable anticoagulation for patients treated 
with acenocoumarol compared to those treated with phenprocoumon was 2.5 with 
a 95% confidence interval (CI) of 2.0 to 3.3, after adjustment for possible 
confounding variables as described in the methods section. 
Of the 19 participating anticoagulant centres, 52% used TDAS® and 48% 
TROD IS dosage systems. Again, the percentage of patient-days within the optimal 
therapeutic range of 2.8-4.8 was calculated using approach 3 and is presented for 
both systems in Table 4.3. The therapeutic achievement within target range for both 
dosage systems is given in Figure 4.3. TDAS® and TRODIS systems provided 
similar levels of therapeutic effectiveness. Using the logistic regression model to 
control for the possible confounding variables, age and gender, and applying the 
same definition of stability as above, the relative risk of unstable anticoagulation 
associated with TDAS® was 1.20 (95% CJ, 0.97 to 1.47). 
DISCUSSION 
The most common approach to characterize anticoagulant therapy is to count the 
number of times the prothrombin time lies within the therapeutic range expressed 
as percentage of the total determinations performed, known as the 'cumulative' 
approach ('INR-oriented' technique 1a). This approach was adopted by a number 
of investigators [9-16]. Although this approach has proven popular, its merits were 
questioned by Duxbury, who asserted that, since unstable patients have more 
measurements performed on them than stable patients, the results of the method 
are unrealistic and biased [21]. He proposed a method in which adequacy of 
anticoagulant therapy was expressed as the number of weeks each patient's INR 
was within the therapeutic range. This approach produced an estimate of the 
percent of the time each patient was within the therapeutic range [21]. This 
approach is oriented towards patient and time but assumed a sudden change in the 
INR between two consecutive visits (technique 2a), in Duxbury's proposal the 
change occurred half-way between these visits (technique 2b). This approach was 
not only used by Duxbury, but also by Raper in 1983 [23] and Coppelstone and 
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Legend to Figure 4.2. 
Therapeutic achievement for the two anticoagulant congeners acenocoumarol and 
phenprocoumon. On the x-axis the percent of patients is indicated and on the y-axis 
the least percent of time the patient is within therapeutic range (2.8-4.8 INR). The 
graph indicates that 60% of the patients treated with acenocoumarol were for at 
least 70% of the time within therapeutic range as compared to 80% for those treated 
with phenprocoumon. Patients were defined as stable when at least 70% of their 
observation time was within therapeutic range. The rate of unstable anticoagulation 
for patients treated with acenocoumarol was 2.5 with a 95% confidence interval of 
2.0 to 3.3. 
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Therapeutic achievement 
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Legend to Figure 4.3. 
Therapeutic achievement for the two dosage system TDAS® and TRODIS is 
presented. On the x-axis the percent of patients is indicated and on the y-axis the 
least percent oftime the patient is within therapeutic range (2.8-4.8 INR). The graph 
indicates that 70% of the patients are for at least 70% of the time within therapeutic 
range. Patients were defined as stable when at least 70% of their observation time 
was within therapeutic range. The rate of unstable anticoagulation associated with 
TDAS0 was 1.20 with a 95% confidence interval of 0.97 to 1.47. 
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Roath in 1984 [22]. The technique suggested by Coppelstone and Roath is a 
modification of the latter in that it is assumed that the INR change between two 
consecutive visits took place immediately after the first [oac 22]. The obvious 
drawback of these techniques is that an abrupt change is unrealistic. A patient who 
has an INR below the therapeutic zone at the first visit, and above at the second 
visit, is assumed at no time to have had an INR within the target zone. This is 
unrealistic, since in changing from below to above the target zone, the patient must 
have spent some time within the therapeutic zone. The approach of Duxbury, 
Copplestone and Roath, is not suitable for centres without automated data facilities, 
and the 'cross-section-of-the files' (technique 1b) has been suggested for such 
centres [17-19]. This technique considered the last INR measured per patient, 
expressed as a percentage of all INR measurements within the therapeutic range. 
This technique was based on the assumption that the probability that a patient's 
prothrombin time is adequate at an arbitrary moment is equal to the proportion of 
time spent by the patient within the therapeutic range. This technique was employed 
by Broekmans and Loeliger in 1982 [19], van den Besselaar in 1988 [17] and Smith 
and Arnesen in 1990 [16]. A drawback of this technique is that it uses only a fraction 
of all INR measurements, i.e, a fraction of all available information. This is also its 
advantage: the technique may easily be implemented in non-computerized 
anticoagulant clinics. The 'patient-time' oriented approach, is a newly proposed 
modification to approach 2 [3,24,25] that is different in two aspects: the use of the 
'linear' technique and the application of the concept of patient-time for the calculation 
of incidence rates. Although Duxbury, Copplestone and Roath did incorporate the 
concept of patient-time in their calculations, they tended to 'individualize it' by 
considering "percent of time a percentage of patients" was within the therapeutic 
range [22]. The 'linear' approach, has the obvious benefit over the previous 
approaches in that it recognises that a patient who is below the therapeutic zone at 
the first, and above target zone at the second visit, must have spent some time 
within the therapeutic zone. Finally, this approach has the potential to incorporate 
the calculation of incidence rate data which is a fundamental measure of disease. 
In the present analysis, these approaches were compared in the large 
ASPECT cohort of 1700 anticoagulated post-myocardial infarction patients. Our 
findings show that the different approaches yield values ranging from 63% to 80% 
for INR values or patient-time within the therapeutic target zone. This illustrates that 
therapeutic quality control data from different studies can be compared only if the 
same approaches are used. Although we have no formal reason to consider the 
truth content of one approach to be better than the other, we have good arguments 
to favour approach number 3: the assignment of INR-time is more realistic than 
either any of the other approaches and the possibility to use the patient-time 
dimension for the calculation of incidence rates has obvious advantages. It should 
be emphasised that, using any approach, a substantial number of subjects were 
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under-anticoagulated in· the first six months and that therapeutic achievement 
stabilised only after the first six months of treatment. In addition, under-
anticoagulation was observed more frequently to occur than over anticoagulation. 
This finding indicates that physicians are more cautious regarding over-treatment 
than under-anticoagulation_ 
Three most recently conducted preventive trials [12, 16,Appendix A] have now 
shown the highly beneficial effects of oral anticoagulant treatment in survivors of 
myocardial infarction. It seems likely that the positive results of these trials were the 
result of a high standard of anticoagulant monitoring (Sixty-Plus 72% of all INR 
within the target range, WARIS 67%, ASPECT 63%, all using the 'cumulative INRs' 
technique). This indicates first, the importance of quality control, and the application 
of comparable methods to express the quality in. Secondly, it may be noted that 
even in these carefully designed and performed trials, the target zone was not 
reached in a substantial part of the time. This illustrates the need for analysis on the 
basis of achieved level of intensity, and not on an intention-to-treat basis only [24, 
and see Chapter 5]. 
An interesting finding is that the long-acting anticoagulant phenprocoumon 
was associated with better therapeutic control than the short acting anticoagulant 
acenocoumarol. This finding has been reported by other investigators [30]. After 
correcting for dosage system, anticoagulant centre, age and gender, the results 
again indicated that patients treated with acenocoumarol were two and a half times 
more likely to be outside the therapeutic range than those treated with 
phenprocoumon. 
The participating anticoagulant centres utilized either the TRODIS or the 
TDAS® dosage system. Use of the TRODIS system appeared to result in more 
stable anticoagulation than with the TDAS® system. It must be noted, however, that 
this may be a reflection of differences between centres, who all used only one of the 
two systems, rather than a true difference between the two dosage systems. 
In conclusion, in this article we compared different approaches to assess 
therapeutic achievement, as well as therapeutic achievement for two frequently used 
anticoagulants and different anticoagulant dosage systems. The newly proposed 
approach ('patient-time') is recommended as the method of choice since it 
incorporates time and has the most realistic assumptions. This approach is also 
most suitable for assessing therapeutic anticoagulant control, since calculation of 
incidence rates of events at different intensities can be made. In addition, 
comparison of the therapeutic achievement of the two most used anticoagulant 
congeners in the Netherlands revealed that the short acting congener 
acenocoumarol was more likely to be outside the therapeutic range than the long 
acting phenprocoumon. However, comparison of the therapeutic achievement ofthe 
two dosage systems used in this country showed minor differences. Finally, the 
present data call for an improvement by the standard of control for patients during 
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the first 3 months of anticoagulant treatment. 
APPENDIX 
The participating Thrombosis centres utilize computers to establish the dosage for 
its patients under anticoagulant therapy. Two programs of dosage algorithms have 
been developed: TRODIS based on pharmacokinetic findings and TDAS"', on 
empirical grounds. Both programs are able to provide automated dosage 
prescription for at least 70% of the patients. Although, the physician checks the 
results of the computer generated out-puts, the dosage system makes use of 
predefined INR measurements preceding the visit, the interval between 
measurements and patient's relevant medical data. Details of the TROD IS dosage 
algorithm have been previously described by Wiegeman etal [28]. 
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CHAPTER FIVE 
OPTIMAL INTENSITY OF ORAL ANTICOAGULANT THERAPY IN POST-
MYOCARDIAL INFARCTION PATIENTS 
SUMMARY 
AJ Azar, SC Cannegieter, JW Deckers, FR Rosendaal, 
PFMM van Bergen, JJC Jonker, E Briel 
Treatment with oral anticoagulant therapy entails a delicate balance between over-
(risk of bleeding) and under- (risk of thromboemboli) anticoagulation. However, the 
optimal intensity of therapy in post-myocardial infarction patients required to prevent 
the occurrence of either event (thromboembolic and haemorrhagic) is not known. 
Here, incidence rates associated with specific international normalized ratio (INR) 
intervals were calculated for bleeding and thromboembolic complications in 3404 
post-myocardial infarction patients enrolled in the ASPECT (Anticoagulants in the 
Secondary Prevention of Events) trial. Total treatment period was 7213 patient-
years. Major bleeding occurred in 57 (0.8/1 00 patient-years) and thromboembolic 
complications in 397 patients (5.6/100 patient-years). 
A Poisson regression analysis was performed to determine the independent 
risk of event associated with INR-specific intervals, after adjustment for possible 
confounding variables. Based on INR measurements obtained within 28 days from 
the event and relative to INR intensities below 2, the rate ratio of major bleeding 
associated with INR values between 2 and 3 was 0.2 with a 95% confidence interval 
(CI) of 0.1 to 1.3. The rate ratio was 0.6 at INR between 3 and 4. An 80% increase 
in bleeding risk was associated with INR measurements between 4 and 5, and 5 fold 
increase for INR values exceeding 5. The rate ratio of thromboemboli associated 
with INR values between 2 and 3 was 0.3 with a 95% Cl of 0.2 to 0.6, a reduction 
of 70% compared with INR intensities below 2. An 80% reduction of thromboemboli 
was obtained at INR intensities between 3 and 4, as well as for INR intensities 
above the value of 5. The intensity of anticoagulant therapy at which the incidence 
of bleeding and thromboembolic complications was lowest was between the INR 
range 3.0-4.0. Other significant predictors for major bleeding and thromboemboli 
included higher levels of systolic blood pressure and age. Female patients showed 
a higher trend for bleeding than males. 
These results suggest the optimal intensity of long-term anticoagulant therapy 
for post-myocardial infarction patients to lie between 3.0 and 4.0 INR. 
INTRODUCTION 
The narrow therapeutic range of oral anticoagulant therapy mandates careful and 
frequent monitoring of patients with conditions for which the therapeutic benefit of 
anticoagulant therapy has been established, i.e., in the treatment of patients with 
deep venous thrombosis, pulmonary embolism, atrial fibrillation, severely diminished 
left ventricular function, or in subjects who have undergone major surgery, or 
implantation of endovascular prosthetic materials [1]. However, in conditions in 
which the therapeutic value of long-term anticoagulant therapy is still controversial, 
the risk of life-threatening side effects, in particular that of bleeding complications, 
becomes an impediment to its widespread utilization [1-5]. One such condition is the 
use of anticoagulant therapy in the secondary prevention in patients after a 
myocardial infarction [2,6,7]. 
The findings of the three most recently performed post-myocardial infarction 
trials [8,9,Appendix A] suggested substantial benefits of long-term anticoagulant 
therapy in mortality by achieving lower rates of thromboembolic disorders including 
myocardial infarction and of cerebrovascular events. The trials demonstrated that 
intensive and stable anticoagulant therapy reduced the rate of reinfarction by 34% 
to 55% and cerebrovascular events by 40% to 55%. In these investigations, a high 
quality of anticoagulation was achieved, since 63% to 74% of the prothrombin time 
measurements were within the therapeutic international normalised ratio (INR) range 
between 2.5-5.0. Therapeutic quality control was expressed as the total number of 
INR measurements obtained, the so called 'INR-oriented' assessment of 
anticoagulant therapy (see Chapter 4). 
Randomised trials conducted to compare two intensities of oral anticoagulant 
therapy offer little information on the optimal intensity of anticoagulant therapy, not 
only because the target level is arbitrarily chosen, but also because the intensity of 
anticoagulant therapy actually achieved is not taken into account [1 OJ. Therefore, it 
is not known which intensity of anticoagulant therapy offers the optimal benefit-risk 
ratio, i.e., the optimal balance between prevention of thromboembolic events and 
bleeding complications. 
In order to determine the optimal intensity of anticoagulant therapy, the 
occurrence of haemorrhagic as well as arterial thromboembolic complications were 
quantitatively evaluated with regard to the INR level preceding the event, enabling 
the calculation of INR-specific incidence rates. The study population comprised 3404 
post-myocardial infarction patients randomised to anticoagulant therapy or placebo. 
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METHODS 
Patients 
Subjects who took part in the ASPECT (Anticoagulants in the Secondary Prevention 
of Events in Coronary Thrombosis) trial comprised the study group. This trial has 
been described in detail elsewhere [see Chapter 2]. In short, ASPECT was a 
randomized, double-blind, placebo controlled, multicentre, clinical trial which 
compared anticoagulant therapy with matching placebo on mortality and 
cardiovascular events in post-myocardial infarction patients. 
Hospital survivors of acute myocardial infarction were screened for eligibility 
just prior to hospital discharge. After informed consent was obtained, patients were 
randomly assigned to treatment with oral anticoagulant therapy or to matching 
placebo. From September 1, 1986 until December 31, 1991, a total of3404 patients 
entered the trial. The study population contributed 7213 patient years offollow-up. 
Oral anticoagulation and dose adjustment 
The target anticoagulant range was 2.8 - 4.8 INR [11-14]. Individual dose 
adjustments were guided by the prothrombin time measurements obtained at regular 
intervals at one of the 19 participating anticoagulant clinics. Anticoagulant treatment 
consisted of phenprocoumon, acenocoumarol or matching placebo tablets. Double-
blinding was maintained at the anticoagulant clinics by employment of a 
computerized dosage algorithm that automatically converted (not prolonged) 
prothrombin times to sham values within therapeutic range in placebo treated 
patients. 
At each follow-up visit to the anticoagulant clinic, a shOrt history was taken 
and a blood sample was drawn for determination of the Thrombotes!®, a modified 
prothrombin time test [15]. The prothrombin time is the time needed for a blood 
sample to clot when a small quantity of thromboplastin reagent is added. Patients 
were seen at the initial (i.e. randomization) visit and on a weekly basis thereafter 
until the prothrombin time measurements were within the specified target range. The 
interval between visits was subsequently prolonged until a maximum period of eight 
weeks. Patients requiring frequent dosage adjustments were seen more regularly. 
While on trial medication, patients were strongly advised not to take other anti-
thrombotic (including anti-platelet) medication. At the end of trial on June 1992, trial 
medication was discontinued in all patients. 
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Definition of clinical events 
The following clinical events were considered: major bleeding and thromboembolic 
complications. 
Bleeding was considered major if: (1) it led to death; (2) was clinically 
suspected or proven intracranial (cerebrovascular event leading to death within 24 
hours was considered to be caused by intracranial bleeding unless the findings on 
computed tomography (CT) scanning indicated otherwise. In all other instances, the 
diagnosis of an intracranial haemorrhage had to be confirmed by findings on CT-
scan [16]); or (3) led to hospital admission for treatment of bleeding (hospital 
admission for diagnostic purposes only was not considered a criteria for major 
bleeding). 
Thromboembolic complications included: (1) instantaneous or sudden death, 
occurring within 1 hour after onset of symptoms; (2) recurrent myocardial infarction 
documented by at least two of the following [17,18]: (a) history of chest discomfort 
of at least 30 minutes duration; (b) serial enzyme pattern typical for myocardial 
infarction with at least one cardiac enzyme exceeding twice the upper limit of 
normal; or (c) the development of new Q-waves (lasting >0.03 seconds (sec) or of 
Q-wave equivalent (R >0.03 sec in V1 and RJS >1 in V2)) on the standard 12-lead 
electrocardiogram (ECG). Myocardial infarction was also diagnosed when death 
occurred within 28 days after hospitalization for recurrent myocardial infarction; (3) 
cerebral infarction, classified according to internationally accepted criteria and 
diagnosed on the basis of the CT-scan findings; and (4) other arterial 
thromboembolic complications. 
Information on clinical events was obtained directly from the patients when 
they visited the Thrombosis Centre or from their general practitioners. In case of 
hospitalization, additional information was retrieved from the hospital records. The 
diagnosis and classification of clinical events were established by the Mortality and 
Morbidity Classification Committee of the ASPECT trial who independently reviewed 
the clinical course of each case on the basis of a review of a standardized patient 
report. The committee members were blinded to treatment assignment and were not 
informed of actual prothrombin time measurements. 
Assessment of optimal intensity 
Incidence rates were calculated for different achieved intensities of anticoagulant 
therapy. To obtain the INR-specific incidence rate, data on the INR at the time of the 
untoward event, either bleeding or thromboembolic complications, for different 
intensities were entered in the numerator, while the denominator comprised the sum 
of observation times of all patients at each INR intensity. Patients who were treated 
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with placebo were included in the analysis, since their achieved INR intensity 
corresponding to 'lack' of anticoagulation is of course known and corresponds to 
INR less than 2, at the time of an event, as well as at all other times. INR-specific 
incidence rates were calculated for intervals of 0.5 INR. The optimal intensity of 
anticoagulant therapy will lie at the level at which the incidence of bleeding and 
thromboemboli is lowest, i.e., where the incidence of complications, whatever their 
type, is lowest. 
'Numerator data: events' 
The instantaneous INR measurement at the time of event (bleeding or 
thromboembolism) was retrospectively obtained from the hospital records. lfthe INR 
measurement was not available at the date of event, the last INR measurement 
obtained within a maximum period of 28 days prior to the event was considered. INR 
measurements were considered missing in all other instances. INR measurements 
of placebo patients were assumed to have a value of less than 2 at the time of 
event. 
In a subsequent, more strict analysis, we only included events for which an 
INR measurement obtained no more than three days prior to the event was 
available, whereas all others were considered missing. 
Patients were censored when an event was reached, after 28 days following 
cessation of trial medication or at the end of follow-up, on June 30, 1992, whichever 
occurred first. In case patients experienced more than one event, only the first was 
considered. Four patients with a major bleeding due to an invasive interventional 
procedure during hospitalization were not included in this analysis. 
'Denominator data: INR-time' 
The total number of patient days within INR-specific intervals was entered in the 
denominator (see Chapter 4). In order to calculate the time each patient was within 
an INR-specific range, we assumed that the INR changed linearly between visits 
(see Chapter 4). Patients who used placebo were considered to have INR 
measurement below 2 during the total period of follow-up. 
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Poisson regression analysis 
A Poisson regression analysis [19] was used to calculate the relative risk of bleeding 
and thromboembolic events associated with INR-specific intervals after adjustment 
for age, sex, type of coumarin congener and blood pressure. Age and systolic blood 
pressure, measured during hospitalization for the index myocardial infarction, were 
categorized on the basis of the median value, i.e, below or above 60 years of age, 
and below or over 120 mmHg. The incidence rate ratios obtained from the model 
may be viewed as relative risks, i.e., the risk of event relative to the reference risk 
factor category controlling for the other risk factors. The precision of the rate ratio 
estimates were described by means of 95% confidence intervals obtained from the 
Poisson distribution. In all analyses, the incidence rate associated with INR values 
below 2 was used as reference. 
Table 5.1 Selected demographic, baseline and randomisation characteristics 
Anticoagulant Placebo Total 
No. of patients (%) 1700 (100) 1704 (100) 3404 (100) 
Mean Age,yr (SO) 61 (11) 61 (11) 61 (11) 
Gender(%) 
Male 1370 (81) 1350 (79) 2720 (80) 
Female 330 (19) 354 (21) 684 (20) 
Trial medication (%) 
Phenprocoumon 930 (55) 935 (55) 1865 (55) 
Acenocoumarol 770 (45) 769 (45) 1539 (45) 
Mean SBP,mmHg (SO) 119 (16) 119 (16) 119 (16) 
yr, year; SO, standard deviation; SBP, systolic blood pressure at hospital discharge. 
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RESULTS 
A total of 1700 patients were randomised to anticoagulant therapy (with 3725 
patient-years offollow-up) and 1704 to placebo (with 3488 patient-years of follow-
up). The baseline characteristics of the patient groups are presented in Table 5.1. 
The mean age of the patients was 61 years, 80% were male, and 55% of the 
patients received phenprocoumon and 45% acenocoumaro/. The mean follow-up per 
patient was 2.1 years. Within one year of randomization, 76% of the patients in the 
anticoagulant group were still receiving active therapy compared to 70% in placebo. 
The incidence of major bleeding is shown in Table 5.2. Fifty-seven cases of 
major bleeding (0.8/1 00 patient-years) occurred, of which 51 in the anticoagulated 
(1.4/100 patient-years) and 6 in the placebo group (0.2/100 patient-years). Fatal 
bleeding (9 patients) was only observed in the anticoagulated group (O.V1 00 patient-
years). The most frequent sites of major extracranial bleeding were the gastro-
intestinal tract (26 in the anticoagulated group and 2 in placebo) and 10 muscular 
haematoma in the anticoagulated group. 
The incidence of thromboembolic events is presented in Table 5.3. A total 
number of 397 thromboembolic complications (5.6/1 00 patient-years) occurred of 
which 118 were fatal. One-hundred and twenty-seven thromboembolic events 
(3.4/1 00 patient-years) were observed in the anticoagulated group and 270 in 
placebo (7.9/1 00 patient-years). The major thromboembolic events included sudden 
death (69 patients), recurrent myocardial infarction (293 patients) and cerebral 
infarction (34 patients). 
INR measurements obtained at hospital admission or within 3 days prior to 
the occurrence of major bleeding were available in 42 cases and within a time frame 
of 28 days in 55 patients. INR measurements within 3 days from thromboembolic 
complication were obtained in 294 patients and within 28 days in 375 patients. The 
total number of patient-years within INR-specific intervals for the combined event 
(bleeding and thromboemboli) were: 3559 patient-years (INR<2), 838 patient-years 
(INR 2-3), 1775 patient-years (INR 3-4), 564 patient-years (INR 4-5), and 82 patient-
years (INR>5). 
INR-specific incidence rates based on measurements obtained within 3 days 
for major bleeding and thromboembolic complication are presented in Figure 5.1. 
The incidence of thromboembolic complications was highest, 78 per 1000 patient-
years, for anticoagulant intensities less than 2 INR. The incidence of 
thromboembolic events at anticoagulant intensities between 2 and 3 INR was 14 per 
1000 patient-years, and amounted to 11 per 1000 patient-years for anticoagulant 
intensities within the range of 4 to 5 INR. On the other hand, the INR-specific 
incidence rate of bleeding was lowest, 2 per 1000 patient-years, at anticoagulant 
intensities less than 2 INR and increased to 19 per 1000 patient-years at 
anticoagulant intensities between 4 and 5 INR. The incidence of bleeding was 
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Table 5.2 Incidence of major bleeding during follow-up 
Intracranial bleeding 
Fatal 
Non-fatal 
Extracranial bleeding 
Fatal 
Non-fatal 
First major bleeding 
py, patient-years. 
14 
Anticoagulant 
(n=1700) 
7 
7 
37 
2 
35 
51 (1.4/100py) 
Placebo Total 
(n=1704) 
15 
0 7 
1 8 
5 42 
0 2 
5 40 
6 (0.2/1 COpy) 57 (0.8/1 COpy) 
Table 5.3 Incidence of thromboembolic events during follow-up 
Sudden death 
Recurrent M I 
Fatal 
Non-fatal 
Cerebral infarction 
Fatal 
Non-fatal 
Other arterial thrombo-emboli 
Ftrst maJor thromboemboll 
35 
86 
6 
127 
Anticoagulant 
(n=1700) 
16 
70 
0 
6 
(3.4/1 COpy) 
34 
207 
Placebo 
(n=1704) 
31 
176 
28 
2 
26 
4 
270 (7.9/1 COpy) 
Total 
69 
293 
47 
246 
34 
2 
32 
5 
397 (5.6/1 COpy) 
·sudden death/recurrent Mil cerebral infarction/other arterial thromboemboli whichever event occured 
first. Ml, myocardial infarction; py, patient-years. 
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highest, 66 per 1000 patient-years, at anticoagulant intensities exceeding 5 INR. 
The optimal anticoagulant intensity 
INR-specific incidence rates with corresponding 95% confidence intervals, based on 
INR measurements obtained within 3 days from event, are presented in Figure 5.2, 
for the combined events of bleeding as well as thromboemboli. The incidence of 
complications is observed to be highest at INR values below 2 and above 5. The 
intensity at which the INR-specific incidence rates of the curve is lowest is the 
optimal intensity: between 3 and 4 INR. When the analysis was repeated for INR 
measurements obtained within 28 days from the event, the optimal intensity 
remained essentially unchanged. 
Results of the Poisson regression analysis, performed to determine the 
independent risk of event (bleeding or thromboembolic) associated with INR-specific 
intervals, after controlling for age, sex, systolic blood pressure at discharge and type 
of coumarin congener, are presented in Table 5.4. Based on JNR measurements 
obtained within 28 days from the event and relative to JNR intensities below 2, the 
rate ratio of major bleeding related to INR intensities between 2 and 3 amounted to 
0.2 with 95% confidence interval (CI) of 0.1 to 1.3. The rate ratio was 0.6 at INR 
between 3 and 4, a reduction of 40% and the rate ratio of bleeding associated with 
INR measurements between 4 and 5 was 1.8, an increase of 80%. However, a five 
fold increase in the rate ratio of bleeding was observed in case JNR measurements 
exceeded the value of 5. 
On the other hand, the rate ratios of thromboemboli associated with INR 
intensities between 2 and 3 was 0.3 with a 95% CJ of 0.2 to 0.6, a reduction of 70% 
compared with INR intensities below 2. An 80% reduction of thromboemboli was 
obtained at INR intensities between 3 and 4, as well as for INR intensities above the 
value of 5. 
Other significant predictors for major bleeding and thromboemboli included 
higher systolic blood pressure and age. Female patients showed a higher trend for 
bleeding than males. 
In all analyses, incidence rates based on INR measurements obtained within 
3 days from the event were slightly higher than those achieved when the JNR 
measurements were obtained within 28 days. 
DISCUSSION 
In this analysis involving over 7000 patient-years of follow up with almost 60 major 
bleedings and approximately 400 thromboembolic events, the optimal intensity of 
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Table 5.4 INR-specific rate ratios for haemorrhagic and thromboembolic complications 
INR 
<2 
2-3 
3-4 
4-5 
>5 
Age (years) 
< 60 
"'60 
Gender 
Male 
Female 
Anticoagulant congener 
Phenprocoumon 
Acenocoumarol 
SBP (mmHg) 
,;; 120 
> 120 
INR< 3 days 
RR (95% Cl) 
Haemorrhagic events 
1.0 
0.3 (0.1-3.3) 
0.7 (0.1-5.4) 
3.1 (0.4-24) 
8.2 (1.0- 65) 
1.0 
1.9 (O.g-4.0) 
1.0 
1.9 (0.9-3.7) 
1.0 
1.0 (0.5-2.0) 
1.0 
2.0 (1.0-3.8) 
INR< 28 days+ 
RR (95% Cl) 
1.0 
0.2 (0.1-1.3) 
0.6 (0.1-2.4) 
1.8 (0.4-7.8) 
4.9 (1.1- 22) 
1.0 
1.5 (0.8-2.8) 
1.0 
1.7 (0.9-3.2) 
1.0 
0.9 (0.5-1.6) 
1.0 
2.0 (1.1-3.6) 
Thromboembolic events 
INR 
<2 
2-3 
3-4 
4-5 
>5 
Age (years) 
< 60 
"'60 
Gender 
Male 
Female 
Anticoagulant congener 
Phenprocoumon 
Acenocoumarol 
SBP (mmHg) 
,;; 120 
> 120 
1.0 
0.2 (0.1-0.6) 
0.1 (0.1-0.4) 
0.3 (0.1-1.2) 
0.2 (0.1-1.8) 
1.0 
1.4 (1.0-2.0) 
1.0 
1.1 (0.8-1.6) 
1.0 
0.9 (0.4-2.1) 
1.0 
2.6 (1.2-5.8) 
"Last INR value w·rthin 3 days from event. 
+Last INR value within 28 days from event. 
1.0 
0.3 (0.2-0.6) 
0.2 (0.1-0.5) 
0.5 (0.2-1.0) 
0.2 (0.1-0.7) 
1.0 
1.6 (1.2-2.1) 
1.0 
1.1 (0.8-1.5) 
1.0 
1.0 (0.7-1.5) 
1.0 
3.3 (2.2-4.9) 
!NR, international normalised ratio; RR, rate ratio; Cl, confidence interval; 
SBP, systolic blood pressure at hospital discharge. 
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anticoagulant therapy using a previously proposed method [1 OJ, involving the 
calculation of INR-specific bleeding and thromboembolic incidence rates, was 
evaluated. The optimal intensity, the intensity of anticoagulation at which the 
incidence of haemorrhages as well as thromboembolism was lowest, appeared to 
be located between INR 3.0 and 4.0. In this range, the risk of bleeding was relatively 
low, amounting to 5 major bleedingcomplications per 1000 treatment-years, while 
the reduction in thromboembolic complications, relative to INR intensities below 2, 
was still reduced by 70%. 
The risk of bleeding associated with anticoagulant therapy, observed in 
patients with as well as without coronary heart disease, is well recognized and has 
fostered the conduct of several trials that compared the efficacy of different 
intensities of oral anticoagulant therapy [20-26]. So far, however, these trials have 
been unable to provide the "true" optimal anticoagulant intensity. The main reason 
of course is that achieved anticoagulant intensity are not constant and will invariably 
fluctuate around the pre-specified target level hinging on particular characteristics 
of the patient under treatment as well as on extraneous features related to the 
administration and monitoring of the therapy. 
Given the acknowledged relation between incidence of bleeding complications 
and high anticoagulant intensities [20-27], it is surprising that few attempts have 
been made to quantify this association. In one recent population study [28], in which 
the achieved intensity of anticoagulant therapy was analyzed in 6814 patients, a 
42% increase in the risk of major bleeding was reported for every INR rise. In an 
other recent analysis, a nested case control study of 565 patients starting outpatient 
therapy with warfarin by Landefeld et al, the odds ratio for major bleeding increased 
with increasing prothrombin time-to-control ratios [25]. In the present analysis, the 
risk of major bleeding gradually increased with elevation in the intensity of 
anticoagulation achieved. The risk was increased 80% when INR intensities were 
between 4 and 5 as compared to intensities below 2 INR, while the risk was 
increased almost five fold in case INR intensity exceeded 5. 
Although it seems reasonable to assume an increased risk of thromboembolic 
events with less intense anticoagulation, this conclusion cannot easily be extracted 
from the literature. In addition to the previously mentioned methodological issues, 
the relatively small size of some studies is an other limiting factor. Evidence for 
strong effects of anticoagulant therapy on thromboembolic complications were 
obtained in placebo controlled post-myocardial infarction trials [8,9,Appendix A]. The 
results of the three most recently conducted preventive trials, the Sixty-Plus [8], 
WARIS [9] and ASPECT [Appendix A] convincingly demonstrated that substantial 
reduction in myocardial infarctions and cerebrovascular events, can be achieved 
with this type of therapy, in survivors of myocardial infarction. The intensity of 
treatment in the three trials was characterised by a prothrombin time prolongation 
of 2.5 to 5.0 INR. In the Dutch 'Sixty-Plus' Reinfarction study, the risk of recurrent 
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myocardial infarction was more than halved, while there was a suggestive trend 
toward fewer intracranial events (20 vs 12) in patients receiving anticoagulant 
therapy. In the Warfarin Reinfarction trial (WARIS), the risk of reinfarction was 
reduced by 34%, and that of cerebrovascular accidents by 55%, both highly 
significant. As in the current analysis, the incidence of bleeding in both trials was 
higher in the anticoagulated patients, but due to use of different definitions, the 
observed rates are not quite comparable. 
One criticism of this analysis is that we were unable to obtain INR 
measurements at the time of the event in every instance. However, the association 
between intensity of anticoagulation and events would probably have been stronger 
if these measurements had been acquired at the moment of the incident in each 
patient. On the other hand, a relatively small number of events occurred at moderate 
INR intensities; our estimation of the best INR intensity may therefore be imprecise, 
and the optimal INR range is likely to be smaller than currently estimated. 
In line with findings reported by others, the current analysis confirmed the 
independent contribution of higher systolic blood pressure [29] to increased bleeding 
tendency during anticoagulation therapy. This parameter was also associated with 
increased thromboembolic complications. Our results tend to confirm a recent 
observation [28] of a higher bleeding incidence in the elderly and females [28-30]. 
In contrast to findings of an other analysis that employed the same quantitative 
approach as currently described [28], we were unable to confirm the association of 
the use of acenocoumarol with increased bleeding tendency. 
In conclusion, the optimal therapeutic range for long-term oral anticoagulant 
therapy has been a matter of intense debate for more than 30 years [3]. Findings 
in this large cohort provide a quantitative basis to locate the optimal therapeutic 
anticoagulant intensity within the INR range of 3.0 and 4.0. In this range, which is 
somewhat lower than targeted anticoagulant intensity in the most recent secondary 
prevention trials [31], the incidence of major bleeding during long-term anticoagulant 
therapy is relatively small while a substantial reduction in the rate of thromboembolic 
events is achieved. 
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CHAPTER SIX 
STROKE AND LONG-TERM ANTICOAGULANT THERAPY 
IN POST-MYOCARDIAL INFARCTION PATIENTS 
SUMMARY 
AJ Azar, JW Deckers, AR Wintzen 
PFMM van Bergen, JJC Jonker, P Koudstaal 
In a randomized, double-blind, placebo controlled trial we studied 3404 post-
myocardial infarction patients who suffered a stroke during long-term anticoagulant 
therapy. The duration of treatment ranged from 1 day to six years. Three years 
following randomization, 2% of the patients on anticoagulant therapy had a stroke 
compared to 4% in placebo. The incidence of stroke analyzed on "intention-to-treat" 
was 0.7 per 100 patient-years in the anticoagulant group and 1.2 per 100 patient-
years in placebo, a hazard ratio (HR) of 0.60 with a 95% confidence interval (Cl) of 
0.40 to 0.90, a 40% reduction in the risk of stroke in the anticoagulated group. A 
total of 19 intracranial bleeding was observed. The risk of haemorrhages was 8 
times greater for anticoagulated patients compared to placebo. Eight of the 17 
bleedings were fatal in the anticoagulant group and no fatal haemorrhages occurred 
in placebo. A total of 15 cerebral infarctions occurred in the anticoagulated group 
and 43 in placebo. Of the 14 haemorrhagic strokes, 6 were within INR 3.0-4.0 and 
8 with an INR>4.0. Of the 7 non-haemorrhagic strokes, 2 were at INR< 2, 3 within 
JNR 3.0-4.0, 1 at INR>4.0, and no measurement was available in one patient. The 
total number of patients who died or were severely disabled as a result of cerebral 
stroke amounted to 13 in the anticoagulated group, compared to 18 in placebo. 
The results of this study indicated that long-term anticoagulant therapy 
substantially reduced the risk of stroke in post-myocardial infarction patients. The 
increased risk of bleeding complications associated with anticoagulant therapy was 
offset by a marked reduction in ischemic events. 
INTRODUCTION 
Myocardial infarction survivors have an increased risk of thromboembolic events, 
that has been estimated at approximately 5% to 8% in the first year, including stroke 
[1]. Administration of long-term anticoagulant therapy may reduce the number of 
such events [2]. However, an estimated 10 times increase in risk of bleeding during 
such treatment has been reported [2-7]. Approximately 50% of these bleedings are 
fatal [4]. The presence of some factors, including hypertension, older age, and 
trauma, has been associated with an increased risk of stroke [6]. 
The results of the three conducted post-myocardial infarction trials [8,9, 
Appendix A] indicated a 40% to 55% reduction in the risk of stroke in patients 
treated with anticoagulant therapy for a mean duration of 2 to 3 years as compared 
with placebo. The intensity of anticoagulant therapy in the three trials was targeted 
at 2.5 to 5.0 international normalised ratio (INR). The number of intracranial 
bleedings was higher in the anticoagulated group, but intracranial infarctions were 
more common in the placebo group. Fatal intracranial bleeding was only observed 
in the anticoagulated group in two of the three trials [9, Appendix A]. 
The purpose of this report is to describe the risk of stroke for post-myocardial 
infarction patients treated with long-term anticoagulant therapy. In addition, we 
aimed to examine the relation between the risk of intracranial haemorrhage or 
infarction and the intensity of anticoagulant therapy. The study population comprised 
3404 patients randomised to anticoagulant therapy or placebo. 
METHODS 
Patients 
We studied post-myocardial infarction patients who took part in the ASPECT 
(Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis) 
trial. This trial has been described in Chapter 2. In short, ASPECT was a 
randomized, double-blind, placebo controlled, multicentre clinical trial which 
compared anticoagulant therapy with matching placebo on mortality and 
cardiovascular events in post-myocardial infarction patients. 
Hospital survivors of acute myocardial infarction were screened for eligibility 
just prior to hospital discharge. Informed consent was obtained in all subjects. 
Patients were randomly assigned to treatment with oral anticoagulant therapy or to 
matching placebo. From September 1, 1986 until December 31, 1991, a total of 
3404 patients entered the trial. The study population contributed 10441 patient years 
of follow-up. 
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Oral anticoagulation and dose adjustment 
The target anticoagulant range was 2.8 - 4.8 INR [10-14]. Individual dose 
adjustments were guided by the so called prothrombin time measurements obtained 
at regular intervals at one of the participating anticoagulant clinics. Anticoagulant 
treatment consisted of phenprocoumon, acenocoumarol or matching placebo tablets. 
Double-blinding was maintained by conversion of the actual prothrombin time values 
of placebo treated patients to values within therapeutic range by a computerized 
dosage algorithm at the anticoagulant clinic. 
At each follow-up visit to the anticoagulant clinic, a short history was taken 
and a blood sample was drawn for determination of the prothrombin time test. The 
prothrombin time is the time needed for a blood sample to clot when a small quantity 
of thromboplastin reagent is added [12]. Patients were seen at the initial (i.e. 
randomization) visit and on a weekly basis thereafter until the prothrombin time 
measurements were within the specified target range. The interval between visits 
was subsequently prolonged until a maximum period of eight weeks. Patients 
requiring frequent dosage adjustments were seen more regularly. While on trial 
medication, patients were strongly advised not to take other anti-thrombotic 
medication. At the end of trial on June 1992, trial medication was discontinued in all 
patients. 
If available, prothrombin time measurements immediately before the 
haemorrhagic and non-haemorrhagic episode were obtained. Otherwise, the last 
measurement within a maximum time frame of 28 days prior to the stroke was 
registered. 
Clinical events 
Stroke was diagnosed according to internationally accepted criteria for the 
assessment of cerebrovascular disease [15]. Brief attacks lasting less than 24 hours 
and leaving no residual symptoms were classified as transient ischemic attacks 
(TIA) [15]. If neurological death occurred within 24 hours, the case was classified as 
intracranial bleeding unless findings on computed tomography (CT)-scanning 
indicated otherwise. Events lasting beyond 24 hours were specified as cerebral 
infarction or intracranial bleeding on the basis of CT-scanning, if available. IfaCT-
scan was not available the event was classified as unspecified. 
The functional outcome of all cerebrovascular events was classified as death 
within 24 hour, death beyond 24 hours, survival with no disability, survival with mild 
disability (residual symptoms, but no impact on daily activities), survival with 
moderate disability (symptoms which significantly interfered with normal daily 
activities, with the patient being unable to live independently) or survival with severe 
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Table 6.1. Selected demographic, baseline and randomisation characteristics 
AC Placebo Total 
No. (%) No. (%) No. (%) 
1700 (100) 1704 (100) 3404 (100) 
Age (years) 
<55 507 (30) 490 (29) 997 (29) 
55-65 536 (32) 573 (33) 1109 (33) 
> 65 657 (38) 641 (38) 1298 (38) 
Gender 
Male 1370 (81) 1350 (79) 2720 (80) 
Female 330 (19) 354 (21) 684 (20) 
Previous Mf 
No 1543 (91) 1554 (91) 3097 (91) 
::;; 1 year 25 (1) 18 (1) 43 (1) 
> 1 year 132 (8) 132 (8) 264 (8) 
Previous use of Ac· 
No 1665 (98) 1660 (98) 3325 (98) 
:5 1 year 5 (0) 7 (0) 12 (0) 
> 1 year 30 (2) 37 (2) 67 (2) 
Hematocrit 
< 45 913 (54) 876 (51) 1789 (53) 
,. 45 735 (43) 767 (45) 1502 (44) 
not available 52 (3) 61 (4) 113 (3) 
Beta-blockers 867 (51) 869 (51) 1736 (51) 
Acetyl salicylic acid'f- 118 (7) 104 (6) 222 (7) 
Mean SBP, mmHg (SD) 119 (16) 119 (16) 119 (16) 
History of OM 134 (8) 125 (7) 259 (8) 
Current smokers 894 (53) 888 (52) 1782 (52) 
AC, anticoagulant group; Ml, myocardial infarctions, SBP, systolic blood pressure at discharge, DM, 
diabetes mellitus, SBP, systolic blood pressure at d"1scharge. 
·Prior to the qualifying myocardial infarction. 
+Discontinued at randomization. 
"'"Reported in the patient's medical history. 
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disability (patient completely dependent in all activities of daily living). 
Information on clinical events was obtained directly from the patients when 
they visited the Thrombosis Centre or from their general practitioners. In case of 
hospitalization, additional information was retrieved from the hospital records. The 
diagnosis and classification of clinical events was made by three neurologists who 
independently reviewed the clinical course of each case on the basis of an 
independent review of a standardized patient report. The committee members also 
registered and coded all neurological admissions. The members were blinded to 
treatment assignment and were not informed of actual prothrombin time 
measurements. Other neurological non-vascular complications diagnosed in the 
course of the trial included: cerebral tumour (11 patients), Guillain-Barre, hernia 
nucleus pulposus (20 patients), amyotrophic lateral sclerosis (11 patients), and 
polyneuropathy (3 patients). 
Data Analysis 
A comparison between the anticoagulated and placebo groups with respect to the 
incidence of stroke was made in terms of the hazard ratio, i.e., the risk of stroke per 
unit time for patients randomly assigned to oral anticoagulant therapy divided by the 
risk for those randomly assigned to placebo. Hazard ratios were obtained with the 
use of the Cox proportional-hazards model [16]. The precision of the hazard-ratio 
estimates were described by 95 percent confidence intervals obtained from the Cox 
model. For "intention-to-treat" analysis, all randomized patients were included 
irrespective of previous discontinuation of trial medication. Censoring was applied 
when the patient died, had a stroke, or at the end of follow-up, on June 30, 1992. 
In a subsidiary analysis only those strokes that occurred while the patient was on 
trial treatment (or within 28 days after its cessation) were taken into account ("per-
protocol" analysis). 
RESULTS 
A total of 1700 patients were randomised to anticoagulant therapy and 1704 to 
placebo. The mean follow-up was 3.1 years. Demographics data, smoking habits, 
medical history and medication used during hospitalisation are presented in Table 
6.1. The median age of the patients was 61 years, 80% of the study population were 
men, 8% were known to have or treated for diabetes mellitus, and 7% were given 
acetylsalicylic acid prior to enrolment which was discontinued at randomisation. 
The incidence of stroke analyzed on 'intention-to-treat' and 'per-protocol' 
analysis is presented in Table 6.2. Based on the total observation time ('intention-to-
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Table 6.2 Incidence of stroke in the ASPECT trial 
Anticoagulant 
(1700) 
Placebo 
(1704) 
"intention-to-treat" 
Patient-years of follow-up 5241 5200 
First stroke 37 (0.71100py) 62 (1.211 OOpy) 
intracranial bleeding 17 2 
fatal 8 0 
non-fatal 9 2 
cerebral infarction 15 43 
fatal 2 2 
non-fatal 13 41 
Transient ischemic attack 2 6 
fatal 0 0 
non-fatal 2 6 
unspecified 4 12 
fatal 1 6 
non-fatal 3 6 
"per protocol" 
Patient-years of follow-up+ 3725 3488 
First stroke 
intracranial bleeding 
fatal 
non-fatal 
cerebral infarction 
fatal 
non-fatal 
Transient ischemic attack 
fatal 
non-fatal 
unspecified 
fatal 
non-fatal 
24 (0.611 OOpy) 
14 
7 
7 
6 
0 
6 
0 
3 
1 
2 
42 (1.211 OOpy) 
0 
28 
2 
26 
6 
0 
5 
7 
1 
6 
HR, hazard ratios; Cl, confidence intervals; py, patient-years.-treat') 
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HR (95% Cl) 
0.60 (0.4-0.9) 
0.57 (0.34-0.93) 
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99 patients were diagnosed as having a stroke. The incidence of stroke in the 
anticoagulated group was 0.7 per 100 patient-years and in placebo 1.2 per 100 
patients-years, a hazard ratio (HR) of 0.60 with a 95% confidence interval {CI) of 
0.40 to 0.90, a 40% reduction in the risk of stroke in the anticoagulated group. 
The risk of haemorrhages was 8 times greater for anticoagulated patients 
compared to placebo. Of the 17 intracranial bleeding in the anticoagulated group, 
15 were diagnosed on the basis of a CT-scan (9 intracerebral, 3 subdural, 3 
subarachnoidal). Eight of the 17 bleedings were fatal: 6 were diagnosed by a CT-
scan (3 intracerebral, 2 subdural and 1 subarachnoidal) and two were diagnosed on 
the basis of death within 24 hours. Of the two intracranial bleedings in the placebo 
group, one was subdural and one undefined. No fatal intracranial bleeding occurred 
in the placebo group. The functional outcome of the 9 anticoagulated patients who 
survived the intracranial bleeding was as follows: 2 were not disabled, 4 mildly 
disabled, 1 moderately while 2 patients were severely disabled. Two placebo 
patients who suffered an intracranial bleeding were not disabled. 
The incidence of cerebral infarction was approximately 3 times greater in the 
placebo than the anticoagulated group. The functional outcome of the 13 
anticoagulated patients who survived the intracranial infarction was: 5 were not 
disabled, 4 mildly and 4 moderately disabled. No severely disabled patients occurred 
in the treated group. For the 41 placebo patients who survived the infarction, the 
numbers were: 11 not disabled, 13 mildly disabled, 8 moderately and 9 severely 
disabled. 
Six patients in treated and 18 in placebo group had an unspecified event or 
transient ischemic attack. Six fatal events occurred in placebo compared to one in 
anticoagulated group. The functional outcome of the 3 non-fatal unspecified strokes 
in the anticoagulated group were: 2 were not disabled, and 1 mildly. For the 6 
placebo patients who survived, the numbers were: 3 not disabled, 1 mildly disabled, 
1 moderately and 1 severely disabled. 
When all strokes was combined the following figures were obtained: the 
number of patients who died or were severely disabled amounted to 13 in the 
anticoagulated group, compared to 18 in placebo. When moderately disabled was 
combined the figures were: 18 in the anticoagulated group compared to 27 in 
placebo. 
The distribution of time from randomization to onset of stroke is presented in 
Figure 6.1, analyzed on intention-to-treat. The duration oftreatment ranged from 1 
day to six years. After 3 years following randomization 2% of the patients on 
anticoagulant therapy had a stroke compared to 4% in placebo. 
Trial treatment was discontinued in 1655 patients (768 after anticoagulant 
therapy and 887 in placebo). Reasons for discontinuation were: death (194 patients: 
91 anticoagulant therapy and 103 placebo); non-fatal cerebrovascular event (44 
patients: 12 anticoagulant therapy and 32 placebo); non-fatal myocardial infarction 
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(155 patients: 31 anticoagulant therapy and 124 placebo); non-fatal extracranial 
bleeding (92 patients: 81 anticoagulant therapy and 11 placebo); and patient, 
physician' refusal, change of address or other reasons (1170 patients: 553 
anticoagulant therapy and 617 placebo). 
Among the 24 patients with a stroke in the actively treated group, prothrombin 
times were obtained as measured shortly before (17 patients) or within one month 
prior to the stroke (21 patients). Of the 14 haemorrhagic strokes, 6 were within INR 
3.0-4.0 and 8 with an INR>4.0. Of the 7 non-haemorrhagic strokes, 2 were at INR< 
2, 3 within INR 3.0-4.0, 1 at INR>4.0, and no measurement was available in one 
patient. 
Of the 33 patients who had a stroke after discontinuation of trial medication, 
antiplatelet agents were used by 2 patients with a cerebral infarction and 
anticoagulants by 5: one with a cerebral infarction, 3 an intracranial haemorrhage 
and one a TIA. 
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DISCUSSION 
The results of this study indicated that long-term anticoagulant therapy substantially 
reduced the risk of stroke in post-myocardial infarction patients. Although an 
increased risk in bleeding complications were reported, this was offset by a marked 
reduction of ischemic events. 
A comparison of strokes observed in the two most recently published 
secondary preventive trials is given in Table 6.3. The 'Sixty-Plus' reinfarction trial 
randomly allocated patients already treated with oral anticoagulant therapy to 
continuation of treatment (439 patients), or to discontinuation of treatment (439 
patients) [2,8]. All patients were followed for at least two years. The Warfarin 
Reinfarction trial (WARIS) was carried-out in 1214 patients with a recent myocardial 
infarction who were randomised to either anticoagulant therapy or placebo. Patients 
were followed for a mean duration of three years [9]. The incidence of stroke in all 
three trials was thus reduced by 40% to 55% in favour for the anticoagulant group. 
The incidence in the anticoagulated group in the ASPECT population was lowest 
(0.7 per 100 patient-years) and highest (1.4/100 patient-years) in the 'Sixty-Plus' 
trial. The incidence of stroke in placebo group was similar for both 'Sixty-Plus' and 
WAR IS (2.3/1 00 patient-years) and was again lowest in ASPECT (1.2/1 00 patient-
years). In the 'Sixty-Plus' trial a substantial higher number of deaths was observed 
as compared to the other two studies. This may be attributed to not only the 
selection of patients in these trials but also to new treatment modalities, i.e., 
developments with respect to the institution of thromboly1ic therapy and increased 
frequency of revascularization in patients with myocardial infarction in the eighties. 
In all three trials, characterised by the intensity of treatment of a prothrombin 
time prolongation of 2.5 to 5 INR, intracranial bleeding occurred more frequently in 
the anticoagulated group than in placebo. In the treated group, at least 50% of the 
intracranial bleedings were fatal. The rate of haemorrhagic stroke (fatal or non-fatal) 
in the anticoagulated group was 0.3/100 patient-years for both WARIS and ASPECT, 
and was higher (1.0/1 00 patient-years) in the 'Sixty-Plus' trial. For placebo treated 
patients the risk was lowest in WARIS (0 patients), the risk amounted to 0.04/100 
patient-years in ASPECT and was again highest (0.1/1 00 patient-years) in the 'Sixty-
Plus' trial. 
A total of 35 haemorrhagic strokes were observed in the three trials: 32 in the 
anticoagulated group of which 17 were fatal, and 3 in placebo of which 1 was fatal. 
The risk of haemorrhagic stroke observed in the three trials in the treated group was 
0.4/100 patient-years and in placebo of 0.04/100 patient-years. Thus, the incidence 
of haemorrhagic stroke in the anticoagulated patients was 10 times higher than in 
untreated patients. Furthermore, about 50% of the haemorrhagic strokes were fatal. 
In two population studies conducted in the Netherlands, a similar 8 to 10 times 
increase in the risk of intracranial haemorrhage in long-term anticoagulated patients 
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Table 6.3 Incidence of stroke in the 'Sixty-Plus' and WAR IS trials' 
Anticoagulant Placebo HR (95% Cl) Anticoagulant Placebo RR (95% Cl) 
Sixty-Plus WARIS 
No. of patients 439 439 607 607 
Patient-years of follow-up+ 878 878 1872 1872 
Stroke 12 (1.4/100py) 20 (2.3/100py) 0.60 (0.30;1.21) 20 (1.1/100py) 44 (2.4/1 OOpy) 0.45 (0.23;0.76) 
intracranial bleeding 9 1 6 0 
fatal 5 1 4 0 
non-fatal 4 0 2 0 
non-haemorrhagic 2 13 14 44 
fatal 1 5 0 10 
non-fatal 1 8 14 34 
unspecified 1 6 
fatal 0 0 
non-fatal 1 6 
RR, rate ratios; Cl, confidence intervals; py, patient-years. 
older than 50 years compared to the total population was reported [4,6]. In addition, 
the risk of fatal haemorrhagic stroke was reported to be at least 50% [2-4,6,7]. 
Non-haemorrhagic strokes (excluding the category unspecified) occurred 
more frequently in placebo than in the anticoagulated group. Fatal non-haemorrhagic 
stroke occurred more often in untreated patients than in treated patients in two of 
the three studies [2,9] and occurred equally in both treatment groups in the present 
trial. A total of 31 non-haemorrhagic strokes occurred in the three trials in the 
anticoagulated group compared with 100 in placebo. A combined incidence was 
observed of 0.4/100 patient-years in the treated group compared with 1.3/100 
patient-years in placebo. This finding indicates that untreated patients have at least 
a three fold increased risk of non-haemorrhagic stroke compared to treated patients. 
When the incidence of non-haemorrhagic and unspecified strokes are 
combined, an incidence of 0.4/100 patient-years to 0.7/100 patient-years occurred 
in the anticoagulated group compared with 1.2/100 patient-years to 2.4/1 00 patient-
years in placebo. A total of 36 events occurred in the three trials in the 
anticoagulated group compared with 118 in placebo. The respective incidence of 
treated and untreated patients will be 0.5/1 00 patient-years and 1.5/1 00 patient-
years. The data again indicate at least a 3 fold increase risk for untreated patients 
compared to treated patients. 
The overall outcome of patients treated with anticoagulation is better than for 
placebo, despite the ten fold risk in bleeding for the treated patients. The functional 
outcome for patients treated with anticoagulants resulted in 13 deaths or severely 
disabled compared to 18 patients in placebo. For the anticoagulant group 18 
patients were moderately to severly (inlcuding deaths) disabled compared to 27 in 
placebo. 
The rate of intracranial bleeding has been reported to occur more frequently 
at higher anticoagulant intensities [3,6,17-22, see Chapter 5] and that of infarction 
at lower intensities [2,21 ,22, see Chapter 5]. The therapeutic range for the dutch 
trials was 2.5-5 INR. In our study, we observed that at INR intensities between the 
range 3 and 4, 4 haemorrhages occurred, above the value of 4, eight haemorrhages 
and only two at intensities above 4.8 INR. 
In conclusion, long-term anticoagulant therapy substantially reduces the risk 
of stroke in post-myocardial infarction patients. Although the rate of intracranial 
bleeding, the most serious complication of anticoagulant therapy, is increased 10 
fold, this is more than offset by a marked reduction in ischemic events of 
comparable functional outcome. 
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CHAPTER SEVEN 
GENERAL DISCUSSION 
AJ Azar, JW Deckers, JRTC Roeland! 
INTRODUCTION 
Initial enthusiasm for anticoagulant therapy was dampened in the seventies and 
eighties for reasons associated with problems inherent to the institution of 
anticoagulant therapy itself, as well as to the upcoming popularity of antiplatelet 
therapy in the form of aspirin. Early anticoagulant therapy faced major control 
problems in that different laboratory tests were used to monitor intensity of 
treatment. The thromboplastins used to measure the prothrombin time were 
prepared by different methods, and, consequently their effect on the reduction of the 
vitamin K dependent clotting factors varied significantly [1]. Therefore, whilst different 
thromboplastins employed in the controls resulted in the same prothrombin time, 
they represented different intensities of anticoagulant effects. An international 
scheme of prothrombin time standardization based on international reference 
preparations and a uniform method of reporting of results was only introduced in 
1976 [2]. The international normalized ratio (INR) system is based on a quantitative 
assessment of the responsiveness of a thromboplastin as explained in Chapter I. 
With this standardized INR, the therapeutic efficacy of anticoagulation achieved can 
be compared not only between different anticoagulant clinics but also between 
studies. 
The optimal therapeutic range for anticoagulant therapy was consequently 
advised by three expert groups: The British Society of Haematology (BSH) (1984, 
1990), European consultants who met in Leuven (1985), and the two consensus 
meetings of the American College of Chest Physicians/ National Heart and Lung 
Institute ACCP/NHLBI (1986, 1989) [3] (Table 7.1). 
Table 7.1. Recommended therapeutic INR ranges for anticoagulant therapy in post-
myocardial infarction patients 
British Society of Haematology (1984, 1990) 
European consultants, Leuven (1985) 
ACCP/NHLBI (1986, 1989) 
3.0-4.5 INR 
3.0-4.5 INR 
2.0- 3.0 INR 
Table 7.2. Major events in the three recently conducted trials on long-term anticoagulant therapy in post myocardial 
infarction patients 
Sixty-Plus WAR IS ASPECT Total 
AC Pl AC PL AC PL AC PL 
No. of patients 439 439 607 707 1700 1704 2745 2750 
No. patient-years 878 878 1872 1872 5241 5200 7991 7950 
Death (/1 00 py) 51 (5.8) 69 (7.9) 94 (5.0) 123 (6.5) 170 (3.2) 189 (3.6) 315 (3.9) 381 (4.8) 
Ml (1100 py) 29 (3.3) 64 (7.3) 62 (4.4) 124 (6.9) 114 (5.1) 242 (2.3) 225 (2.8) 400 (5.0) 
Stroke (/1 00 py) 12 (1.4) 20 (2.3) 20 (1.1) 44 (2.4) 37 (0.7) 62 (1.2) 69 (0.9) 126 (1.6) 
AC, anticoagulant group; PL. placebo group. Ml, myocardial infarction 
Table 7.3. D"lstribution of end-po"rnts in the different anti-thrombotic trial 
%Reduction 
No. of patients Mortality Re-infarction Stroke 
Anticoagulant trials 
Sixty-Plus (1980) 878 26 55 40 
WARIS (1990) 1214 24 34 55 
ASPECT (1993) 3404 10 53 40 
Aspirin trials· 
Elwood (1974) 1239 22 
CDPA (1976) 1529 30 12 -10 
Elwood (1979) 1682 17 50 
Bredd"tn (1980) 626 17 33 
AMIS (1980) 4524 -10 18 45 
PARIS I (1980) 2026 17 25 45 
PARIS II (1986) 3128 2 53 38 
~1, myocardial infarction. 
percent reduction indicated for non-fatal myocardial infarction and non-fatal stroke. 
The lower recommended range in North America can be explained by the higher 
incidence of bleeding complications previously observed during anticoagulant 
therapy in the United States, due to lack of prothrombin time standardisation as 
previously discussed and less efficiently organised monitoring network. 
Recently conducted clinical trials 
Recommendations by the BSH and the European consultants were to a large extent 
influenced by the results of the Dutch 'Sixty-Plus' Reinfarction study [4], with a target 
INR range between 2.7 and 4.5. Although the 'Sixty-Plus' trial suggested substantial 
benefits of long-term anticoagulant therapy with regard to mortality, myocardial 
infarction and cerebrovascular events, the results were criticised since it assessed 
the value of discontinuation of long-term therapy. On the other hand, the positive 
findings of the trial did provide a challenge to physicians who had abandoned the 
use of anticoagulant therapy. The findings of the three most recently [4,5, Appendix 
A] conducted trials are summarized in Tables 7.2 and 7.3. These indicate that the 
risk of mortality is reduced by 10% to 26%, of reinfarction by 34% to 55% and of 
stroke by 40% to 55%. 
ANTICOAGULANTS OR ASPIRIN ? 
Further to the three most recently anticoagulant trials, pooled analysis of data from 
other anticoagulant trials demonstrated reduction in mortality in favour of 
anticoagulant therapy varying from 14% to 40% [6-10], and in myocardial infarction 
from 44% to 65% [6, 1 0] (Table 7.4). The review by Chalmers [6] which included all 
randomized trials on anticoagulant therapy in the acute phase of myocardial 
infarction, had been criticised because it had pooled trials of very dissimilar study 
design. Pete and Armitage [7,8] reanalysed the data using more rigorous statistical 
methods and reported comparable results of those of Chalmers. Leizorovicz [9] 
considered only long-term anticoagulant trials. Loeliger [1 0] selected long-term 
anticoagulant trials with similar anticoagulant intensities (INR 2.5-5), and reported 
the largest reductions in mortality and reinfarction. In the present pooled analysis of 
the three most recent trials, all randomised, double-blind placebo controlled and with 
INR between 2.5 and 5.0, a reduction in mortality of 19%, in myocardial infarction 
and stroke of 44% was found (Table 7.4). 
How do these data compare to those obtained with anti-platelet agents, in 
particular that of aspirin ? The randomised double-blind, placebo controlled trials 
which evaluated the effect of aspirin at doses of 300 to 1,500 milligrams/day in post-
myocardial infarction are summarized in Table 7.3 [11]. The time between index 
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infarction and entry into the trial ranged from one week to seven years, with the 
majority of patients recruited within one year. Trial duration varied from one to four 
years. The reduction in mortality ranged from 2% to 30%, in non-fatal myocardial 
infarction from 12% to 53% and in non-fatal stroke from 10% to 45% (Table 7.3). 
The pooled results of the trials [12], totalling more than 15,000 patients, 
demonstrated a reduction in vascular mortality of 13%, in non-fatal reinfarction of 
31%, in non-fatal stroke of42%, and in vascular events (defined as first occurrence 
of either myocardial infarction, stroke or death) of 25% (Table 7.4). 
Table 7.4. Pooling of the different anti-thrombotic trials 
Anticoagulant trials 
Chalmers (1977) 
Pete (1978) 
Armitage (1980) 
Leizorovicz (1983) 
Loeliger (1984) 
Azar (1993) 
Aspirin trials 
Antiplatelet Group" (1988) 
No. of trials 
32 
32 
32 
7 
9 
3 
10 
Mortality 
21 
20 
20 
14 
40 
19 
13 
% Reduction 
Re-infarction 
55 
65 
44 
31 
... Cardiovascular mortality, non-fatal myocardial infarction and non-fatal stroke. 
Stroke 
44 
42 
Until present, only two prospective trials have been conducted which directly 
compared long-term use of anticoagulant therapy with aspirin: The German-Austrian 
trial (Breddin) [13] and 'Enquete de Prevention Secondaire de l'lnfarctus du 
Myocarde' (EPSIM) [14]. The Breddin trial had three intervention groups: aspirin 
1,500 mg/day (317 patients) or matching placebo (309 patients), and 
phenprocoumon (320 patients). The trial was double-blind for aspirin and placebo 
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and open for phenprocoumon. The mean follow-up was two years. A total of 39 
deaths occurred in the anticoagulant group compared to 32 in placebo and 27 in 
aspirin. The EPSIM group randomized patients to anticoagulant therapy (652 
patients) or aspirin 500 mg/day (651 patients). The mean follow-up was 29 months. 
A total of 67 deaths were reported in the anticoagulant group as compared to 72 in 
aspirin. Although in both trials aspirin was as effective as anticoagulant therapy in 
reducing mortality and morbidity, the intensity of anticoagulant therapy was poorly 
controlled. In addition, the small number of patients (and endpoints) make these 
findings inconclusive. 
The optimal intensity of anticoagulant therapy 
The previously presented recommendation of the British Society of Haematology 
(1984, 1990), the European consultants, Leuven (1985) and the ACCP/NHLBI 
(1986, 1989) were based on trials conducted to assess the efficacy of treatment in 
prevention of mortality and vascular events, and on trials which compared different 
intensities of treatment. So far, however, these trials did not provide the optimal 
anticoagulant intensity. One reason is that the achieved anticoagulant intensity is not 
constant and invariably fluctuates around the targeted level hinging on 
characteristics of the patient as well as on extraneous features related to the 
administration and monitoring of the therapy. As described in Chapter 5, the optimal 
intensity of anticoagulant therapy was evaluated with use of INR specific incidence 
rates of bleeding as well as thromboembolic complications. On the basis of that 
analysis, involving over 7000 patient-years of follow up with almost 60 major 
bleeding and approximately 400 thromboembolic events, the optimal intensity of 
anticoagulation at which the incidence of haemorrhages as well as 
thromboembolism was lowest is situated between an INR range of 3.0 and 4.0. In 
that range, the risk of bleeding was relatively low, amounting to 5 major bleeding 
complications per 1000 treatment-years, while the reduction in thromboembolic 
complications amounted to 70% [Figure 7.1]. It should be noted that the advised 3.0 
to 4.0 INR range is lower than that advocated by the BSH and Leuven group and 
higher than the American guidelines. 
EPICRISIS 
It is obvious that anticoagulant treatment with coumarin derivatives as well as with 
the antiplatelet agent aspirin result in a substantial reduction in mortality, myocardial 
infarction and stroke in survivors of myocardial infarction. Admittedly, the reduction 
in mortality in ASPECT [Appendix A] was relatively modest compared to that found 
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in WARIS [5] and the Sixty-Plus trial [4]. This finding is probably related to the 
selection of the patients, survivors of an uncomplicated myocardial infarction at 
relatively low risk of subsequent events. Furthermore, new treatment modalities such 
as thrombolytic therapy and revascularization procedures, both associated with 
improved survival, have changed relative to the two previous trials. Nevertheless, 
in ASPECT, reductions in recurrent myocardial infarction of 53% (95% confidence 
interval 41%, 62%) and vascular events (reduction 35%, 95% confidence interval 
24%, 45%) were more substantial than that established in the pooled results of the 
Anti-platelet Tria lists group (reduction in myocardial infarction 31%, 95% confidence 
interval 26%, 36%, in vascular events 25%, 95% confidence interval 21%, 29% 
respectively) and, although this comparison is based on indirect evidence, are 
suggestive of a more pronounced effect of anticoagulant therapy. 
Although the direct costs of anticoagulant therapy are higher than that of 
aspirin, by approximately hfl 500,- per patient-year of treatment, these are not 
prohibitive compared to other medical regimens. The more obvious advantage of 
aspirin over anticoagulant therapy is its ease of use, and the frequent monitoring 
necessarily associated with anticoagulant therapy could well impede its widespread 
utilization. 
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With the growing realization that modification of platelet function simultaneously with 
fibrin formation may be more effective than either process on its own [15], the worth 
of the concurrent use of aspirin and anticoagulants in low doses is currently being 
investigated in other trials [16]. Recent data have identified elevated levels of factor 
VII as a risk indicator for increased cardiovascular disease incidence [16]. Since low 
dose anticoagulant therapy decreases levels of factor VII, this treatment modality is 
also being investigated in the British Thrombosis Prevention Trial. However, on the 
basis of our findings, it is unlikely that anticoagulant therapy with intensity of INR < 
3 will be effective in the prevention of thromboembolic complications. 
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Table 1. Thrombosis centers 
AC Placebo Total 
No. of patients· 1700 100% 1704 100% 3404 100% 
Amsterdam 218 13% 220 13% 438 13% 
The Hague 143 8% 146 9% 289 8% 
Groningen 102 6% 105 6% 207 6% 
Leiden 174 10% 172 10% 346 10% 
Rotterdam 133 8% 129 8% 262 8% 
Utrecht 211 12% 213 13% 424 12% 
Lichtenvoorde 45 3% 47 3% 92 3% 
Enschede 171 10% 179 10% 350 10% 
Haarlem 132 8% 128 8% 260 8% 
Breda 34 2% 38 2% 72 2% 
Middelburg 129 7% 128 7% 257 7% 
Til burg 30 2% 30 2% 60 2% 
Den Bosch 26 2% 25 1% 51 2% 
Eindhoven 17 1% 15 1% 32 1% 
Arnhem 57 3% 55 3% 112 3% 
Almelo 5 0% 3 0% 8 0% 
Hilversum 47 3% 47 3% 94 3% 
Deventer 14 1% 12 1% 26 1% 
Hengelo 12 1% 12 1% 24 1% 
AC, anticoagulant group. 
*Patients randomized prior to 1 January 1992 with follow-up until 30 June 1992. 
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Table 2. Selected demographic and clinical baseline characteristics 
AC Placebo 
No. of patients 1700 100% 1704 100% 
Age (years) 
<55 507 30% 490 29% 
55-65 536 32% 573 33% 
> 65 657 38% 641 38% 
Gender 
Male 1370 81% 1350 79% 
Female 330 19% 354 21% 
Previous Mf 
No 1543 91% 1554 91% 
~ 1 year 25 1% 18 1% 
> 1 year 132 8% 132 8% 
Previous use of Ac· 
No 1665 98% 1660 98% 
:::;; 1 year 5 0% 7 0% 
> 1 year 30 2% 37 2% 
AC, anticoagulant group; Ml, myocardial infarctions. 
"Prior to the qualifyin~ mvocardial infarction. 
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Total 
3404 100% 
997 29% 
1109 33% 
1298 38% 
2720 80% 
684 20% 
3097 91% 
43 1% 
264 8% 
3325 98% 
12 0% 
67 2% 
3 
Table 3. Electrocardiographic baseline characteristics 
AC Placebo Total 
No. of patients 1700 100% 1704 100% 3404 100% 
New 0-waves (clinician's opinion) 
no 528 31% 594 35% 1122 33% 
yes 1172 69% 1110 65% 2282 67% 
No. of available EGGs~ 
(last ECG before discharge) 
AC Placebo Total 
Heart rate (min-1) 1692 100% 1694 100% 3386 100% 
< 60 233 14% 258 15% 491 15% 
60-80 1233 73% 1253 74% 2486 73% 
> 80 219 13% 179 11% 398 12% 
not available 7 0% 4 0% 11 0% 
0-waves .. 
Anteroseptal 497 29% 515 30% 1012 30% 
Lateral 98 6% 83 5% 181 5% 
Inferior/posterior 708 42% 711 42% 1419 42% 
None 389 23% 385 23% 774 23% 
Q-waves (M-C)' 
1.1.n 464 27% 434 26% 898 26% 
1.2.n 479 28% 480 28% 959 28% 
1.3.n 313 19% 315 19% 628 19% 
None 435 26% 464 27% 899 27% 
not available 1 0% 1 0% 2 0% 
AC, anticoagulant group; M-C, Minnesota-coding. 
"18 ECGs were missing . 
.. 0-waves ::::::0.03 sec and ~0.1 mV; anteroseptal leads V1, V2 , V3 , V4 or V5; 
lateral leads I, aVL or V6;inferior/posterior leads II, Ill, aVF and R>0.03 sees in V1 and R!S in V2• 
ECGs with more than one location are included in the highest of the above 
categories. 
sMeasure of the severity of the 0-wave. 
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Table 4. Maximum activities of creatine kinase and serum glutamate oxalotransaminase 
CK 
< 200%-
200%- 500% 
500% -1000% 
1000% - 2000% 
> 2000% 
not available 
AC 
1700 
103 
407 
523 
417 
182 
68 
100% 
6% 
24% 
31% 
25% 
10% 
4% 
AC, anticoagulant group; CK, creatine kinase. 
1704 
108 
427 
544 
397 
160 
68 
Placebo Total 
100% 3404 100% 
6% 211 6% 
25% 834 25% 
32% 1067 31% 
23% 814 24% 
10% 342 10% 
4% 136 4% 
·Maximal values during index admission are expressed as percentages of the upper 
reference limit. 
ASAT/SGOT AC Placebo Total 
1700 100% 1704 100% 3404 100% 
237 14% 263 15% 500 15% < 200%-
200%- 500% 
500% -1000% 
1000% -2000% 
668 39% 684 40% 1352 40% 
> 2000% 
not available 
517 
204 
25 
68 
30% 
12% 
1% 
4% 
503 
184 
20 
50 
30% 1020 
11% 388 
1% 45 
3% 118 
AC, anticoagulant group; ASAT/SGOT, serum glutamate oxalotransaminase. 
·Maximal values during index admission are expressed as percentages of the upper 
reference limit. 
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30% 
11% 
1% 
3% 
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Table 5. Use of anticoagulants, aspirin and thrombolytic drugs during index admission 
AC Placebo Total 
No. of patients 1700 100% 1704 100% 3404 100% 
Coumarin derivatives 
No 254 15% 255 15% 509 15% 
Yes 1446 85% 1449 85% 2895 85% 
Heparin Lv. 
No 1348 79% 1367 80% 2715 80% 
Yes 352 21% 337 20% 689 20% 
Neither coumarin 
nor heparin 205 12% 204 12% 409 12% 
Aspirin 
No 1224 72% 1227 72% 2451 72% 
Yes 474 28% 475 28% 949 28% 
Unknown 2 0% 2 0% 4 0% 
Thrombolytic i.v. 
No 1281 75% 1285 75% 2566 75% 
Yes 419 25% 419 25% 838 25% 
SK 307 73% 325 78% 632 76% 
rtPA 75 18% 55 13% 130 15% 
apsac 37 9% 38 9% 75 9% 
other 0 0% 0% 1 0% 
Thrombolytic Lc. 
No 1682 99% 1683 99% 3365 99% 
Yes 18 1% 21 1% 39 1% 
AC, anticoagulant group; i.v., intravenous ;;::; 10,000 units/day; i.e., intracoronary; 
sk, streptokinase; rtPA, alteplase; apsac, anistreplase. 
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Table 6. Complications during index admission 
AC Placebo Total 
No. of patients 1700 100% 1704 100% 3404 100% 
VTNF <24 h 
No 1478 87% 1485 87% 2963 87% 
Yes 222 13% 219 13% 441 13% 
VTNF > 24 h 
No 1664 98% 1666 98% 3330 98% 
Yes 36 2% 38 2% 74 2% 
Heart failure· 
Class 1 1115 66% 1124 66% 2239 66% 
Class II 489 29% 487 29% 976 29% 
Class Ill 70 4% 68 4% 138 4% 
Class IV 26 1% 25 1% 51 1% 
2° AV-block 
No 1658 98% 1667 98% 3325 98% 
Yes 42 2% 37 2% 79 2% 
3° AV-block 
No 1634 96% 1637 96% 3271 96% 
Yes 66 4% 67 4% 133 4% 
Extended infarction 
No 1662 98% 1665 98% 3327 98% 
Yes 38 2% 39 2% 77 2% 
AC, anticoagulant group; VfNF, ventricular tachycardia or ventricular fibrillation; 
AV, atrio-ventricular. 
-Highest KILUP or MIRU class reached in hospital. 
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Table 7. Cardiac medications at hospital discharge 
AC Placebo 
No. of patients 1700 100% 1704 100% 
Cardiac glycoside 108 6% 102 6% 
Diuretics 37S 22% 380 22% 
Beta-blockers 867 51% 869 51% 
Long-acting nitrates 644 38% 623 37% 
Calcium antagonists 284 17% 302 18% 
ACE-inhibitors 160 9% 146 9% 
Antiarrhythmic drugs 58 3% 54 3% 
Nitroglycerin sublingual 759 45% 744 44% 
Acetyl salicylic acid~ 118 7% 104 6% 
Other 12 1% 19 1% 
AC, anticoagulant group. 
"Discontinued at randomization. 
Table 8. Non-.cardiac medications at hospital discharge 
No. of patients 
Sedatives 
Analgetics 
Antidiabetics 
Antibiotics 
Pulmonary drugs 
Gastrointestinal drugs 
Corticosteroids 
Thyroid drugs 
Other drugs 
AC, anticoagulant group. 
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AC 
1700 
173 
40 
102 
36 
95 
115 
50 
10 
99 
Placebo 
100% 1704 100% 
10% 155 9% 
2% 54 3% 
6% 93 5% 
2% 23 1% 
6% 65 4% 
7% 113 7% 
3% 49 3% 
1% 20 1% 
6% 109 6% 
Total 
3404 100% 
210 6% 
759 22% 
1736 51% 
1267 37% 
586 17% 
306 9% 
112 3% 
1503 44% 
222 7% 
31 1% 
Total 
3404 100% 
328 10% 
94 3% 
195 6% 
59 2% 
160 5% 
228 7% 
99 3% 
30 1% 
208 6% 
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Table 9. Risk factors at admission 
AC Placebo Total 
No. of patients 1700 1704 3404 
Hypertension· 389 23% 395 23% 784 23% 
History of Diabetes Mellitus 134 8% 125 7% 259 8% 
Family history"'" 278 16% 305 18% 583 17% 
Current smokers 894 53% 888 52% 1782 52% 
AC, anticoagulant group. 
"Reported in the patient's medical history. 
"'"Myocardial infarction of first or second degree family members. 
Table 10. Randomization characteristics 
AC Placebo Total 
No. of patients 1700 100% 1704 100% 3404 100% 
Trial medication 
Phenprocoumon 930 55% 935 55% 1865 55% 
Acenocoumarol 
4 mg 127 7% 138 8% 265 8% 
1 mg 643 38% 631 37% 1274 37% 
Randomization delay ... 
< 2 weeks 1565 92% 1599 94% 3164 93% 
2-4 weeks 82 5% 67 4% 149 4% 
4-6 weeks 53 3% 37 2% 90 3% 
not available 0 0% oo;() 1 O% 
AC, anticoagulant group. 
"Patients are randomized to placebo or true medication after the physician has determined the 
type of medication. 
·Interval between hospital discharge and randomization. 
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Table 11. Incidence of patients with major clinical events during follow-up ("on ·mtention-to-treat") • 
AC group 
(n=1700) 
Placebo 
(n=1704) 
HR (95%C.I.)+ 
Total patient years of follow-up 5241 5200 
no. of events 
Death from any cause 170 (3.21100py) 189 (3.6/100py) 
Vascular death 134 (2.5/100py) 142 (2. 7/1 OOpy) 
lnstantaneous/Sudden 57 43 
UnobseJVed/Unexpected 12 21 
Recurrent Ml 24 40 
Congestive heart failure 27 30 
Cerebrovascular event 11 8 
Extracranial bleeding 3 0 
Non vascular death 36 47 
First recurrent Ml 114 (2.3/100py) 242 (5.1/100py) 
One Ml 101 208 
Two Mls 12 28 
Three Mls 1 5 
Four Mls 0 
First cerebrovascular event 37 (0.7/100py) 62 (1.211 OOpy) 
Intracranial bleeding 17 2 
Cerebral infarction 15 43 
Transient ischemic attack 2 6 
Unspecified 4 12 
Vascular event+ 239 (4.8/1 OOpy) 366 (7.9/1 OOpy) 
Major bleedings 73 (1 .4/1 OOpy) 19 (0.4/100py) 
Major extracranial bleeding 56 17 
Macroscopic haematuria 2 0 
Genital tract bleeding 1 0 
Haematoma ->1 0 em 4 1 
Epistaxis >30 min 2 2 
Gastrointestinal 33 8 
Respiratory tract 2 1 
Muscular 8 1 
Haemarthrosis 0 0 
Other 4 4 
HR, hazard ratio; Cl, confidence interval: Mr. myocardial infarction. 
·censoring was applied when the patient died or by the end offol!ow-up (30 June 1992). 
+The hazard ratio estimates are indicated. 
+vascular death/myocardial infarction/cerebrovascular event whichever event occurred first. 
'lntracraniaUextracraniaJ bleeding wh"1chever event occurred first. 
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0.90 (0.73-1.11) 
0.94 (0.75-1.20) 
0.47 (0.38-0.59) 
0.60 (0.40-0.90) 
0.65 (0.55-0. 76) 
3.87 (2.33-6.41) 
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Table 12. Incidence of patients with major clinical events during follow-up ("per protocol")" 
AC group 
(n=1700) 
Placebo 
(n=1704) 
HR(95% C.t.)+ 
Total patient years of follow-up 3725 
no. of events 
Death from any cause 91 (2.4/1 OOpy) 
Vascular death 81 (2.211 OOpy) 
Instantaneous/Sudden 35 
Unobserved/Unexpected 10 
Recurrent M! 16 
Congestive heart failure 10 
Cerebrovascular event 8 
Extracranial bleeding 2 
Non vascular death 10 
First recurrent M! 86 (2.3/1 COpy) 
First cerebrovascular event 24 (0.6/100py) 
Intracranial bleeding 14 
Cerebral infarction 6 
Transient ischemic attack 1 
Unspecified 3 
Vascular event+ 163 (4.4/100py) 
Major bleeding$ 55 (1.5/1 COpy) 
Major extracranial bleeding 42 
Macroscopic haematuria 
Genital tract bleeding 
Haematoma >1 0 em 4 
Epistaxis >30 min 1 
Gastrointestinal 26 
Respiratory tract 0 
Muscular 6 
Haemarthrosis 0 
Other 3 
HR, hazard ratio; Cl, confidence interval; MI. myocardial infarction. 
3488 
105 (3.0/1 OOpy) 
99 (2.8/1 OOpy) 
34 
17 
31 
14 
3 
0 
6 
207 (6.1/100py) 
42 (1.2/100py) 
1 
28 
6 
7 
305 (9.0/100py) 
6 (0.2/100py) 
5 
0 
0 
0 
1 
2 
0 
0 
0 
2 
0.86 (0.65-1.14) 
0.81 (0.61-1.09) 
0.41 (0.32-0.53) 
0.57 (0.34-0.93) 
0.53 (0.44-0.64) 
9.05 (3.90-21.0) 
'End·points occurring while the patient was on trial medication (or within 28 days after its cessation). 
+rhe hazard ratio estimates are indicated. 
+vascular death/myocardial infarction/cerebrovascular event whichever event occurred first 
$1ntracraniallextracranial bleeding whichever event occurred first 
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Table 13. Why and When trial medication was discontinued in the study medication groups 
Variable 
No. of permanent discontinuations 
Reasons for discontinuation 
deaths 
Non-fatal cerebrovascular event 
Non-fatal myocardial infarction 
Non-fatal extracranial bleeding 
Patient's refusal 
Physician's refusal 
Change of address 
Other 
% of patients still alive and 
still on medication 
at 3 mo 
at 6 mo 
at 1 yr 
at 2 yr 
at 3 yr 
at 4 yr 
Ml, myocardial infarction. 
"Major or minor bleeding. 
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AC Placebo 
768 887 
91 103 
12 32 
31 124 
81 11 
165 170 
12 14 
75 70 
301 363 
89 85 
82 79 
76 70 
64 59 
54 48 
48 41 
12 
Table 14. Invasive procedures after randomization 
AC 
Angiography 340 
Angioplasty 71 
Bypass surgery 128 
Pacemaker 14 
Thrombolysis 24 
Table 15. Prothrombin time measurements· 
INR 
<2.8 
2.8-4.8 
>4.8 
Cumulative approach 
(n=57,634) 
29% 
62% 
9% 
INR, international normalized ratio. 
Placebo Total 
440 780 
94 165 
142 270 
23 37 
69 93 
'Cross-section-of-the files' 
(n=1172) 
20% 
74% 
6% 
Verum patients up to discontinuation of trial medication. 
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figure 1: survival curve (on 'intention-to-treat') 
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figure 2: event free survival 
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APPENDIX 8.1 
Ruimte afslagplaatje 
U:J:fi:"'~<>.;.=;::r.JS VAN 
7 :~~ ~' _ -\L.fi 
TOELATINGSFORMULIER ASPECT-ONDERZOEK 
Vul dit formulier bij ontslag in voor iedere patient 
diagnose 'acuut myocard infarct' is gesteld. 
bij wie in het zlekenhuis de 
Vul dit formu!ier volledig in. tenzij door u Mn van de volgende vragen is beantwoord middefs het 
aankruisen van een hokje gevolgd door [stop]. 
Dit betekent dan dat de patient niet in het onderzoek wordt opgenomen. 
Het formulier behoeft dan niet meer verder te worden ingevuld. 
Wei dient het formu!ier oak in dit geval ondertekend te worden (zie hieronder) en opgestuurd naar het 
co6rdinatie centrum. teneinde het aantal van deelname uitgesloten patienten te kunnen berekenen. 
lndien geen identificatieplaatje van de patie!nt aanwezig is, s.v.p. de volgende gegevens 
hieronder noteren. 
2. Geslacht : MN (doorhalen wat niet van toepassing is) 
3. Geboortedatum :___./_/ __ (dag/maand/jaar) 
4. Qpnamedatum :___./_/ __ (dag/maand/jaar) 
Sehandelend arts 
Ziekenhuis ·naam 
-plaats 
Datum : _____;_____;__ (dag/maand/jaar) 
Ad res co6rdinatie centrum: 
ASPECT- onderzoek, 
Glashaven 68. 
3011 XK Rotterdam. 
INCLUSIECRITERIUM 
5. Toonden de hartenzymen het karakteristieke infarctpatroon, 
met tenminste een enzym meer dan 2X de normaalwaarde? 
EXClUSI ECRITERIA 
""6a. Bestaat er een strikte indicatie voor orale anticoagulantia behandeling? 
Zo ja, welke? _____________________ _ 
'"6b. Bestaat er een strikte conrraindicatie veer orale anticoagulantia· 
behandeling? 
Zoja,welke? _______________________ _ 
7. Heeft patient een andere ernstige ziekte dan het cardiale lijden? 
Zo ja, welke? _____________________ _ 
8. Heeft in de 6 maanden v66r de ziekenhuisopname 
orale antistollingsbehandeling plaatsgehad? 
9. Heeft een ander fid van het huishouden een antistollingsbehandeling? 
10. Staat patient op de wachtlijst voor coronary bypass opera tie of 
coronairangioptastiek (PTCA)? 
11. Zijn er moeilijkheden te verwachten t.a.v. een goede medewerking 
(b.v. langdurig verblijf buiten de huidige woonplaats)? 
12. Wilt u de patient tot de studie toelaten? 
Zonee.waarom? __________________________________________ __ 
13. Is toestemming verkregen? 
INFARCTGEGEVENS 
Ja 
D 
D [stop] 
D [stop] 
0 [stop] 
D [stop] 
0 [stop] 
o [stop] 
o [stop] 
D 
D 
14. Ontstonden nieuwe Q·golven (:::0:0.03 sec.) of Q·goff equiva/enten ~ 
(R;::0.03 sec. in V1 en RS·ratio :=::1 in V2) in het ziekenhuis? 
15. Ontstond ventrikeltachycardie of ventrikelfibrifferen in het ziekenhuis? 
< 24 uur na opname [J.AJ 
> 24 uur na opname ~ 
... 16. Wat was in het ziekenhuis de slechtste (hoogste) klasse 
vlgs Killip of MIRI.f? 
---17. Hoe is bij ontslag de validiteitsscore vo!gens NYHA t.a.v. 
a:dyspneu 
b: angina pectoris 
D 
II 0 
Ill 0 
IV 0 
D 
II 0 
Ill 0 
IV 0 
D 
II 0 
11! 0 
IV 0 
18. Wat is de cardiothoracale ratio (CTR) bij ontslag, indien bepaald? 
(Geef hierbij de absolute waarden aan.) (____j __ ) 
19. B!ijft patient onder uw centrale? 
Zo nee. in welk ziekenhuis? _________________ _ 
Meld patient aan als ASPECT-patient bij de trombosedienst---
en stuur dit formu!ier op naar het coOrdinatie centrum . 
... zie toelichting aan de linkerzijde. 
Nee 
o [stop] 
D 
D 
D 
D 
D 
D 
D 
o [stop) 
D [stop] 
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ASPECT- onderzoek, Glashaven 68, 3011 XK Rotterdam. 010· 411 20 74 
juli 1991 
Geachte mevrouw fmijnheer, 
Bij u is vastgesteld datu een hartinfarct heeft gehad. Een hartinfarctwordt meestal veroorzaakt door 
een afsluiting van een van de bloedvaten die het hart zelf van bleed voorzien. Antistollingsmiddelen 
zijn medicijnen die "bloedverdunnend~ werken waardoor de kans op een nieuwe afsluiting en 
daarmee een volgende hartinfarct zou kunnen worden verminderd. Behandeting met 
antistollingsmiddelen heeft als nadeel dat soms bloedingen kunnen ontstaan. 
Tot op heden bestaat echter onvoldoende zekerheid dat langdurige behandeling met 
antistollingsmiddelen inderdaad een gunstige werklng heeft op het voork6men van een volgende 
hartinfarct. Zo komt het dat een gedeelte van de hartinfarctpatienten in Nederland op dit moment 
antistolling krijgt ais nabehandeling en een ander gedeelte niet. Daarom wordt op dit moment 
onderzoek gedaan naar het nut van deze behandeiing. Dit onderzoek heet kort en bondig ASPECT, 
en deze letters staan voor: Anticoagulants in the Secondary Prevention of Events in Coronary 
Thrombosis. Een groot aantal ziekenhuizen neemt aan dit onderzoek deel datwordt uitgevoerd in 
samenwerking met de Federatie van Nederrandse Trombosediensten. 
In dit belangrijke onderzoek krijgt de helftvan de patienten antistollingstabienen en de andere helft 
tabletten die eruit zien als antisto!!ingstabletten maar niet het antistollingsmiddel bevanen (z.g. 
placebo-tab/etten). U noch uw hartspecialist zullen weten welke tabletten u krijgt. Aileen op deze 
wijze kan een juiste indruk worden verkregen over het nut van antistolling na een hartinfarct. Wij 
verwachten momenteel dat het onderzoek nog ongeveer 1 jaar gaat duren. Na be€indiging van het 
ASPECT-onderzoek zal uw specialist op basis van de verkregen resultaten beslissen over eventuele 
voortzetting van de antistollingsbehandeiing. 
Jndien u aan dit onderzoek wilt meedoen, wordt voor u een afspraak gemaakt bij de dlchtstbijzijnde 
trombosedienst. De trombosedienst zar de gebruikelijke controles uitvoeren en u regelmatig van 
nieuwe tabletten voorzien. Van de trombosedienst krijgt u ook informatiemateriaal dat voor de 
antistollingsbehandeiing befangrijk is. 
De controles op de trombosedienst staan los van controle afspraken of polik!inische afspraken die 
uw specialist met u maakt. 
Wanneer u toestemmlng geeft, behoudt u natuurlijk het recht om zich te allen tijde uit het onderzoek 
terug te trekken. 
Bent u bereid om aan dit onderzoek mee te doen? 
pat.inf 
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ATAL St1cht1ng Amsterdamse Tromoosed1enst en Artsenlaboratonum Jan Tooropstraat 138 1061 AD Amsterdam 
01rekt1e: A Jelet1Ch·Bast1aanse. arts Drs. J_ l. J. Smlt. kl1nlsch-chem1cus 
Ref. Datum. 
Aan de deelnemers van het ASPECT-onderzoek 
Geachte heer/mevrouw 
In het ziekenhuis ·hebt u b2sloten deel te nemen aan het z.g. 
ASPECT-onderzoek. De achtergronden en het doel van dit onderzoek 
zijn tijdens uw ziekenhuisopnante aan u uit.gelegd. Voor de 
volledigheid treft u hierbij nog een exemplaar aan van het 
patii2nten-informatieformulier. Bij de aan;nelding bij de Trombose-
dienst is voor u een z.g. onderzoeksnummer gekozen, bestaande nit 
3 letters en 4 cijfers {bijv. LHA 0021). 
Graaag wil ik u nag enkele praktische richt.lijnen geven voor een 
goed verloop van ]let ASPECT-onderzoek: 
1. Draag de aan u uitgereikte ASPECT-informatiekaart ALTIJD btj u. 
Laat deze kaart zien bij bezoeken aan hu:Lsarts en speciaiisten. 
2. De trombosedienst zorgt ervoor datu steeds nieuwe antistollings·· 
tabletten krijgt. Bij het eerste bezock aan de trombosedienst 
krijgt u 2 ·potjes met antistollingstablel.tE:n', met vermelding 
van u'"' onderzoeksnummer op het etiket. Indien §i§n potje dreigt 
leeg te raken, wilt u dan kontakt opnernen met de trombosedient 
zodat bij het volgende bezoek aan de trombcsedienst u een nieuw 
potje met tabletten kunt krijgen. 
Dit betekent dat u geen antistollingstabletten mag ge~ruiken 
die door m-1 eigen apotheek zijn verstrekt! 
Bij een ziekenhuisopname dient u 66k u•,.r eigen antistollings-
tabletten te blijven gebruiken. 
3. Na elke centrale door de trornbosedienst ontvangt u een doserings-
kalender waarop staat aangegeven hoeveel tabletten u per dag 
dient in te nemen. Op deze doseringskalender staat uw onder-
zoeksnummer verrneld. 
4. Het ASPECT-onderzoek duurt tot ongeveek:' april 1992- Tot die 
tijd blijft u de antistollingstabletteq gebruik~ die u door 
de trombosedienst worden verstrekt. 
Tijdens he t ASPECT-onderzoek z ij n u g·~en beperkingen opgelegd · 
Dit betekent o.a. datu ge·.·;oon op vakantie kunt gaan. \'lel is 
het dan van belang dat u voldoende antistollingstabletten 
meeneemt voor die vakantie. 
Macht u nag vragen hebben dan kunt u dit bcspreken met de zuster 
van de trombosedienst. 
!'let vriendelijke groeten, 
Stichting ATAL, 
A. Jeletich-B3stiuanse, arts 
Trombosedlenst 
Artsenlaboratonum · 
PostreKen1ng 
BanK 
telefovn 020·1 1 49 11 
telefoon 020·11 38 11 
28559 
Morgan Labouchere N.V. Amsterdam, rek.nr. 26.20.26.848 
APPENDIX B.IV 
ROTTERDAMSE TROMBOSEOIENST 
Geb.datum 
Adrea Ziekenfonds: ______________ ___ 
Woonplaate Part~lier: ____________ __ 
Post code ________________ Tel-nr. pat. : --------------------- Buisarts 
Gezonden door: _________________________________________________________________________________ _ 
ASPECT-nummer: _________________________ _ 
======================================================-----==========================--=== 
INDICATIES 
o 110 Hartinfarct vraag ook hiernaar:--> 0 001 ASPECT 
0 
0 
0 
0 
0 
0 
0 
0 
0 
120 Recidief 
130 Angina pectoris 
410 Trombose v/d diepe vaten 
416 recidief Tromboee onder AS 
430 Oppervlakkige tromboflebitis 
140 Aneurysma cordis/aortae 
geopereerd j a/nee 
520 Atheroaclerose 
760 gedotterd 
700 Vaat-operaties (veneus Bypass) 
0 421 Tramboae v/d vena centralia retinae 
(009) 
o 600 cerebrale vaataandoeningen (hersenen) 
0 210 Atrium/boezem£ibrilleren 
o 710 ~epprotheae 
0 800 Profylactisch 
o 730 Coronair bypass 
0 540 Arteriijle embolie in de 
grote cireulatie 
geopereerd ja/nee 
0 550 Longembolie 
Bij opnieuw oatienten reden van opname navragenl 
- ontslag ziekenhuis/thuis begonnen datum=--------------------------------------------------
- Eerder bij de trombosedienst onder behandeling ja/nee 
- Leverfunktiestoornia ja/nee 
Nierfunktiestoornia ja/nee 
'l'enaie/bloeddruk I 
- Welk preparaat: Sintrommitia/Maryoumar•) 
- Post of aan huia be zoe ken datum:-------------------------
*) Sintrom 4 mg. gaat uit de handel! 
Rotterdam 
9048.sta 
"" HT 
'l'r~=---------------------
wijk nr. ____________________ _ 
Paraaf 
APPENDIX B.V 
De Weledelgeleerde 
Rotterdam, 26 februari 1991 
Betreft: 
Geboren: 
Zeer geachte collega , 
Bij deze deel ik u mee, dat bovengenoemde patient( e) toestemming heeft gegeven om aan het 
ASPECT -onderzoek dee! te nemen. 
Het ASPECT -onderzoek is een gerandomiseerd, placebo gecontroleerd onderzoek naar het effect 
van langdurige behandeling met antistolling na een recent rnyocardinfarct. 
Ik wil u verzoeken om in het geval dat uw patient(e) wederom in een ziekenhuis wordt 
opgenomen mij zonodig informatie te verschaffen over deze heropname. 
Hetzelfde geldt voor het geval dat uw patient( e) komt te overlijden. 
Verder is bet voor u van belang te weten dat uw patient( e) de antistollingsmedicatie van ons krijgt 
zodat ik u wil vragen geen andere antitrombotische medicijnen (aspirine, sulfinpyrazon of 
dipyridamol) voor te schrijven. 
Bij voorbaat mijn hartelijke dank. 
Met vriendelijke groer, 
A APPENDIX B.VI STUDtE NR. ASPECT STUDlE NR. 
Omum r~ndomisotic ~1-1-
D<:Ltum opn<:~mo _;_;_ I . ! v ~ Dmum ontsk:lg _;_;_ :;- v ~ ENZYMEN: 
OPNA~.1E CK bcpJ<:~Id 
Opnamc SBD ___ mmHg 0 01 0-m-,wv.;lon:cn - m.:>Y 
DBD ___ mmHg VT /VF m :kh_ < 24 um f(ll 
:> 24uur • CK·MB bcpilakJ- ~· !::J I 
Opn,:,mc HF ___ /min docomp.cord1t. 111 zkh. 1 - 111JX 
vltJ~ K1II•P/MIRU " ~ ref: 
Ontsl.:lg SBD ___ mmHg Ill- LDH bcp.;,Jid-
DBD ___ mmHg IV ~ m;:n::_ 
(ii~PMU b11 Ont~l<>g I - ref· 
OmsiJg HF ___ /min I] ~ ,. A-HBDH bcp;dd - -~, 
Ill- m;:.x:. 
Hb ~~~'] IV L::-i ref: AP b•J ontsi<~g I • c SGOT-ASAT b-~P.:>illd -: 
H' ___ % I]. L' m" 
9 
max.opn./ontsl. Ill· r.:::; ref: 
Trombo"s ___ x 10/1 JV~ L: SGPT-ALAT b.:pJald · 
Jndcro compllc.Jt•es qcon - c m;:.x· 
Cholc:>tNol ___ mmoVI twcedc gr. AV - LJ rof:. 
dordc gr. AV- 0 ONTSLAGMEDICATIE 
CTR (bij ontsJag) _;_ uitbrciding Ml - l:':l digllillls 
ovcrig - 0 c'iurctic<:L -~ 
.. OAC bchandoling - 0 bcw·blockors .:=_j 
VERRICHTINGEN: longw_ nmotcn -:::J 
EDV ___ mm J £c1Jo- 0 CJ·JnWgcnistcn -::J 
EDV v<Jrgroot - c ~~ ort. vJ.Jtvorw•JdCrs -C.~ 
hypok•nCSic/.Jkm<!sic - ~ ~ CJ .:mto·JntmiC..1·__.:; 
c.Jyskoncsrc - C1 =I ovcng -·--
EF ___ % RadJon(JCiid~·:;c,1n - _:j VOORGESCHIEDENIS: 
EF 
% ] Vo>ntfJCulogr.:Jf,e - ' AP $4 wkn -:::--.1 EDV ___ mlfm' EDV vcraroot - ~ > 4 v;-kn -:::"'J 
ll;po~incsoo/ak•nt:r~lo -
·-
~- OudMI < 1 rr- .:~-, '-
dysk1ne~•c - > 1 jf -:·:.: 
Ccron,-ur.:Jngrogr.:;lie - -, Cvthctcrlsatlo 
' 
1 jf -LJ C' 
>50 , vcrnouwtn\.]: goon - - > 1Jr-C 
LM ~ Bypa::;s ch1r. < 1jr-C 
LAD~ > 1 Jr -L." 
{Ll ex-
-
.. PTCA $1 jr-C· 
RCA ~ > 1Jr-C 
Trombolytic.:J-IV_ - G omiplo.Jtjcs middclcn $1Jr-O 
-
Trombo!yrica r.c. - __j 0 > 1 Jr-0 
Thallium pcrf.sc.:Jn - _, 0 c.ntistoll•n<;J $1jr-O C' 
PTCA ~ ~ 0 :- 1 Jr -0 
8yp.:Jss chiturgrc - L 0 rodcn <:~ntiStollong: MI-D 
Oven¢ card chiturgic - L" Ll CVA -CJ 
Ovr:ngr: ch1rurgir: • c 0 DVT/LE -C 
Pacemaker - c Ci ovorig -D 
CDrdro\-c~ie/defibrt!I.:Jric - 0 CJ blnnko -0 
HF rust ___ /min !nsp.:mningsprae'f - CJ -, uvorig -0 
HF mJx. ___ /min redcn vr.n stoppcn: AP ~ 0 onbckcnd .CJ 
SBD rust ___ mmHg dyspncu - 0 RISICOFACTOREN: 
SBD mnx. ___ mmHg ovong p<lt bopa:Jid - 0 gcen -0 
Max_ inspanning ___ WJtt door Jrts OOpJJid · 0 hypcrtensio -D 
Norm. inspanning 
---""" 
ntmestoorn1sscn -
r~, diabetes mellitus -0 "~ 
onbckcnd - ~ fJmilto:Jn:Jmncso -0 
lngovuld datum _;_;_ ST-segmcnt: OIWCf:lndcrc.J - rokon -0 
n.:Jnm clcv.ltic - ~---' DIVERSEN: 
Afgcwerkt d:Jtum 
_j_f_ dcprassoo - ~- Kopio ontsi.:Jgbricf -0 
nJom toopJnno > 10.000 E/dag · r::c ~~~ Ontslog E.C.G. -0 
Lot op. bij invulling bcslist 28 potlood gobruikonl Kof)ic lab.uitsk10on .r_:: 
STUDIE NR._ 
Toelichtlng: 
frequontie > 5 afrooden Nar boven in wolwud van 10 
8. N - normaal s"'usmme (50 ~ HF -10 100 
? - ritmc niet te beootdektn 
9.N ~{ll)etl"codeorbaro"divor.;en 
3.1 ~ RAO: rochter atrium~ 
3.2 -LAO: linl«!r atnum ~ng 
B<J normalo ijlt: 0,1 mV = 1 mm 
b•J halve 1jk 0,1 mV- 0,5 mm. 
codoor "J" indien Q ..,. 0,03 sec. of >.0, 1 mV 
codoor "N" •nd'en 0 < 0.03 soc. of < 0.1 mV 
codeer "NTB· indien noet ro bcoordelen 
b11 OOrmi!le ijk: 0,1 mV ~ 1 mm 
boj halv(l IJk :0.1 mV = 0.5 mm 
Let op. b1j 1nvulling beshst 2B potiood gebru1k(!lll 
ukco/thorax 86.2 
APPENDIX B.VII 
ECG KENMERKEN 
ASPECT STUDlE NR--·· 
DAlUM: _f _f _ 
ECG kwaliten - good - D matig - 0 slecht - D 
~rek.wentie - EJ ~ §] [@ §I ~ ~ ~ §] 0 c_; 
CU$-SCORE _ 
'· 
a AVL. (msec) -
2a. Tpoo.AVL < 1/2mrn.~3mm- [!] 0 
T nag.. AVL (mm) -
neg. doflectie ORS AVR (mm) - 0QJ000GGJ00!::! 
[@§} 
4. Tneg.AVR(mm)- @JIJJmmmmmmm 
.. 
6. 
7. 
.. 
•. 
'"· n. 
QRUotAVF~1/S - f!l [!] 
OlllofR(niotnl!Ol·AIII...~40msoe. [!) QJ 
"Tnog.lll > 1 mrn- [!) m 
Tpoa.VI>2mm- !!I 0 
RV2<t;3mm.>14rnm.· r:!J. GJ 
Tnog. V2 ~ 1f4mtn • [!l 0 
Q/RV3 > 1/20 - [!! 0 
SV5<2mm- !!l QJ , .. 
MINNESOJ"A-CODE ... 
'· 
OQOif - 0 li1l @ ~ S [!I ES ~ 
ai!@f§GSH:EI!!!J§:!ll?B 
!]I§§]B3§JB3 
2. 
4. 
5. 
6. 
7. 
8. 
9. 
LOKALISATIE 0-.GOLVEN .. 
(Q ;:, 0.03 we. 
en:?; 0.1mV) 
Q-GOLF EQUIVAL.ENTEN 
R > 0,03 sec en ;:, 
=-
R "P -
ST :l<)gment -
TWO -
AVgeleiding -
w geleiding -
.rmtmieen -
divQ~ -
afloodong: '-
"-
111-
v' 
V2 
V3-
'·' 
mV1nV1 
R/S ratoO >. 1 In V2 
(;) 
(;) 
@ 
0 
0 
0 
@ 
0 
[!) 
0 
0 
0 
0 
[!] 
m 
0 
[!) [!) [!) m [!) 
[!) [!] [!) m 
E:l [§ 
[!) [!) 0 
m [!) [!) 0 
m [!) [!) 0 [!] 0 0 
, 
m [!) [!) 0 [!] [!) [!) 0 
[j] [!] [!] 
"' "' [!) [!) 0 m m [!) [!] m 
m [!) 
E:l l!!l 
El 8J 
[]) 
@3 [§] 
[!) 
" 
afloiding: AVR- G 
0 
" 
AVL- G 
0 
" 
AVF- G 
JJ [§ V4- :S 
[)] 
" 
V5- GJ 
0 
'" 
V6- G 
,_,_ 
" :JJ 
"' 
[lJ 
[!) 
0 
0 
0 
0 
c:: 
~ 
?!"' 
:-·· 
E.·· 
?cc~ 
~"· 
ZJEKENHUISOPNAME CARDIAAL APPENDIX B.VIII 
ASPE:CT ~nummer: Naam beoordeler: . 
Opnamedatum· ........ / ...... ./. .. . Ontslagdatum: ....... ./ ....... ;. 
Is de naofddi;Jgnose indercaad cardiaai? 
0 j.:J. 
o nee: lndien neen geef aan naar wie deze opname dan verstuurd diem te worden· 
o NeL!roloog a Internist o Retour Co6rdinatiecenrrum 
HCOFDDIAGNOSE 
a A. Myac:J.rainfarct 
0 E 
o ~ Overleden onder klinisch beeld 
o : .ll.anwezigheid van tenminste 2 van de 3 onderstaande mogelijkheden 
o a pijn op de borst 
o b stijgtng van de nanenzymen (CK. CK-MB. LDH. HSOH. ALAT. ASAT) 
met :en minste een enzym grater dan 2x de bovengrens van de normaalwaarce. 
o :::ontstaan Q-golf grater dan 0.03 sec. (of R grater dan 0.03 sec. in V1 en RS ratio 
grater dan 1 in V2) 
G=-:f !ocatJe infarct: (aanwezigheid van Q-golven in mmstens 2 afleidingen l 
o 1 amero ·;_sep~all (V1-V4) 
o - anterosepraal op basis van ST-T en/ofT-golf verandenngen 
o 3 3!l!erolareraal (VS; VS1 1, AVL) 
o .l an:erolateraal op basis van ST-T en;of T-golf veranderrngen 
o ~ ,nfercoosre~ior (I~ II~. AVF) 
o 5 :-:fer a posterior op basis van ST-7 en/ofT-golf veranderingen 
o - 'ltE-t ~e bepalen 
Qnst<:tbie!e Angma Pectoris 
0 ~Fin rust 
0 - ?mgressteve AP a·eifort 
0 ~ieuwe AP d'eifort 
0 
" 
Geen onstabiele AP 
J 
-
j,p 'Tlet hanenzymsrijgrng :-- 1 maar·· 2 
o .... Staore!e . .!.ngma Pecrons 
o 0; Anders 
o 1 Aitme / geleidingsstoornis 
o 2 Pompfunctiestoornis 
o 3 Aneurysma dissecans 
o 4 ?encarditis 
o 5 Endocarditis 
o 6 Eiectieve opname voor cardiale diagnostiek; vernchring 
o 7 Overige in de thorax gesitueerde pijnklachten van niet cardiale oorzaak 
o 8 Aspecifieke "pre-cordiale klachten" 
a 9 Geen van bovenstaande 
COMP~iCATiES (meerdere mogelijkheden) 
a 1 Cerebra vascu!air accident 
o 2 Extracraniele aneri§le thromboembo!ie 
o 3 ExtracraniE!Ie veneuze thromboembolie 
o 4 Anders 
o 5 Geen 
vE:=:;;;:JC!-fTINGEN (meerdere mogelijkheden) 
a Angiografie 
a 2 Thrombolyse 
o 3 Coronair angioplastiek 
a 4 Coronaire bypass operarie 
a 5 Pacemaker implantatie 
a 5 Overig cardiaal invasief 
o - Geen 
/door CC ingevuld 
Geef complicaries van verrichtingen (meerdere mogelijkheden) 
o 1 Overlijden 
o .:. Myocardinfarct 
o 3 Bleeding 
a 4 Extracranie!e anerii?le thromboembolie 
0 5 Exrracranii?le veneuze thromooi?mbolie 
o 6 Cerebraal 
a 7 Overtg 
o 8 Geen 
card::: 
!s de patient overteden? 
a 1 Ja Datum: f .. ./ ..... . 
a 2 Neen 
lndien ja. geef acute omstandigheden aan: 
o lnstantane dood 
a 2 Plotseling (minder dan 1 uur na ontstaan van klachten) 
o 3 Niet geobserveerd. onven.vacht 
a 4 Ritmestoornis geobserveerd 
o 5 Pompfunctie stoornis 
o 6 Tijdens verrichting 
o 7 Bloeding 
o 8 Extracraniele arterie!e thromboi?mbolie 
a 9 Extracranii?!e veneuze thromboi?mbolie 
o 1 0 Cerebraal 
o 11 Overig cardiaal 
o 12 Overig 
Is de medicatie gestaakt? /door CC ingevuld 
o 1 Ja Datum: ...... / .... .;.. 
o 2 Nee 
o 3 Eerdar gestaakt 
Ind!en Ja. vervolgmedicatle na staken ASPECT medicatie: 
a 1 AmistoJiing 
a 2 Plaatjes aggregatieremmer 
o 3 Geen antitrombotische medicatie 
o 4 Onbekend 
o Hervanlng ASPEC7 medicatie 
o Ja Datum· .... ./ .... .;.. 
o nee 
o Oez'2 ep1sode diem besprcken te worden 
HANOTEKENING. __________________________________ _ 
carc3 
(ZIEKENHUISOPNAME) EXTRA-CRANIELE BLOEDING 
ASPECT-nummer: Naam beoordeler: 
Eventn': 
Is de hoofddiagnose inderdaad extracraniiHe bleeding? 
o ja 
o nee: lndien neen geef aan naar wie deze opname dan verstuurd dientte worden: 
o Neuroloog a Cardioloog a Retour CoOrdlnatiecentrum 
Heeft de extracranieJe bleeding geleid tot ziekenhuisopname? 
o ja Opnamedatum: ... ; ...... .;.. Ontslagdatum: .... ; ....... .;. .. . 
o nee Datum van gebeurtenis: ....... ; ...... .;.. 
HOOFDD!AGNOSE 
0 1 M~~:;rQSCQRisg;h~ h~em~tyri~ diagnostische Onderliggend Jijden 
rode urine (stolsels) bleeding 0 1 neen 
o 2 ja .................. 
0 2 [21QeQing tr. genitaliS diagnostlsche Onderli~:Jend lijden 
geen haematurie, geen bleeding 0 1 neen 
menstrueel bloedverlies o 2 ja 
····················· 
0 3 81Q~Qing !:;Qnjyn)C!Iv~ diagnostische Onderliggend lijden 
rood cog met onver- bleeding 0 1 neen 
anderde visus a 2 ja 
····················· 
04 81Qf!d'mg hy'1d dlagnostische Onder!iggend lijden 
10 em. of multipel bleeding 0 1 neen 
o 2 ja ................... 
0 5 BIQftding neus diagnostische Onderliggend lijden 
30 min. of med. bleeding 0 1 neen 
behandeld o 2 ja 
extra1 
0 6 Bleeding tr,digestivus diagnostische Onderllggend lijden 
haematemesis, melaena. bleeding 0 1 neen 
rect bloedverlies. o 2 ja 
pas. benzidine 
0 7 BIQ~Qing tr re~Q diagnostische Onderliggend lijden 
hemoptbe. geen neus- bleeding 0 1 neen 
bleeding o 2 ja 
0 8 Bloeding spier diagnostlsche Onderliggend lijden 
pijnlijke zwelling, bleeding 0 1 neen 
(bewegingsbeperking) o 2 ja 
retroperitoneale bleeding, 
buikwand haematoom 
0 9 t21Q~Qing gewri~:;ht diagnostische Onderlfggend lijden 
hydrops gewricht met bleeding 0 1 neen 
haematoom of met o 2 ja 
··················· 
bleed bij punctie 
010 BIQ~ding intr2:QQlliS!ir diagnostische Onderliggend Hjden 
incl. oogfundusbloeding bleeding 01 neen 
( excl.retinopathie) o 2 ja 
011 §IQe:Qing ~nQe:r~ dlagnostische Onderliggend lijden 
niet anders te classi- bloeding 0 1 neen 
ficeren, we! specificeren o 2 ja ............................... 
extra2 
ZIEKENHUISOPNAME JNTRACRANIEEL 
ASPECT-nummer: ........................... Naarn beoordeler: .......•.................••.... 
Eventn°: ................... . 
ls de hoofddiagnose inderdaad neurologisch ? 
a 1 Ja 
o 2 Neen 
o 3 Onzeker 
lndien neen. geef aan aan wie deze opname gestuurd dientteworden: 
o Cardioloog o Internist o Retour CoOrdinatiecentrum 
Heeft de gebeurtenis geleid tot ziekenhuisopname? 
o ja Opnamedatum: ........ / ........ ;........ Ontslagdatum: ........ ; .....•.. ; ....... . 
o nee Datum van gebeurtenis: ........ ;. ....... ; ....... . 
L Cerebrate gebeurtenissen: CT-scan aanwezig 
o A/ Hersenbloeding 
o 1 lntracerebraal 
o 2 Arachno"idaal 
o 3 Su bduraal 
o 4 Epiduraal 
Afloop: 
o 1 Overleden < 24 uur 
o 2 Overleden > 24 uur ( ..... dagen) 
o 3 Niet overleden en niet tnvaliderend 
o 4 Niet overleden en gering invaliderend 
o 5 Niet overleden en matig invaliderend 
o 6 Niet overleden en ernstig invaliderend 
o 6 f Herseninfarct 
Afloop: 
o 1 Overleden < 24 uur 
o 2 Overleden > 24 uur ( .... dager) 
o 3 Niet overleden en niet !nvaliderend 
o 4 Niet overleden en gering invaliderend 
o 5 Niet overleden en matig invaliderend 
o 6 Niet overleden en ernstig invaliderend 
o C/ Niet te beoordelen intr1 
.!!... Acute cergbra!g m~benrumissen: mwn CT -scan aanwgzjg 
Afloop: 
o 1 Overleden < 24 uur 
o 2 Overleden > 24 uur ( ...... dagen) 
o 3 Genezen < 24 uur 
o 4 Genezen > 24 uur ( ...... dagen) 
o 5 Niet overleden en niet invaliderend 
o 6 Niet overleden en gering invaliderend 
o 7 Niet overleden en matig invaliderend 
o 8 Niet overleden en ernstig invallderend 
!.lL. Spinale pathologje (bleeding of infarct) 
o 1 Ja 
o 2 Neen 
o 3 Mogelijk 
.DL Overim~ neurologische aandoening 
o 1 Ja=------------------------
0 2 Neen 
Is de patient overleden? 
o 1 Ja Datum: ........ ; ........ ; ....... . 
o 2 Neen 
Is de medicatie gestaakt? /door CC lngevuld 
o 1 Ja Datum: ........ ; ....... .;. ...... . 
o 2 Nee 
o 3 Eerder gestaakt 
Jndien ja. vervolgmedicatie na staken ASPECT medicatie: 
o 1 Antistolling 
o 2 Plaatjes aggregatieremmer 
o 3 Geen antitrombotische medicatie 
o 4 Onbekend 
o Hervattlng ASPECT medlcatie 
o ja Datum: ..... .; ...... ; ..... . 
onee 
o Deze episode dient besproken te worden 
HANDTEKENING: ______________ _ intr2 
Z!EKENHUISOPNAME OVERIG J INTERN 
ASPECT-nummer: . Naam beoordeler: . 
Js de hoofddiagnose inderdaad overig? 
o ja 
o nee; lndien neen geef aan naar wie deze opname dan verstuurd dientte worden: 
o Neuroloog o Cardioloog o Retour Co6rdinatiecentrum 
Heeft de gebeurtenis geleid tot ziekenhuisopname? 
o ja Opnamedatum: ....... ; ....... / .. . Ontslagdatum: ........ / ....... ; .. 
o nee Datum van gebeurtenis: ........ ; ....... ; ....... 
HOOFDD!AGNOSE 
o 1 Extracraniele arteriele thromboembolie 
o 2 Extracraniele veneuze thromboembolie 
o 3 Perifeer arterieel vaatlijden 
o 4 Tractus respiratorius aandoening 
o 5 Tractus digestivus aandoening 
o 6 Tractus urogenitalis aandoening 
o 7 Jntoxicatie 
o 8 Overige tractus 
o 9 Electieve chirurgie 
o 10 Trauma 
o 11 su·lcide 
o 12 Homocide 
o 13 Geen diagnose te stellen 
overig1 
STAKEN MEDICA TIE (zonder ziekenhuisopname) 
ASPECT·nummer: ..................... . Naam beoordeler: .............................. . 
Eventn°: ................... . Datum staken medicatie: ....... .; ....... ./ ... . 
Medicatie gestaakt in verband met: 
o 1 Weigering patient zonder verdere medische reden 
o 2 Verhuizing 
o 3 Weigering huisartsjspecialist zonder expliciete reden 
o 4 Boezemfibrilleren 
o 5 Recent ontstane angina pectoris 
o 6 Progressie stabiele angina pectoris 
o 7 Thoracale klachten 
o 8 Overig cardiaal 
o 9 Onvermogen de medicatie behoorlljk in te nemen 
o 1 0 Aneurysma cordis 
o Overige indicatie voor antistolling: ................................................. . 
o Overlge contraindicatie voor antlstolling: ......................... . 
o Overig, a.u.b. specificeren: ............................................... . 
o Verandering van medicatie: Datum: ....... .; ....... ;. ...... . 
o 1 Antistolling 
o 2 Plaatjesaggregatieremmers 
o 3 Geen antltrombotische medicatle 
o 4 Onbekend 
o Hervatting ASPECT medlcatle 
o ja Datum: ........ ; ........ / ....... . 
onee 
HANDTEKENINGo _______________ _ 
=:x7~A:viURAAL OVERLIJDEN (inc!usiet verpleeghuis- en beJaardenhuisopnamen) 
A~:==:•:7-nummer· Naam beoordeler: 
Datum overlijden· 
J n:;;:3r.rane dood (zonder vooratgaande specifieke k1achten 1 
,J =lotseiing en onverwacht (minder dan 1 uur na ontstaan klachtenl 
J ·\i:n:s-:n ceela recidief infarct (langdurige p1jn ECG"s in am bulan eel 
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ASPECT- onderzoek, Gl8shaven 68, 3011 XK Rotterdam, 010-411 20 74- 414 86 44, tst. 46 
Geachte collega, 
Uw patient(e) is met zijn:haar toestemming opgenomen in het ASPECT-
onderzoek. Inmiddels is de behancleling via de thrombcr.=e::::lienst gestaakt. 
Een verdere registratie van het klinisch beloop is echter voor het 
onderzoek van belang. Via de throrrrl:osedienst kunnen cleze gegevens 
niet meer achterhaald worden. 
Zou u zo vriendelijk willen zijn door middel van het bijgevoegde 
formulier ons infonneren over het verdere klinische verlcop 
en eventuele anti trombotische vervolgmedicatie? 
Een antw::ordenveloppe is bijgesloten. Vanzelfsprekend zullen de door 
u verstrekte gegevens als medisch ~heim ;-,lOrden behandeld. 
Mo:::ht u vragen hebben met betrekking tot het onderzcek dan kunt u zich 
wenden tot ondergetekende. tel. :DlD-4112074. 
Bij voorbaat hartelijk dank voor uw medewerking. 
Met vriendelijk greet, 
datum 
ons kenmerk 
onderwerp 
ASPECT· onderzoek, Glashaven 68, 3011 XK Rotterdam, 010-411 20 74- 414 86 44, tst. 46 
Betreft: Datum laatste centrale: .... : .... : .... 
I. Is pai:ient(e) na bovengenoemcle datum nog in een ziekenhuis opgenomen 
geweest? ja j n<=>..e 
Indien ja: 
Eerste opname: 
-Datum opname: ..• : ... : .. . -Datum ontslag: ... : ... : .. . 
-Ziekenhuis naam: ....... . -Specialist naam: ........ . 
-Ontslagdiag~: 
Tweede opname: 
-Datum opname: ... : ... : .. . -Datum ontslag: _ .. : ... : .. . 
-Ziekenhuis naarn: ....... . -Specialist naam: ........ . 
-Ontslagdiagnoe~: 
Indien rre::Jr dan twe"'e ziekenhuisopnarnen hebben plaatsgevonden. 
s.v.p. op andere zijde vermelden. 
II. Patient( e) is: in leven:overleclen (datum: ... : ... : ... ) 
Patient( e) is overleden in: o ziekenhuis t.w.: ............. . 
o verpleegtehuis t.w ............. . 
o thuis of elders 
Omschrijf s.v.p. onderstaand de omstandigheden waaroncler de patient(e) 
is over·leden. 
BLKFUP:PtZAR:90 
N.B: Gebruikt patient( e) Aspirine? ja:nee, zo ja. sedert: (clatum) ... : ... : 
Opmerkingen: 
!);: .... tum: ... : ... : ... Naam: •••••••••••••. 
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SUMMARY 
The therapeutic effects of anticoagulants in the treatment of patients with deep 
venous thrombosis, pulmonary embolism, prosthetic heart valves, atrial fibrillation 
and heart failure are well established. However, long-term anticoagulant therapy for 
secondary prevention of morbidity and mortality in post-myocardial infarction patients 
remains controversial. Anticoagulant therapy carries potential bleeding risks and 
therefore requires continuous anticoagulant monitoring by the clinician and demands 
patient compliance. However, the relation of bleeding and thromboembolic 
complications to intensity of anticoagulant therapy has not yet been investigated. In 
this thesis, the optimal intensity of long-term anticoagulant therapy in preventing the 
occurrence of thromboembolic as well as haemorrhagic complications in 3404 post-
myocardial infarction patients was assessed. 
Chapter 1 reviewed the value of long-term anticoagulant therapy after 
myocardial infarction based on more than thirty trials which have been reported in 
the literature in the past 40 years. The early studies were performed with 
inappropriate methodologies and demonstrated a non-significant reduction in 
mortality. Beneficial effects in reduction of thromboembolic complications were offset 
by a higher risk of haemorrhagic episodes. These studies also faced laboratory 
control problems in that different laboratory tests were used to monitor intensity of 
treatment. However, at present, any prothrombin time established with any 
thromboplastin reagent can be translated into an internationally agreed norm, the 
international normalised ratio (INR). 
In the seventies, debate over the effectiveness of long-term anticoagulant 
therapy was prominent but, in that decade, only three randomized controlled studies 
were performed: Breddin, EPSIM and 'Sixty-Plus'. The first two studies failed to 
demonstrate a reduction in mortality by use of oral anticoagulant therapy. In both 
trials aspirin was as effective as anticoagulant therapy in reducing mortality and 
morbidity, however anticoagulant control was relatively poor and the small size of 
the trials makes the findings inconclusive. The 'Sixty-Plus' trial did demonstrate a 
positive treatment .effect of oral anticoagulant therapy as compared to placebo. In 
this trial72% of the patients were within 2.7-4.5 INR. The merits of the "Sixty-Plus' 
study were debated by many because of its specific design: it assessed the value 
of discontinuation of long-term therapy rather than of its initiation. Nevertheless, the 
positive findings of this study reopened the long standing debate of long-term use 
of oral anticoagulant therapy after myocardial infarction. 
Subsequently, results ofthe carefully performed WArfarin Re-lnfarction Study 
(WARIS) was published in 1 990. A total of 607 patients were assigned to warfarin 
and 607 to placebo. Mean follow-up was over three years. The results clearly 
demonstrated the benefits of oral anticoagulant therapy in patients surviving an 
acute myocardial infarction in preventing death: mortality in placebo was 123 
compared to 94 in patients treated with warfarin (24% reduction). In addttion, the 
rate of myocardial re-infarction was reduced by 34% and stroke by 55%. 
Anticoagulant control was adequate: 67% ofthe patients had values within the range 
of 2.8-4.8 INR. 
The results of the largest randomized, double-blind, placebo controlled, 
multicentre ASPECT (Anticoagulants in the Secondary Prevention of Events in 
Coronary Thrombosis) trial are given in Appendix A. ASPECT compared oral 
anticoagulant therapy (acenocoumarol or phenprocoumon) in 1700 patients to 
placebo in 1704 patients surviving an acute myocardial infarction with a mean 
follow-up of three years. A total of 170 deaths in actively treated group compared 
to 189 in placebo was observed (1 0% reduction in mortality), the rate of myocardial 
re-infarction was reduced by 53%, stroke by 40% and vascular event by 35%. These 
beneficial effects were offset by a 1 0 fold increase in the incidence of major bleeding 
for the actively treated group (55 in the actively treated group and 6 in placebo). 
Anticoagulant control was adequate: 63% of the patients had INR measurements 
within 2.8-4.8 INR. 
Chapters 2 and 3 described in detail the methods for double-blind 
anticoagulant titration as employed in ASPECT. Anticoagulant therapy is not a fixed 
dose therapy but patients who use these drugs have to visit the anticoagulant clinic 
regularly for INR monitoring and dosage adjustments. Placebo patients also visited 
the clinics and fake INR values were obtained in this group. Similarly, dosage 
adjustments were made for this group just as in patients on active therapy. This 
method ensured the double-blind collection of data and thereby prevention of 
information bias. 
Chapter 4 reviewed the different approaches to assess therapeutic quality 
control using the INR: (1) the 'cumulative-INRs' considered the number of INR 
values and the 'cross-section-of-the-files' considered the most recent INR obtained 
in each patient. The results are expressed as a percentage of all INR values within 
therapeutic range; (2) an estimate of the percent of time each patient was within the 
therapeutic range, where the INR change occurred either directly after the first or 
half-way between visits; and (3) total volume of observation time of all patients 
categorised into classes of INR values assuming that INR values changed linearly 
between visits. These approaches were evaluated in the ASPECT patients on active 
anticoagulant therapy. Total treatment period comprised 3725 patient-years and 
61,471 INR measurements. The data revealed that, irrespective of the approach 
used, therapeutic achievement stabilized after 6 months of treatment. Under-
anticoagulation decreased between the first and third month and was again lower 
after six months of treatment. Over-anticoagulation (INR>4.8) occurred between 8% 
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to 10% at any time interval using approaches 1 and 2, and around 5% of the time 
using approach 3. TDAS® and TRODIS dosage systems provided similar levels of 
effectiveness. Therapeutic achievement is recommended to be evaluated using the 
third approach, since it incorporates time and has the most realistic assumptions. 
This approach is also most suitable for assessing anticoagulant control, since 
incidence rates of events at different intensities can be calculated. Finally, the 
present data call for an improvement by the standard of control for patients during 
the first 3 months of anticoagulant treatment. 
Chapter 5 proposed a method to determine the optimal intensity of long-term 
anticoagulant therapy required to prevent the occurrence of thromboembolic and 
haemorrhagic complications. This involved the calculation of incidence rates 
associated with specific INR intervals for both events (bleeding or thromboembolic) 
in the ASPECT population. Total treatment period was 7213 patient-years. Major 
bleeding occurred in 57 (0.811 00 patient-years) and thromboembolic complications 
in 397 patients (5.611 00 patient-years). A Poisson regression analysis was 
performed to determine the independent risk of event associated with INR-specific 
intervals, after adjustment for possible confounding variables. Based on INR 
measurements obtained within 28 days from the event and relative to INR intensities 
below 2, the rate ratio of major bleeding associated with INR values between 2 and 
3 was 0.2, while 0.6 at INR between 3 and 4, an 80% increase in bleeding risk was 
observed for INR between 4 and 5, and 5 fold increase for INR values exceeding 
5. A reduction of 70% in the rate of thromboemboli associated with INR values 
between 2 and 3 was observed compared with INR intensities below 2, an 80% 
reduction at INR intensities between 3 and 4, as well as for INR intensities above 
the value of 5. The intensity of anticoagulant therapy at which the incidence of 
bleeding and thromboembolic complications was lowest was between 3.0-4.0 INR. 
Other significant predictors for major bleeding and thromboemboli included higher 
levels of systolic blood pressure and age. Female patients showed a higher trend 
for bleeding than males. These results suggest the optimal intensity of long-term 
anticoagulant therapy for post-myocardial infarction patients to lie between 3.0 and 
4.0 INR. 
Chapter 6 presented a detailed description of the 99 ASPECT patients with 
stroke including intracranial bleeding, cerebral infarctions, unspecified and transient 
ischemic attacks. Three years following randomization, 2% of the patients on 
anticoagulant therapy had a stroke compared to 4% in placebo. The incidence of 
stroke analyzed on "intention-to-treat" was 0.7 per 100 patient-years in the 
anticoagulant group and 1.2 per 100 patient-years in placebo, a hazard ratio (HR) 
of 0.60 with a 95% confidence interval (CI) of 0.40 to 0.90. A total of 19 intracranial 
bleeding was observed. The risk of haemorrhages was 8 times greater for 
anticoagulated patients compared to placebo. Eight of the 17 bleedings were fatal 
in the anticoagulant group and no fatal haemorrhages occurred in placebo. A total 
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of 15 cerebral infarctions occurred in the anticoagulated group and 43 in placebo. 
The total number of patients who died or were severely disabled as a result of 
cerebral stroke amounted to 13 in the anticoagulated group, compared to 18 in 
placebo. The results indicated that long-term anticoagulant therapy substantially 
reduced the risk of stroke in post-myocardial infarction patients. The increased risk 
of bleeding complications associated with anticoagulant therapy was offset by a 
marked reduction of ischemic events. 
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SAMENVATIING 
Het therapeutisch effect van anticoagulantia bij de behandeling van patienten met 
diep veneuze thrombose, long-embolie, kunstkleppen, atrium fibbrilleren en hartfalen 
is onomstreden. Echter, de langdurige behandeling van patienten die een hartinfarct 
hebben overleefd is nog steeds controversieel. Antistollings behandeling verhoogt 
het bloedingsrisico en vereist een voortdurende bewaking door de arts en goede 
therapie-trouw van de patient. In dit proefschrift wordt, gebaseerd op de gegevens 
van 3404 post-infarct patienten, een advies opgesteld over de optimale intensiteit 
van de behandeling met antistolling in de preventie van zowel tromboembolische als 
bloedings complicaties. 
Hoofdstuk 1 geeft een overzicht van de waarde van behandeling met 
antistolling na het hartinfarct gebaseerd op de resultaten van meer dan dertig 
therapeutische experimenten die in de afgelopen veertig jaar zijn gerapporteerd in 
de literatuur. De eerste studies, die nog niet volgens juiste methoden werden 
uitgevoerd, toonden een niet significante reductie in sterfte en een voordelige effect 
het terugdringen van thromboembolische complicaties aan; deze werden echter 
geneutraliseerd door een hager bloedings risico. Verder hadden deze studies te 
kampen met problemen betreffende de eenduidigheid van de laboratorium waarden, 
omdat verschillende laboratorium bepalingen werden gebruikt om de intensiteit van 
antistolling te controleren. Tegenwoordig is het echter mogelijk om elke bloedingstijd 
die met een thromboplastine reagent is bepaald om te rekenen in een internationaal 
erkende norm: de International Normalized Ratio (INR). 
In de zeventiger jaren vond een uitgebreide discussie plaats over de 
effectiviteit van langdurige behandeling met antistolling, maar erwerden slechts drie 
gerandomiseerde, gecontroleerde studies uitgevoerd: Breddin, EPSIM en 'Zestig 
Plus'. De eerste twee studies slaagden er niet in om een afname in sterfte door het 
gebruik van orale anticoagulantie aan te tonen. In beide therapeutische 
experimenten was de behandeling met aspirine even effectief in het terugdringen 
van mortaliteit en morbiditeit als de behandeling met antistolling; de bewaking van 
de antistolling was echter relatief slecht. Bovendien was de omvang van de 
experimenten niet afdoend. Het Zestig Plus onderzoek toonde wei een positief 
behandelingseffect aan voor anticoagulantia in vergelijking met placebo. In dit 
onderzoek bevond 72% van de patienten zich binnen de 2.7-4.5 INR. De verdienste 
van het 'Zestig Plus' onderzoek werd door velen aangevochten vanwege het 
specifieke antwerp van deze studie: eerder werd de waarde van het continueren van 
behandeling met antistolling aangetoond dan het starten van deze behandeling. 
Desalniettemin, de positieve bevindingen van dit onderzoek heropenden het reeds 
lang durende debat over de langdurige behandeling van antistolling na het 
hartinfarct. 
Vervolgens werden in 1990 de resultaten van de omzichtig uitgevoerde 
WArfarine Re-lnfarct Studie (WARIS) gepubliceerd. In totaal werden 607 patienten 
toegewezen aan een behandeling met warfarine, en 607 aan placebo. De 
gemiddelde duur van de vervolgperiode was drie jaar. De resultaten toonden 
overduidelijk de voordelen van orale behandeling met antistolling aan op het 
voorkomen van de dood bij patienten die een acuut hartinfarct hadden overleefd: de 
sterfte in de patientengroep behandeld met placebo was 124, in vergelijking met 94 
doden in de met warfarine behandelde groep (een afname van 24%). Het aantal 
recidief infarcten werd met 34% gereduceerd, de cerebro-vasculaire accidenten met 
55%. De bewaking van de antistolling was afdoende: 67% van de patienten had 
waarden binnen de 2.8-4.8 INR. 
De resultaten van he! grootste gerandomiseerde dubbelblinde placebo-
gecontroleerde onderzoek, genaamd ASPECT (Anticoagulants in the Secondary 
Prevention of Events in Coronary Thrombosis), worden weergegeven in Appendix 
A ASPECT vergeleek 1700 patienten behandeld met antistolling tegen 1704 
patienten behandeld met placebo. Aile patienten hadden een hartinfarct overleefd; 
de gemiddelde vervolgperiode was 3 jaar. In de aktief behandelde groep werden 
170 doden geteld in vergelijking tot 189 doden in de placebo-groep (een 10% 
afname in sterfte). He! aantal recidief infarcten werd gereduceerd met 53%, cerebro-
casculaire accidenten met 40%, en aile vasculaire complicaties met 35%. De 
keerzijde werd gevormd door een tienvoudige verhoging in het optreden van 
ernstige bloedingen in de aktief behandelde groep (55 tegen 6). De bewaking van 
antistolling was afdoende: 63% van de patienten had INR waarden binnen de 2.8-
4.8. 
In de hoofdstukken 2 en 3 worden de methoden, die in ASPECT zijn 
toegepast met betrekking tot de dubbelblinde titratie van de antistolling, in detail 
beschreven. In de behandeling met antistolling wordt geen vaste dosering gebruikt. 
Patienten die deze behandeling ondergaan moeten de thrombose dienst regelmatig 
bezoeken om de INR waarde te Iaten bepalen en desgewenst de dosering aan te 
Iaten passen. Patienten behandeld met placebo bezochten eveneens de trombose 
dienst, waarbij er nep-waarden voor deze patienten groep werden bepaald. Op 
vergelijkbare wijze werd zo de dosering in deze groep aangepast. De methode 
verzekerde het dubbelblinde karakter van de gegevensverzameling en voorkwam 
daardoor informatie bias. 
Hoofdstuk 4 bespreekt de verschillend benaderingen om met behulp van de 
INR een kwaliteitsbewaking van de antistollings behandeling te verkrijgen: (1) de 
"cumulative INR's" beschouwt het totaal aantal INR waarden, en de "cross-section-
on-files" beschouwt de laatst verkregen INR waarde van iedere patient De 
resultaten worden uitgedrukt als het percentage van aile INR waarden binnen het 
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therapeutisch gebied; (2) een schatting van het percentage van de tijd die een 
patient binnen het therapeutisch gebied verbleef, waarbij de verandering in INR 
waarde of direct na het eerste bezoek of midden tussen de twee bezoeken in 
plaatsvond; (3) het totale "volume" van de geobserveerde tijd die patienten 
doorbrengen in een bepaalde INR waarde, aannemende dat de INR waarden lineair 
over de tijd veranderen. Deze drie benaderingen werden geevalueerd aan de hand 
van de aktief behandelde patienten in ASPECT. De totale behandelings periode 
omvatte 3725 patientjaren en 67471 INR waarden. De gegevens toonden aan dat, 
onafhankelijk van de gebruikte methode, de intensiteit waarin de patienten ontstold 
waren na zes maanden van behandeling stabiliseerde. Het aantal patienten met een 
te lage intensiteit van antistolling verminderde tussen de eerste en de derde maand, 
en was wederom kleiner na zes maanden. Onafhankelijk van de tijd kwam een te 
hoge intensiteit van antistolling (INR > 4.8) voor in 8% tot 10% van de gevallen na 
gebruikmaking van de benaderingen 1 en 2, en in 5% van de gevallen na 
gebruikmaking van benadering 3. De TDAS and TRODIS doserings systemen 
leverden vergelijkbare niveaus van effectiviteit op. De derde benadering wordt 
aanbevolen om het therapeutisch succes van de antistollings behandeling te 
evalueren, omdat deze benadering gebaseerd is op de meest realistisch aannames 
en bovendien de factor tijd in beschouwing neemt. Ten slotte Iaten de 
gepresenteerde gegevens zien dat een verbetering van de standaard bewaking van 
de behandeling met antistolling gedurende de eerste drie maanden wenselijk is. 
In hoofdstuk 5 word! een methode om de optimale intensiteit van langdurige 
behandeling met antistolling in post-infarct patienten, die nodig is om het optreden 
van tromboembolische en bleedings complicaties te voorkomen, onderzocht. Dit 
vond plaats met behulp van incidentie rates van beide complicaties, geassocieerd 
met bepaalde INR intervallen. De totale behandelings periode omvatte 7213 
patientjaren. Ernstige bloedingen kwamen voor in 57 (0.8/1 00 patientjaren) en 
tromboembolische complicaties in 397 patienten (5.6/1 00 patien~aren). Een Poisson 
regressie analyse werd uitgevoerd om, na correctie voor mogelijke confounders, het 
onafhankelijke risico van de INR-specifieke intervallen op de genoemde complicaties 
vast te stellen. Gebaseerd op de INR metingen verkregen binnen 28 dagen voor de 
complicaties en gerelateerd aan INR intensiteiten onder de 2, bedroeg het relatieve 
risico van ernstige bloedingen geassocieerd met INR waarden tussen 2 en 3 0.2, 
vervolgens 0.6 bij INR waarden tussen 3 en 4, 1.8 bij INR waarden tussen 4 en 5, 
en 5 bij INR waarden groter dan 5. Op vergelijkbare (maar omgekeerde) wijze nam 
het (relatieve) risico op thrombo-embolische complicaties toe met afnemende INR 
intervallen. De intensiteit van de behandeling met antistolling waarbij de incidentie 
van zowel bloedingen als tromboembolische complicaties het laagst bleek, was in 
het INR interval 3.0-4.0. Andere significante voorspellers van ernstige bloedingen 
en tromboembolieen waren hogere systolische bloeddruk en leeftijd. Vrouwelijke 
patienten vertoonden een verhoogd risico op bloedingen in vergelijking met mannen. 
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De resultaten suggereren dat de optimale intensiteit van langdurige behandeling met 
antistolling bij post infarct patienten tussen de 3.0 en 4.0 INR ligt. 
In hoofdstuk 6 wordt een uitvoerige beschrijving gegeven van de 99 ASPECT 
patienten met een CVA. waaronder intracraniele bloedingen, herseninfarcten, niet-
gespecificeerde en kortstondige ischemische aanvallen gerekend worden. Drie jaar 
na randomisatie kreeg 2% van de patienten behandeld met antistolling een 
cerebrovasculair accident in vergelijking met 4% van de patienten behandeld met 
placebo. De incidentie van CVA's, geanalyseerd op basis van het "intension-to-treat" 
principe, bedroeg 0.7 per 100 patientjaren in de antistollings groep en 1.2 per 100 
patientjaren in de placebo groep. Dit resulteerde in een hazard ratio van 0.60, met 
een 95% betrouwbaarheidsinterval van 0.40 tot 0.90. In totaal werden 19 
intracraniele bloedingen waargenomen. Het risico op bloedingen was 8 maal zo 
groat in patienten behandeld met antistolling vergeleken met patienten behandeld 
met placebo. Acht van de 17 bloedingen in de antistollings groep waren dodelijk; in 
de placebo groep kwamen geen dodelijke bloedingen voor. In de antistollings groep 
kwamen 15 en in de placebo groep kwamen 43 herseninfarcten voor. Het aantal 
patienten dat overleed of ernstig gehandicapt raakte door een cerebrovasculair 
accident bedroeg 13 in de antistollings groep en 18 in de placebo groep. De 
resultaten geven aan dat langdurige behandeling met antistolling het risico op een 
CVA in postinfarct patienten aanzienlijk verlaagt. Het verhoogde risico op bleedings 
complicaties geassocieerd met antistollings behandeling werd (meer dan) 
gecompenseerd door een afname van het aantal ischemische complicaties. 
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